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2 LIST OF ABBREVIATIONS 
ΔP: Pressure difference 
2D: Two-dimensional 
3D: Three-dimensional 
ACC/AHA: American College of Cardiology/American Heart Association 
AI: Aortic valve insufficiency/regurgitation 
ANOVA: Analysis of variance 
AS: Aortic valve stenosis 
AVA: Aortic valve area 
AVAI: Aortic valve area index 
BAV: Bicuspid aortic valve 
CHD: Congenital heart disease 
CI: Confidence interval 
ECG: Electrocardiogram 
ERO: Effective regurgitant orifice 
ESC: European Society of Cardiology 
GIM: General internal medicine 
GUCH: Grown-up with congenital heart disease 
HOCM: Hypertrophic obstructive cardiomyopathy 
ICD: International Statistical Classification of Diseases and Related Health Problems 
ICE: International Collaboration on Endocarditis 
ICE-PCS: International Collaboration on Endocarditis-Prospective Cohort Study 
IE: Infective endocarditis 
IQR: Interquartile range 
IVDU: Intravenous drug user 
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LA: Left atrium 
LSIE: Left-sided infective endocarditis 
LV: Left ventricle 
LVOT: Left ventricular outflow tract 
MI: Mitral valve insufficiency 
MR: Mitral regurgitation 
MRI: Magnetic resonance imaging 
MS: Mitral valve stenosis 
MVA: Mitral valve area 
MVP: Mitral valve prolapse 
N/A: Not available 
NBTE: non-bacterial thrombotic endocarditis 
NVIE: Native valve infective endocarditis 
NYHA: New York Heart Association 
PHT: Pressure half-time 
PI: Pulmonary valve insufficiency/regurgitation 
PS: Pulmonary valve stenosis 
PVIE: Prosthetic valve infective endocarditis 
PW: Pulsed wave 
Q1: Question 1 
Q2: Question 2 
RF: Regurgitant fraction 
RVol: Regurgitant volume 
sPAP: Systolic pulmonary pressure 
TDI: Tissue Doppler imaging 
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TI: Tricuspid valve insufficiency/regurgitation 
TOE: Transoesophageal echocardiography 
TS: Tricuspid valve stenosis 
TTE: Transthoracic echocardiography 
VC: Vena contracta 
Vmax: Maximum velocity 
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3 ABSTRACT 
The term ͚predisposing heart condition͛ is used as an indication of antimicrobial prophylaxis to 
prevent infective endocarditis (IE) and as a criterion for diagnosing IE according to the modified Duke 
criteria. Whereas the use of the term for antimicrobial prophylaxis is well defined, the criterion for 
diagnosing IE is not. 
The general objective of this thesis is to narrow the definition of a predisposing heart condition in 
͚native͛ valves for the diagnosis of IE. Therefore, we reviewed the literature and the evidence about 
specific heart conditions reported to be a risk factor for IE. In parallel, we reviewed the imaging 
technique available at the time these studies were published and compared the results with imaging 
fƌoŵ todaǇ͛s peƌspeĐtiǀes aŶd ĐuƌƌeŶt defiŶitioŶs of a specific heart condition (i.e. valvular disease). 
Finally, we evaluated the knowledge and opinion of clinicians about the term predisposing heart 
condition. 
Our literature review included 207 studies, the vast majority of which were descriptive. Only a few 
studies investigated valve pathology as a risk factor for IE via analytical statistics. In addition, three-
quarters of all included studies involved patients who presented with IE prior to the publication of 
the modified Duke criteria.  
Studies focussing on mitral valve prolapse (MVP, 116 publications), prior IE (96 publications), and 
bicuspid aortic valve (BAV, 78 publications) provided the most data. The odds ratio of developing IE 
for a patient who had previously experienced an episode of it was approximately 2.5. The mean 
proportion of patients with IE plus a history of previous IE was 8.3% (median 7.1%, interquartile 
range [IQR] 4.9%–10.2%). One study associated BAV with a higher risk of IE (hazard ratio 6.3). In 77 
descriptive studies, a median of approximately 6% of patients with IE had BAV as an underlying 
condition. Our literature review on the evolution of imaging methods indicated, however, a 
considerable influence of medical progress on the diagnosis of MVP. Six analytical studies and 90 of 
the 110 descriptive studies included patients prior to the publication of the modified Duke criteria in 
2000. For many years, MVP was diagnosed via auscultation only, and echocardiographic means for 
diagnosis were used in the late 90s. Therefore, both the risk of developing IE and the proportion of 
patients with IE and MVP as a predisposing factor could not be quantified.  
The literature review on mitral valve stenosis (MS, 23 publications) and pathologies involving the 
pulmonary valve (18 publications) and the tricuspid valve (nine publications) provided little data. 
These publications had inconsistent results and low proportions of patients with IE had these valve 
pathologies.  
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The significance of aortic valve stenosis (AS, 46 publications), mitral valve insufficiency (MI, 41 
publications), and aortic valve insufficiency (AI, 39 publications) as a predisposing heart condition 
ǁas diffiĐult to assess fƌoŵ todaǇ͛s peƌspeĐtiǀe ďeĐause of the progress made in imaging methods; of 
these studies, 75.6%, 78.6%, and 79.5%, respectively, included patients prior to the publication of the 
modified Duke criteria in the year 2000. In addition, except for AS (1989), the categorisation of mild, 
moderate, and severe valve pathology was established in 1998 or 2006. The publications had 
considerable heterogeneity with a wide distribution of results. An observational study indicated that 
with an increased incidence of AS, the risk of developing IE rises. Only one of these 126 publications 
for these three valve pathologies used analytical statistics. Congenital AS was associated with a 
higher risk of IE (hazard ratio of 4.9). 
The results from the literature review parallel those from a survey that we performed to evaluate the 
knowledge and opinion of clinicians on the term predisposing heart condition. The survey indicated 
that there is significant uncertainty among clinicians regarding what is considered to be a Duke minor 
criterion for a predisposing heart condition in a native valve. The results from 318 questionnaires 
with responses from specialists in the fields of internal medicine, infectious diseases, and cardiology 
provided a wide range of answers. Their answers also showed that what the participants believed to 
be a current Duke minor criterion and what they thought should be a minor criterion had a median 
accordance of 33%. 
Taken together, these findings demonstrate that there is uncertainty about what is considered a 
predisposing heart condition for the diagnosis of IE. This uncertainty is demonstrated in our 
extensive literature review and reflected in our survey among clinicians. The vast majority of studies 
used only descriptive statistics and included patients prior to the publication of the modified Duke 
criteria (2000). The tremendous progress in imaging methods and categorisation of valve pathologies 
since then makes it difficult to iŶteƌpƌet the liteƌatuƌe ƌeǀieǁ aŶalǇses fƌoŵ todaǇ͛s peƌspeĐtiǀe. 
Nonetheless, studies on MVP, a prior episode of IE, and BAV had the highest representation in the 
literature. Among these three pathologies, MVP is most likely to be affected by the evolution of 
imaging methods, and therefore its risk cannot be quantified. Sensitivity analyses and mathematical 
models performed on the data obtained in this systematic review may help to further narrow the 
definition of a predisposing heart condition.  
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4 INTRODUCTION 
4.1 DEFINING A PREDISPOSING HEART CONDITION IN NATIVE VALVE IE 
4.1.1 PATHOGENESIS 
Intact vascular endothelium is thought to be protective against the invasion of bacteria. On the basis 
of histopathology and animal studies, it is presumed that the deposition of platelets and fibrin occurs 
spontaneously on ͚abnormal͛ valve surfaces (e.g. endothelial lesions). A so-called non-bacterial 
thrombotic endocarditis (NBTE) is then formed. These locations serve as sites for the adherence of 
microorganisms during transient bacteraemia. The latter can arise spontaneously with chewing, 
tooth brushing, and other ͚normal activities leading to skin lesions͛.6-9 
In the formation of NBTE, two major mechanisms seem to be important: first, an endothelial injury 
and second, a hypercoagulable state. NBTE predominantly occurs at the valve closure contact line on 
the atrial surfaces of the mitral and tricuspid valves and on the ventricular surfaces of the aortic and 
pulmonic valves. From a haemodynamic point of view, three circumstances may injure the 
endothelium, initiating NBTE: 
1. A high-velocity jet striking the endothelium 
2. Flow from a high-pressure to a low-pressure chamber 
3. Flow across a narrow orifice at high velocity6 
Bacteraemia with subsequent colonisation of the vegetation is the condition that converts NBTE to 
IE. The first inoculating bacteraemia can be clinically silent. Bacteria in the blood, which flows 
through a narrow orifice, will, e.g. precipitate at the low-pressure niches immediately beyond as a 
consequence of the Venturi effect. The damaged endothelium at these sites will allow adherence of 
the microorganisms. 
Hence, the ͚iŶfeĐtious͛ event in the pathogenesis of IE is bacterial adherence to damaged valves or 
endocardium during transient bacteraemia. The second step involves persistence and growth of 
bacteria within these lesions, usually associated with local extension and growing tissue damage.10 
Cytokines and pro-coagulant factors contribute to further enlargement of the infected coagulum, 
forming the well-known ͚vegetation͛. 
The description of IE pathogenesis highlights the core question of this dissertation, namely whether 
or not an anatomical structure predisposes to infection in a clinically significant number of patients. 
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The detailed mechanisms of the host-pathogen interaction in IE are beyond the scope of this thesis. 
In brief, bacterial surface molecules (adhesins) mediate the adherence of microorganisms to the 
NBTE or to apparently intact valve endothelium. These adhesins are referred to as MSCRAMMs 
(microbial surface components recognising adhesive matrix molecules).11 They bind to fibronectin, as 
has been shown for Staphylococcus aureus and viridans streptococci.10 Other proteins include 
integrins of the 1 family. Pathogens possess fibronectin-binding proteins A and B (e.g. surface of S. 
aureus), or FimA (e.g. surface of viridans streptococci). The disease cascade is supported by an 
ongoing host response. Monocytes are attracted by particles released by the attached bacteria. They 
produce tissue factor and cytokines, which again triggers the coagulation pathway and attracts and 
activates blood platelets. Conceivably, the vegetation grows over the course of the disease. 
  
13 
 
4.1.2 PATIENTS AT RISK, MOST COMMON MICROORGANISMS, AND INCIDENCE  
William Bart Osler (1849–1919) described endocarditis in a clinical context in 1885 in ͚The Gulstonian 
Lectures on Malignant Endocarditis͛.12 The first description came from a FƌeŶĐh ‘eŶaissaŶĐe 
phǇsiĐiaŶ, JeaŶ FƌaŶĐo̧is FeƌŶel, appƌoǆiŵatelǇ ϯϱϬ Ǉeaƌs earlier and has been mentioned by several 
physicians at different medical events over the centuries.13  
IE remains a challenging and important differential diagnosis for each clinician because of its high 
mortality and complication rates. In 2004, Moreillon et al. stated that the median incidence was 3.6 
per 100,000 people per year (range 0.3–ϮϮ.ϰͿ aŶd ƌaŶged fƌoŵ чϱ to шϭϱ peƌ ϭϬϬ,000 per year in 
individuals younger than 50 years and older than 65 years, respectively.10 The male-to-female ratio 
was 2:1, and the median hospital mortality rate was 16% (range 11%–26%). However, the incidence 
of IE has not changed over the past three decades, despite improvements in health care.10 This is 
most likely because a progressive change in risk factors for IE counterbalances the improvement in 
health care. Whereas in the pre-antibiotic era, the majority of patients with IE had a history of 
rheumatic heart disease, patients at risk nowadays include intravenous drug users (IVDUs); elderly 
people with degenerative valve disease; and patients with intravascular prostheses, with nosocomial 
disease, or who are undergoing haemodialysis. Staphylococci and oral streptococci account for most 
cases of IE. Together with enterococci, they are responsible for more than 80% of all cases.10 In 
developing countries, Streptococci spp. remain the predominate causative agent of IE in rheumatic 
heart disease.14 
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Figure 1 – Definition of IE by von Reyn criteria4/’The Beth Israel Criteria’, 1981  
IE: infective endocarditis 
Definite IE 
 Direct evidence of infective endocarditis based on histology from surgery or autopsy, or 
on bacteriology (Gram stain or culture) of valvular vegetation or peripheral embolus. 
Probable IE 
 Persistently positive blood cultures (at least two blood cultures obtained, with two of 
two positive, three of three positive, or at least 70% of cultures positive if four or more 
cultures obtained) plus one of the following:  
o New regurgitant murmur, or 
o Predisposing heart disease (definite valvular or congenital heart disease or a 
cardiac prosthesis, excluding permanent pacemakers) and vascular phenomena 
(petechiae, spliŶteƌ heŵoƌƌhages, ĐoŶjuŶĐtiǀal heŵoƌƌhages, ‘oth spots, Osleƌ͛s 
nodes, Janeway lesions, aseptic meningitis, glomerulonephritis, and pulmonary, 
central nervous system, coronary, or peripheral emboli). 
 Negative or intermittently positive blood cultures (any rate of blood culture positivity 
that does not meet the definition of persistently positive) plus all three of the following: 
o Fever 
o New regurgitant murmur, and 
o Vascular phenomena 
Possible IE 
 Persistently positive blood cultures plus one of the following: 
o Predisposing heart disease, or 
o Vascular phenomena 
 Negative or intermittently positive blood cultures with all three of the following:  
o Fever 
o Predisposing heart disease, and 
o Vascular phenomena 
 For viridans streptococcal cases only: at least two positive blood cultures without an 
extra-cardiac source, and fever 
Rejected 
 Endocarditis unlikely, alternate diagnosis generally apparent 
 Endocarditis likely, empiric antibiotic therapy warranted 
 Culture-negative endocarditis diagnosed clinically, but excluded by postmortem 
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4.1.3 DEVELOPMENT OF THE DUKE CRITERIA 
IE is difficult to diagnose and is determined in the presence of multiple findings.1 Guidelines and 
diagnostic criteria have therefore been developed and are intermittently updated.1 
Von Reyn et al. published the first criteria in 1981 (Figure 1, page 14) on the basis of 123 IE cases that 
were treated between 1970 and 1977.4 The aim was to reduce mortality from IE through early 
recognition and treatment.4 
As illustrated in Figure 1, predisposing heart conditions were recognised early. They included definite 
congenital or valvular heart disease or cardiac valve prosthesis. 
The von Reyn criteria were rapidly accepted and widely used until new criteria, which included 
specific echocardiographic findings, were introduced by Durack et al. from the Duke Endocarditis 
Service in 1994.3 The Duke criteria (Figure 2, page 15) emphasised the diagnostic tool of 
echocardiography. Major (Figure 3, page 17) and minor (Figure 4, page 18) criteria were proposed. 
Definite IE 
 Pathologic Criteria 
o Microorganisms: demonstrated by culture or histology in a vegetation, or in a 
vegetation that has embolized, or in an intracardiac abscess, or 
o Pathologic lesions: vegetation or intracardiac abscess present, confirmed by 
histology showing active endocarditis 
 Clinical criteria using specific definitions (listed in Figure 3 and Figure 4) 
o two major criteria, or 
o one major and three minor criteria, or 
o five minor criteria 
Possible IE 
 FiŶdiŶgs ĐoŶsisteŶt ǁith IE that fall shoƌt of ͚defiŶite͛ ďut Ŷot ͚ƌejeĐted͛ 
Rejected IE 
 Firm alternate diagnosis for manifestations of endocarditis, or  
 Resolution of endocarditis, with antibiotic therapy for 4 days or less, or 
 No pathologic evidence of infective endocarditis at surgery or autopsy, after antibiotic 
therapy for 4 days or less 
Figure 2 – Duke criteria3 for IE 
IE: infective endocarditis 
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They played a crucial role in defining definite and possible IE. The most important difference from the 
earlier definition was that the diagnosis of definite IE no longer required histological/pathological 
findings. 
The term predisposing heart condition was adopted as a minor criterion under the topic 
͚predisposition͛. Major and minor criteria were clinical criteria that used specific definitions. 
Predisposing conditions were related to a JAMA article from 1990. Dajani et al.15 listed several 
cardiac conditions in which endocarditis prophylaxis was recommended:  
 Prosthetic cardiac valves, including bioprosthetic and homograft valves 
 Previous bacterial endocarditis, even in the absence of heart disease 
 Congenital cardiac malformations 
 Rheumatic and other acquired valvular dysfunction, even after valvular surgery 
 Hypertrophic cardiomyopathy 
 MVP with valvular regurgitation 
 
Conditions in which endocarditis prophylaxis was NOT recommended included: 
 Isolated secundum atrial septal defect  
 Surgical repair (without residua beyond 6 months) of secundum atrial septal defect, 
ventricular septal defect, or patent ductus arteriosus  
 Previous coronary artery bypass graft surgery  
 MVP without valvular regurgitation  
 Physiologic, functional, or innocent heart murmurs  
 Previous Kawasaki disease without valvular dysfunction 
 Previous rheumatic fever without valvular dysfunction 
 Cardiac pacemakers and implanted defibrillators 
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In a population-based registry from Oregon (USA), Morris et al.16 tried to determine the long-term 
incidence of endocarditis after repair of congenital heart defects in childhood. Included were 
individuals aged 18 years or younger who had surgical repair between 1958 and 1982. The analyses 
showed a continuing incidence of IE at 25 years after surgery, particularly for valvular AS, with a 
cumulative incidence of 13.3%. The investigators concluded that education about endocarditis 
prophylaxis for children and adults with repaired congenital heart defects is necessary. They 
underlined the importance of antibiotic prophylaxis because the number of adult survivors of 
corrected congenital heart defects will increase.  
Major Criteria 
 Positive blood culture for infective endocarditis 
o Typical microorganism for infective endocarditis from two separate blood 
cultures 
 Viridans streptococci (including nutritional variant strains), Streptococcus 
bovis, HACEK group, or  
 Community-acquired Staphylococcus aureus or enterococci, in the 
absence of a primary focus, or 
o Persistently positive blood culture, defined as recovery of a microorganism 
consistent with infective endocarditis from: 
 Blood cultures drawn more than 12 hours apart, or 
 All three or a majority of four or more separate blood cultures, with first 
and last drawn at least 1 hour apart 
 Evidence of endocardial involvement 
o Positive echocardiogram for infective endocarditis 
 Oscillating intracardiac mass, on valve or supporting structures, or in the 
path of regurgitant jets, or on implanted material, in the absence of an 
alternative anatomic explanation, or 
 Abscess, or 
 New partial dehiscence of prosthetic valve, or 
o New valvular regurgitation (increase or change in pre-existing murmur not 
sufficient) 
Figure 3 – Major criteria as defined in Duke criteria3 
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In 2000, another group from the Duke Endocarditis Service (Li et al.) proposed modifications of the 
old Duke criteria from 1994 (Figure 5, page 19; Figure 6, page 20; Figure 7, page 21).1 On the basis of 
their analysis of more than 800 cases since 1984, the databases on echocardiography, and their 
experience with the Duke criteria in clinical practice, the most important adaptations were as 
follows. Possible IE should be defined as at least one major and one minor or three minor criteria. 
The term ͚echocardiogram consistent with IE but not meeting major criterion͛ as a minor criterion 
was eliminated because of the widely used transoesophageal echocardiography (TOE) and its high 
informative value. Bacteraemia with a typical pathogen (Staphylococcus aureus, Streptococcus bovis, 
viridans streptococci, HACEK group) in patients who tested positive for Q-fever by serological testing 
or bacteriological proof of Coxiella burnetti in a single blood culture became major criteria. 
 
 
Minor Criteria 
 Predisposition: predisposing heart condition or intravenous drug use 
 Feǀeƌ: шϯϴ.Ϭ°C ;ϭϬϬ.ϰ°FͿ 
 Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic 
aneurysm, intracranial hemorrhage, conjunctival hemorrhage, Janeway lesions 
 IŵŵuŶologiĐ pheŶoŵeŶa: gloŵeƌuloŶephƌitis, Osleƌ͛s Ŷodes, ‘oth spots, ƌheuŵatoid 
factor 
 Microbiologic evidence: positive blood culture but not meeting major criterion as noted 
previously (excluding single positive cultures for coagulase-negative staphylococci and 
organisms that do not cause endocarditis) or serologic evidence of active infection with 
organism consistent with infective endocarditis 
 Echocardiogram: consistent with infective endocarditis but not meeting major criterion 
as noted previously 
 Figure 4 – Minor criteria as defined in Duke criteria3 
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Figure 5 – Definition of IE according to the modified Duke criteria1 
IE: infective endocarditis 
Definite IE 
 Pathologic Criteria 
o Microorganisms: demonstrated by culture or histology in a vegetation, or in a 
vegetation that has embolized, or in an intracardiac abscess specimen, or 
o Pathologic lesions, vegetation, or intracardiac abscess confirmed by histology 
showing active endocarditis 
 Clinical criteria using specific definitions (listed in Figure 6, page 20 and Figure 7, page 21) 
o two major criteria, or 
o one major and three minor criteria, or 
o five minor criteria 
Possible IE 
 one major criterion and one minor criterion, or 
 three minor criteria 
Rejected IE 
 Firm alternate diagnosis for manifestations of endocarditis, or  
 Resolution of endocarditis, with antibiotic therapy for 4 days or less, or 
 No pathologic evidence of infective endocarditis at surgery or autopsy, after antibiotic 
therapy for 4 days or less 
 Does not meet criteria for possible IE, as above 
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Major Criteria 
 Positive blood culture for infective endocarditis 
o Typical microorganism for infective endocarditis from two separate blood 
cultures: 
 Viridans streptococci (including nutritional variant strains), Streptococcus 
bovis, HACEK group, or  
 Staphylococcus aureus; or  
 Community-acquired enterococci, in the absence of a primary focus, or 
o Microorganisms consistent with IE from persistently positive blood cultures, 
defined as follows: 
 At least two positive cultures of blood samples drawn >12 hours apart, or 
 All three or a majority of шϰ separate cultures of blood (with first and last 
sample drawn at least 1 hour apart) 
o Single positive blood culture for Coxiella burnetii or antiphase I IgG antibody titer 
>1:800 
 Evidence of endocardial involvement 
 Echocardiogram positive for IE (TEE recommended in patients with prosthetic valves, 
ƌated at least ͚possiďle IE͛ ďǇ ĐliŶiĐal Đƌiteƌia, oƌ ĐoŵpliĐated IE [paƌaǀalǀulaƌ aďsĐess]; TTE 
as first test in other patients), defined as follows:  
 Oscillating intracardiac mass, on valve or supporting structures, in the 
path of regurgitant jets, or on implanted material, in the absence of an 
alternative anatomic explanation, or 
 Abscess, or 
 New partial dehiscence of prosthetic valve 
o New valvular regurgitation (worsening change in pre-existing murmur not 
sufficient) 
Figure 6 – Major criteria as defined in modified Duke criteria1 
IE: infective endocarditis; TEE: transesophageal echocardiography; TTE: transthoracic echocardiography 
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Minor Criteria 
 Predisposition, predisposing heart condition, or intravenous drug use 
 Fever, temperature >38°C 
 Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycotic 
aŶeuƌǇsŵ, iŶtƌaĐƌaŶial heŵoƌƌhage, ĐoŶjuŶĐtiǀal heŵoƌƌhage, aŶd JaŶeǁaǇ͛s lesioŶs 
 IŵŵuŶologiĐ pheŶoŵeŶa: gloŵeƌuloŶephƌitis, Osleƌ͛s Ŷodes, ‘oth͛s spots, ƌheuŵatoid 
factor 
 Microbiological evidence: positive blood culture but does not meet a major criterion as 
noted above (excludes single positive cultures for coagulase-negative staphylococci and 
organisms that do not cause endocarditis) or serologic evidence of active infection with 
organism consistent with IE 
Figure 7 – Minor criteria as defined by the modified Duke criteria1 
IE: infective endocarditis 
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4.1.4 ANTIMICROBIAL PROPHYLAXIS 
Antibiotic prophylaxis of IE has been recommended for persons with predisposing cardiac conditions 
since 1955 by the American Heart Association (AHA).17 Despite the lack of evidence, these guidelines 
were used for several decades. Duval et al. extrapolated the results of 2805 subjects to the French 
population and calculated the risk of developing IE as 1 in 46,000 for procedures without 
antimicrobial prophylaxis and as 1 in 150,000 for those with antimicrobial prophylaxis.18  
Clinical evidence is still not sufficient to support antimicrobial prophylaxis.14 Some guideline 
committees of several national cardiovascular societies re-evaluated the existing scientific evidence 
and independently drew four conclusions: 14 
 
1. The existing evidence does not support the extensive use of antibiotic prophylaxis 
recommended in previous guidelines. 
2. Prophylaxis should be limited to the highest risk patients (patients with the highest incidence 
of IE and/or highest risk of adverse outcomes from IE). 
3. The indications for antibiotic prophylaxis for IE should be reduced in comparison with 
previous recommendations. 
4. Good oral hygiene and regular dental review are of particular importance for the prevention 
of IE. 
 
4.1.5 PREDISPOSING HEART CONDITIONS 
The term predisposing heart condition is stated in the latest modified Duke criteria from 2000 for the 
diagnosis of IE as a minor criterion, together with the term ͚injection drug use͛.1 It was previously 
mentioned in the von Reyn criteria4 as ͚predisposing heart disease͛ under the topics probable and 
possible IE, as well as in the first Duke criteria from 1994,3 also as a minor criterion. 
In the literature of the 1970s and 1980s, several authors tried to define and elucidate underlying 
cardiac lesions in patients with IE and came to the conclusion that (i) rheumatic heart disease, (ii) 
MVP, (iii) congenital heart disease, and (iv) degenerative valve lesions predispose individuals to IE.19-
23 With the help of two-dimensional (2D) echocardiography, cardiologists were able to diagnose valve 
diseases such as MVP and degenerative calcified valve lesions, although, with the current diagnostic 
methods, the term ͚degenerative valve lesions͛ includes a wide spectrum of valvular diseases.  
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In the Western world, the incidence of rheumatic heart diseases is decreasing, and hence, less 
frequently mentioned as a risk factor.  
Among the above-mentioned predisposing heart conditions, the role of MVP became significant. In 
1983, a study reported an incidence of MVP of 4%–6%.21 In the hallmark case-control study by 
Clemens et al. in 1982,20 individuals with MVP had an 8.2 higher risk of developing IE. However, it 
should be noted that fƌoŵ todaǇ͛s perspective, a diagnosis of MVP was made by either auscultatory 
or echocardiographic criteria. Auscultation – before the time when echocardiography was commonly 
available – was accepted for diagnosis and required the description of an apical late-systolic murmur 
and at least one systolic non-ejection click. Echocardiography was done in M-Mode and required ш2 
mm of pansystolic bowing or midsystolic buckling of the CD segment of the mitral tracing. The 
echocardiogram of 16% of the cases and 13% of the controls was not available for review. Patients 
with ruptured chordae tendineae were excluded. 
4.1.6 PREDISPOSING HEART CONDITIONS FROM TODAY’S PERSPECTIVES 
When analǇsiŶg the teƌŵ pƌedisposiŶg heaƌt ĐoŶditioŶ fƌoŵ todaǇ͛s peƌspeĐtiǀe, thƌee parameters 
should first be reviewed to make the evaluation of a patient cohort meaningful. 
1. What is the evidence for a specific heart condition putting a patient at risk of IE? The 
literature on this question is difficult to follow, and few analyses have tackled this question.  
2. How is a specific heart condition diagnosed when it is being considered as a risk factor for IE? 
Over the past decades, the technology has improved significantly. Modern three-dimensional 
(3D) echocardiography and high-definition screens are available. Moreover, definitions on 
valvulopathies have changed over the last decades. Thus, it is important to align the evidence 
for a given heart condition with the corresponding imaging technique and definition at the 
time of a corresponding study. These findings should then be compared with todaǇ͛s 
perspectives.  
3. In the guidelines on IE and the modified Duke criteria, the term predisposing heart condition 
is still not well defined. The European Society of Cardiology guidelines state that deficiencies 
remain and that modifications of the Duke criteria still await formal validation.14 Moreover, 
they should be regarded as useful for classifying IE, but they do not replace clinical judgment. 
Nonetheless, a predisposing heart condition is mentioned as a minor criterion. Therefore, it 
plays a role in the daily routine of a clinician who has to decide which cardiac lesion is 
considered a predisposing heart condition. Hence, it is important to evaluate the knowledge 
and opinion of clinicians. 
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4.2 HISTORY – EVOLUTION OF ECHOCARDIOGRAPHY 
1880: Pierre Curie and Jacques Curie: Discovery of piezoelectricity.24 
1942: First A-Mode use in medicine by neurologist Karl Dussik for detecting lateral ventricles of the 
brain (first attempt to use ultrasound in medicine).25 
1954 (technology first used in 1953): Carl Hellmuth Hertz (physicist from Lund University, Sweden) 
and Inge Edler (cardiologist from Sweden) published their first paper on ͚The Use of Ultrasonic 
Reflectoscope for Continuous Movements of the Heart Wall͛ in which they described the use of M-
Mode technology. Edler called the technique ultrasound cardiography.26 The technology was initially 
used by Edler for the diagnosis of MS and MI. 
1965: Harvey Feigenbaum first described pericardial effusion with ultrasound and M-Mode.27 
1968: M-Mode was used to measure left ventricle (LV) dimensions (Feigenbaum).28 
1973: 2D images were first reconstructed from M-Mode tracings by Gramiak (linear scanner).29 
1973: First real-time, 2D scanner was developed by Bom et al.30 
1973: Johnson et al. combined 2D with pulsed Doppler imaging to enable the detection of flow 
signals from specific locations within the heart or great vessels (duplex scanning).31 
1974: Development of a hand-held transducer for 2D echocardiography by Griffith and Henry (sector 
scanner).32 
1974: First 3D reconstruction of 2D images by Dekker et al.33 
1975: First commercially successful mechanical scanner (B-Mode) by Eggleton.34 
1976: Introduction of TOE by Frazin et al.35 
1979/1980: Doppler ultrasound, first used by Holen36 in 1979 and by Hatle37 in 1980 with the 
modified Bernoulli equation to detect pressure gradients across stenotic valves, demonstrated that 
haemodynamic data could be accurately determined. 
1980: TOE was first performed by putting a 2D transducer on a fiberoptic endoscope.38  
1981: A phased-array ultrasound transducer was attached to the tip of a flexible gastroscope by 
Hanrath and colleagues.39 
1982: PW-Doppler was introduced to measure transmitral blood flow velocities to assess LV diastolic 
function as the main clinical modality for non-invasive assessment of diastolic filling patterns.40 
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1983: Schlüter and Hanrath showed the clinical usefulness of TOE in adults.41 
(1992–)1994: Tissue Doppler imaging was introduced to measure myocardial velocities.155,156 
1992: The first 3D TOE was performed by using reconstruction techniques of 2D images.42 The 
technique was applicable only to research. 
2001/2003: First acquisition of 3D images in real time was reported.43,44 
2004: Speckle tracking imaging (2D strain) was introduced to measure the shift of one marker 
(speckle) between two consecutive frames in a certain period.45,46 
2012: First 3D echocardiography recommendations were published by the European Association of 
Echocardiography (EAE)/American Society of Echocardiography (ASE).47 In the 1960s, the idea of the 
3D technique was developed and 3D scans of the heart were first reported in 1974 by Dekker et al. 
(see above).33 
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5 OBJECTIVES AND AIMS 
Our general objective is to narrow the definition of a predisposing heart condition in native valves for 
the diagnosis of IE. We divided the objective into three specific aims: 
1. To review the literature and the evidence on specific heart conditions reported to be a risk factor 
for IE. 
2. To align the findings from the first aim with the imaging technique available at that time, as well as 
to theoretically compare, via extrapolation, the results of iŵagiŶg fƌoŵ todaǇ͛s peƌspeĐtiǀes and 
current definitions of a specific heart condition (i.e. valvular disease).  
3. To evaluate the knowledge and opinion of clinicians about the term predisposing heart condition. 
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6 METHODS 
6.1 AIM 1 – LITERATURE REVIEW 
A thorough literature review was conducted by searching Medline 
(http://www.ncbi.nlm.nih.gov/pubmed/). To identify relevant articles, the following keywords were 
defiŶed: ͚eŶdoĐaƌditis͛, ͚pƌedisposiŶg͛, ͚pƌedispositioŶ͛, ͚ƌisk faĐtoƌ͛, ͚heaƌt ĐoŶditioŶ͛. The primary 
literature search was conducted in August 2015. 
The following search strategy was used: 
 
 Endocarditis AND (predisposing OR predisposition OR risk factor OR heart condition) 
 
Relevant articles cited by the articles identified in the search were tracked in the reference list of the 
corresponding article and, if relevant, also included. The retrieved articles were reviewed and the 
articles were included or excluded after screening for predefined criteria. 
 
6.1.1 INCLUSION AND EXCLUSION CRITERIA 
Conditions considered relevant for this study were as follows: prior endocarditis, AS or AI, BAV, MS or 
MI, MVP, pulmonary valve insufficiency (PI) or pulmonary valve stenosis (PS), and tricuspid valve 
insufficiency (TI) or tricuspid valve stenosis (TS). 
 
Articles were first screened for language and year of publication. Only articles published after 1970 
were included because von Reyn et al.4 published criteria on the basis of IE cases that were treated 
between 1970 and 1977. Only articles published either in English or German were included. 
 
The selection procedure was applied as follows:  
 
1. If the title of the article indicated that the study did not concern adult humans or that it concerned 
diseases other than endocarditis or the cardiac conditions reviewed in this dissertation, the article was 
excluded. 
2. If a publication did not contain any new patient group or did not match the aforementioned criteria 
in the abstract or full text, the article was excluded. 
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Data concerning the number of patients/cases included in the study, as well as patients with one of 
the diseases specifically described in this thesis, were extracted. Primary data analysis was conducted 
in Microsoft Excel 2013. Statistical analysis was conducted by using GraphPad Prism. 
 
6.2 AIM 2 – IMAGING CRITERIA 
6.2.1 DEFINITION OF VALVULOPATHIES 
In order to find a valid definition of each valvulopathy, we screened all published American College of 
Cardiology/AHA (ACC/AHA) guidelines. Within these guidelines, references were tracked. In addition, 
a Medline (see above) search was conducted. The terms searched were the valve pathologies 
themselves: ͚aoƌtiĐ steŶosis͛, ͚aoƌtiĐ iŶsuffiĐieŶĐǇ͛, ͚ďiĐuspid aoƌtiĐ ǀalǀe͛, ͚ŵitƌal steŶosis͛, ͚ŵitƌal 
iŶsuffiĐieŶĐǇ͛, ͚ŵitƌal ǀalǀe pƌolapse͛, ͚tƌiĐuspid steŶosis͛, ͚tƌiĐuspid iŶsuffiĐieŶĐǇ͛, ͚pulŵoŶaƌǇ 
steŶosis͛, aŶd ͚pulŵoŶaƌǇ iŶsuffiĐieŶĐǇ͛. Finally, definitions of valvulopathies were searched on the 
websites of the following journals: Circulation, Journal of the American College of Cardiology (JACC), 
and The New England Journal of Medicine (NEJM). 
 
6.2.2 EVOLUTION OF ECHOCARDIOGRAPHY 
The search for papers in which milestones in echo technique were mentioned was conducted with 
MedLine (PubMed) and with an Internet-ďased seaƌĐh foƌ the teƌŵ ͚eǀolutioŶ of eĐhoĐaƌdiogƌaphǇ͛. 
Given the fact that the search focussed on the historical perspective, we also used review articles to 
find reference articles. Thus, the search was not performed systematically, because the aim was to 
identify articles in which specific echo techniques were first mentioned.  
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6.3 AIM 3 – QUESTIONNAIRE 
 
Figure 8 – Questionnaire 
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6.3.1 QUESTIONNAIRE DESIGN 
The questionnaire (Figure 8, page 29) was designed and validated for the feasibility of completing it 
within 5 minutes. It was developed in conjunction with the Institute of Social and Preventive 
Medicine and Clinical Trials Unit (Bern University Hospital, Bern, Switzerland).  
It included questions about the training, degrees, and clinical experience of the study participants, as 
well as two knowledge and two opinion questions. We visited 19 departments in 13 different 
institutions within Switzerland to perform the survey (see 6.3.2 Study Participants, page 30). 
Questionnaires were distributed at morning meetings and collected directly afterwards. All 
questionnaires were filled out anonymously. A sample size of 300 was targeted prior to the study. 
Participants included either physicians undergoing postgraduate education and specialisation, or 
specialists in the fields of internal medicine, infectious diseases, or cardiology. Answers were 
independently evaluated by two members of the study team and categorised as acceptable (wide 
range of answers) or definitely wrong (narrow range of answers). The rationale to accept a wide 
range of answers relied on the fact that the term predisposing heart condition in native valves is not 
well defined; thus, for many answers, it was scientifically difficult to categorise them as definitely 
wrong. In case of disagreement, a third member of the study team was involved and the decision was 
made by the majority. Accordance between knowledge and opinion was analysed and illustrated in a 
bidirectional graph. For this analysis, foreign body material was excluded because the focus in the 
opinion question was on native valves, whereas ͚foreign body material͛ was a correct answer in the 
knowledge question. GraphPad Prism 5.0 was used for statistical analysis. Differences in group 
proportions were assessed by contingency tables and the chi-sƋuaƌe test, oƌ ďǇ Fisheƌ͛s eǆaĐt 
probability test if cell values were less thaŶ ϱ. The StudeŶt͛s t-test was applied where appropriate. A 
two-tailed p-value of 0.05 or less was considered significant. 
All procedures followed were in accordance with the ethical standards of the responsible committee 
on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as 
revised in 2013. Informed consent was obtained from all patients included in the study. 
6.3.2 STUDY PARTICIPANTS 
The questionnaires were distributed at lectures and meetings. The following institutions were 
included:  
 Department of General Internal Medicine, Bern University Hospital, Bern, Switzerland 
 Department of Intensive Care Medicine, Inselspital, Bern University Hospital, Bern, 
Switzerland 
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 Department of Infectious Diseases, University Hospital Bern and University of Bern, 
Switzerland 
 Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, 
Switzerland 
 Department of Cardiology, Kantonsspital, Aarau, Switzerland 
 Department of Cardiology, Luzerner Kantonsspital, Lucerne, Switzerland 
 Department of Cardiology, Triemlispital, Zurich, Switzerland 
 Department of Internal Medicine, University Hospital Basel, Switzerland 
 Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and 
Clinical Research, University Hospital Basel 
 Division of Infectious Diseases, Kantonsspital, St. Gallen 
 Clinic of Internal Medicine, Bürgerspital, Solothurn, Switzerland 
 Clinic of Cardiology, Kantonsspital, Olten, Switzerland 
 Division of Cardiology, Department of Internal Medicine, Kantonsspital Winterthur, 
Winterthur, Switzerland 
 Department of Internal Medicine, Spitäler FMI, Interlaken, Interlaken, Switzerland 
 Department of Internal Medicine, Regionalspital Emmental, Burgdorf, Burgdorf, Switzerland 
 Department of Internal Medicine, Regionalspital Emmental, Langnau, Langnau i.E., 
Switzerland 
 Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital Baselland, University 
of Basel, Basel, Switzerland 
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7 RESULTS 
7.1 LITERATURE REVIEW 
 
Figure 9 – Algorithm for literature review 
Studies identified: 8966 
Studies in English and German 
6966 
Before 1970: 403 
Language other than German or 
English: 1597 
Title: not concerning adult 
humans: 549 
Title: not concerning IE: 1252 
Title: concerning subgroups of IE: 
1169 
Title: concerning other 
predisposing conditions: 1823 
Title: irrelevant study design: 
1418 
Studies with relevant title: 755 
Text/Abstract: no original data: 
269 
Text/Abstract: no relevant data: 
277 
Relevant studies: 207 
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7.2 DEFINITION OF VALVULOPATHIES AND METHOD IMAGING 
Specific definitions of valvulopathies were published by ACC/AHA first in 1998, followed by guidelines 
in 2006 and 2014. Results regarding the definition of valvulopathies and imaging methods are 
combined in an overview in the next sections. 
 
7.3 PRIOR IE 
Of the 207 studies considered relevant in the literature review, 91 mentioned prior IE.  
7.3.1 PUBLICATIONS THAT INCLUDED ANALYTICAL STATISTICS 
Strom et al.9 reviewed 279 cases of IE from 1988 to 1990 from 54 hospitals in Delaware Valley (USA). 
Compared with that of the controls, the odds ratio for developing IE with prior IE in these cases was 
35.2.  
Todd et al.48 described a study of 29 patients with echocardiographically confirmed IE and 79 controls 
(with echocardiograms) from 2002 to 2004 in the UK. They reported that a patient with a history of IE 
had an odds ratio of 2.2 (95% confidence interval [CI] 0.4–10.3, p-value 0.383) for developing IE. 
Alagna et al.49 reported the results of a study of 1874 patients from the International Collaboration 
on Endocarditis cohort from 2000 to 2006 with a 1-year follow-up. Prior IE had a reported odds ratio 
of 2.8 (95% CI 1.5–5.1) for causing IE.  
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7.3.2 PRIOR IE – PUBLICATIONS WITH DESCRIPTIVE STATISTICS 
Reference Time Place Cases of (NV)IE Cases with Prior IE % with Prior IE Study Design 
Pelletier50 1963–1972 USA 125 20 16.0% Retrospective review of patient charts, 
multicentre  
Pedersen51 1944–1973 Denmark 80 3 3.8% Retrospective, single centre 
Garvey52 1968–1974 USA 154 12 7.8% Retrospective analysis of patient records, 
autopsy files, and files of the infectious 
diseases department 
Lowes53 1966–1975 UK 60 1 1.7% Retrospective survey, single centre 
Welton54 1967–1976 USA 96 18 18.8% Retrospective, single centre 
Haddy55 1964–1979 USA 66 4 6.1% Retrospective, single centre 
Hammel56 1971–1980 Switzerland 31 9 29.0% Single centre, not indicated whether 
prospective or retrospective 
Venezio57 1972–1980 USA 32 2 6.3% Retrospective, single centre 
Bayliss58 1981–1982 UK 541 34 6.3% Retrospective, multicentre (British Isles) 
Terpenning59 1976–1985 USA 154 6 3.9% Retrospective review of patient charts, 
multicentre  
King60 1985–1986 USA 75 8 10.7% Prospective, multicentre 
Steckelberg61 1970–1987 USA 697 105 15.0% Retrospective from prospectively collected 
records, multicentre (comparison of a 
population- based cohort vs. cohort of Mayo 
Clinic) 
Kim62 1975–1987 USA 56 2 3.6% Retrospective, single centre 
Varstela63 1976–1987 Finland 58 3 5.2% Retrospective, single centre 
Jaffe64 1983–1988 USA 70 9 12.9% Retrospective review, single centre 
Hogevik65 1984–1988 Sweden 98 14 14.0% Prospective non-randomised, single centre 
Van der Meer8 1986–1988 Netherlands 349 30 8.6% Prospective epidemiologic study, 
multicentre 
Nissen66 1980–1989 Denmark 132 5 3.8% Retrospective, multicentre 
Schon67 1980–1989 Germany 51 7 13.7% Retrospective, single centre 
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Gentry68 1983–1989 USA 54 15 28.0% Retrospective review, single centre 
Watanakunakorn69 1980–1990 USA 181 13 7.2% Retrospective 1980–1985, prospective 
1986–1990, single centre 
Strom9 1988–1990 USA 279 17 6.1% Population-based, case-control study, 
multicentre 
Roberts70 1954–1991 USA 104 4 3.8% Retrospective, multicentre 
Delahaye71 1990–1991 France 415 46 11.0% Prospective survey, multicentre 
Selton-Suty72 1990–1991 France 297 19 6.4% Prospective, multicentre 
Tornos73 1975–1992 Spain 194 12 6.2% Prospective observational, single centre 
Rognon74 1983–1993 Switzerland 179 19 10.6% Retrospective, multicentre 
Sandre75 1985–1993 Canada 80 4 5.0% Retrospective review, single centre 
Werner76 1989–1993 Germany 106 2 1.6% Retrospective, single centre 
Ferreiros77 1992–1993 Argentina 294 30 10.2% Prospective registry, multicentre 
Weng78 1984–1994 Taiwan 109 2 1.8% Retrospective, single centre 
Lamas79 1985–1996 UK 100 4 4.0% Prospective, single centre 
Bouza80 1994–1996 Spain 109 17 15.6% Prospective observational case series, single 
centre 
Castillo81 1987–1997 Spain 95 2 2.0% Prospective case series, single centre 
Mouly82 1997–1998 France 90 8 9.0% Retrospective observational, single centre 
Abramczuk83 1988–1998 Poland 152 7 4.9% Retrospective, single centre 
Cetinkaya84 1974–1999 Turkey 228 5 2.2% Retrospective (hospital charts) review, single 
centre 
Fefer85 1990–1999 Israel 108 7 9.0% Retrospective (medical records), single 
centre 
Pachirat86 1990–1999 Thailand 203 4 2.0% Single centre, combined retrospective and 
prospective data collection 
Tleyjeh87 1970–2000 USA 107 8 7.0% Retrospective (population-based survey), 
multicentre 
Netzer88 1980–2000 Switzerland 212 9 4.2% Retrospective review of clinical records, 
single centre 
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Alestig89 1984–2000 Sweden 98 14 14.0% Prospective clinical studies carried out in 
Göteborg since 1984, data obtained from a 
Swedish national registry of IE since 1995 
and existing literature 
Gotsman90 1991–2000 Israel 100 22 22.0% Retrospective, single centre 
Koegelenberg91,92 1997–2000 South Africa 47 1 2.1% Prospective observational study, single 
centre 
Castillo93 1987–2001 Spain 154 3 2.0% Prospective observational, multicentre 
Moura94 1989–2001 Portugal 69 6 8.0% Retrospective, single centre 
Yoshinaga95 1997–2001 Japan 239 15 6.3% Retrospective observational cohort study, 
multicentre (66 institutes) 
Chu96 1997–2002 New Zealand 65 5 7.7% Retrospective, single centre 
Yousuf97 2000–2002 Malaysia 45 10 22.2% Retrospective analysis of case records, single 
centre 
Ferreiros77 2001–2002 Argentina 470 53 11.3% Prospective, multicentre 
Cicalini98 1980–2003 Italy 267 38 13.4% Retrospective (patient records), single 
centre 
Nashmi99 1993–2003 Saudi Arabia 47 3 6.4% Retrospective, single centre 
Hsu100 1995–2003 Taiwan 315 22 7.0% Retrospective review, single centre 
Jain101 1996–2003 USA 247 42 17.0% Retrospective, single centre 
Hill102 2000–2004 Belgium 203 24 12.0% Prospective observational cohort study, 
single centre 
Giannitsioti103 2000–2004 Greece 195 19 9.7% Prospective cohort study, multicentre 
Benito104 2000–2005 ICE cohort 1622 58 3.6% Prospective cohort study, multicentre (data 
from the ICE-PCS) 
Murdoch105 2000–2005 ICE cohort 2781 222 8.0% Prospective cohort study, multicentre (ICE-
PCS) 
Walls106 2000–2005 ICE cohort 336 34 10.1% Prospective cohort, multicentre 
Correa de Sa107 1970–2006 USA 150 14 9.3% Retrospective, multicentre 
Galvez-Acebal108 1984–2006 Spain 705 57 8.0% Observational multicentre study 
Pazdernik109 1998–2006 Czech Republic 106 5 4.7% Retrospective, single centre 
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Alagna49 2000–2006 ICE cohort 1783 135 7.4% Prospective, multicentre 
Tugcu110 1997–2007 Turkey 28 2 7.1% Retrospective review, single centre 
Mokhles111 1998–2007 Netherlands 138 18 13.0% Retrospective observational cohort study, 
single centre 
Baskerville112 2002–2007 Australia 89 13 14.6% Retrospective review (medical records), 
multicentre 
Wong113 2002–2007 New Zealand 57 5 9.0% Retrospective review, single centre 
Khaled114 2006–2007 Yemen 72 1 1.4% Prospective, single centre 
Mokhles115 2001–2008 Netherlands 191 27 14.1% Retrospective observational cohort study, 
single centre 
Nunes116 2001–2008 Brazil 62 14 23.0% Prospective, single centre 
Erbay117 2004–2008 Turkey 107 10 9.3% Retrospective, single centre 
Dzupova118 2007–2008 Czech Republic 134 8 6.0% Prospective, multicentre 
Selton-Suty119 2008 France 497 32 6.4% Prospective population-based observational 
study, multicentre 
Nomura120 1996–2009 Japan 62 3 5.0% Retrospective, single centre 
Fernandez-Hidalgo121 2000–2009 Spain 337 17 5.0% Prospective observational cohort study, 
single centre 
Leone122 2004–2009 Italy 753 33 4.4% Prospective, multicentre 
Wu123 2004–2009 Taiwan 205 5 2.4% Retrospective, single centre 
Knudsen124 2007–2009 Denmark 147 8 5.4% Prospective, single centre 
Knudsen125 2007–2009 Denmark 149 9 6.0% Prospective, single centre 
Ferraris126 2003–2010 Italy 111 12 10.8% Retrospective, single centre 
Poesen127 2003–2010 Belgium 88 8 9.1% Retrospective, single centre 
Gupta128 2005–2010 India 83 5 8.2% Retrospective, single centre 
Mirabel129 2005–2010 New Caledonia 51 4 7.8% Retrospective, single centre 
Koeda130 1997–2011 Japan 119 7 5.9% Retrospective, single centre 
Fernandez-Hidalgo131 2000–2011 Spain 438 7 2.9% Prospective observational cohort study, 
single centre 
Ferreira132 2000–2011 Portugal 147 5 3.4% Retrospective, multicentre (2 hospitals) 
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Rizzi133 2004–2011 Italy 1056 55 5.2% Retrospective analysis of a multicentre, 
prospective observational cohort study 
Korem134 2009–2011 Israel 37 2 5.4% Prospective observational study, single 
centre 
Turak135 2009–2011 Turkey 122 11 9.0% Retrospective, single centre 
Chu136 2008–2012 ICE-PLUS cohort 1296 100 7.8% Prospective cohort study, multicentre (ICE-
PLUS cohort) 
Olmos137 1996–2013 Spain 1122 88 7.8% Prospective, multicentre 
Simsek-Yavuz138 2000–2013 Turkey 325 18 5.5% Prospective 102 cases (first 5 years) and 
retrospective 223 cases thereafter, single 
centre 
Fukuchi139 2008–2013 Japan 82 2 2.4% Prospective, multicentre 
Gupta140 2010–2013 India 109 8 7.3% Retrospective, single centre 
Table 1 – Literature for prior IE 
ICE: International Collaboration on Endocarditis; ICE: International Collaboration on Endocarditis; ICE-PCS: International Collaboration on Endocarditis-Prospective Cohort Study; IE: infective 
endocarditis; NVIE: native valve infective endocarditis  
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Figure 10 – Comparison of study size with prevalence of prior IE in patients with IE and in association with IE criteria prior to and after modified Duke criteria 
IE: infective endocarditis 
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7.3.3 SUMMARY OF RESULTS: PRIOR IE  
We identified three studies showing that a history of IE was associated with a higher risk of a second 
episode of IE. While two studies showed an odds ratio of approximately 2.5,48,49 one calculated an 
odds ratio of >35.9 Considering the overview of the results, we postulate that the odds ratio in that 
study was overrated. 
Ninety-five studies were identified that published descriptive statistics on the proportion of patients 
with a history of IE in newly diagnosed IE cases. Of these studies, 23 (24.2%) included patients in the 
study after the publication of the modified Duke criteria. A two-tailed t-test of the number of 
publications before and after 2001 was highly significant, with a p-value of <0.0001. The mean 
number of patients included in the 95 studies was 263 (median 122, IQR 80–239), in the studies prior 
to 2001 was 264 (median 128.5, IQR 80–245), and in the studies after 2001 was 259 (median 111, 
IQR 82.5–198). Of the 95 studies, the mean proportion of patients with IE plus a history of previous IE 
was 8.3% (median 7.1%, IQR 4.9%–10.2%). The mean proportion of patients with IE plus a history of 
previous IE in studies prior to 2001 was 8.4%, the median was 7%, and the IQR was 4.3%–10.5%. 
After 2001, the numbers were as follows: mean 8.1%, median 7.8%, IQR 5.4%–9.2%. These 
differences were not significant in an unpaired t-test. These results are in line with the dot plot that 
compares the study size with the prevalence of prior IE in patients with IE and in association with IE 
in accordance with primary and modified Duke criteria. The strongest cluster was seen between the 
prevalence lines 5% to 10%. Studies with small sample sizes and above the prevalence line of 15% 
indicated a publication bias, whereas studies with large sample sizes (e.g., >700 patients) confirmed 
the 5% to 10% estimate.  
In the preliminary meta-analysis, the proportion of patients with IE and prior IE as an underlying 
condition was 6.9% (95% CI 6.5%–7.2%) in a fixed effects model and 7.4% (95% CI 6.5%–8.2%) in a 
random effects model. As a few studies contributed greatly to the overall heterogeneity, a second 
meta-analysis with stricter clinical inclusion/exclusion criteria is planned. 
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Figure 11 – Contribution of studies to overall heterogeneity for prior IE 
IE: infective endocarditis 
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7.4 AORTIC VALVE 
7.4.1 AORTIC VALVE STENOSIS (AS) 
Of the 207 articles considered relevant after the literature review, 46 mentioned AS. 
7.4.1.1 ANALYTICAL STATISTICS 
In 2011, Verheugt et al.141 described patients from the CONCOR national registry for adults with 
congenital heart disease from the Netherlands. Of 922 patients with congenital AS, 26 (2.8%) 
developed IE. This equals a hazard ratio of 4.9 (95% CI 2.2–10.5). 
7.4.1.2 DESCRIPTIVE STATISTICS 
Gersony et al.142 described 462 patients with AS from the Second Natural History Study of Congenital 
Heart Defects conducted in the USA between 1958 and 1965. They reported a prevalence rate of 
21.6 per 10,000 patients (95% CI 0.5–120.6). Follow-up was conducted for 8115 person-years; 
patients with conservative management had an incidence rate of 15.7 per 10,000 person-years (95% 
CI 6.3–ϯϮ.ϰͿ. PatieŶts ǁith a peak sǇstoliĐ gƌadieŶt of шϱϬ mmHg had an incidence rate of 54.4 per 
10,000 person-years (95% CI 33.2–84.1), and patients with a peak systolic gradient of <50 mmHg had 
an incidence rate of 4.5 per 10,000 person-years (95% CI 0.6–16.4). The investigators stated that only 
the severity of AS is related to the occurrence of IE. 
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Reference Time Place Patients with (NV)IE Cases with AS % with AS Study Design 
Keane143 1958–1965 USA 462.0 14 3.0% Prospective cohort study, multicentre 
Pelletier50 1963–1972 USA 125.0 25 20.0% Retrospective review of patient charts, 
multicentre  
Thell144 1960–1974 USA 42.0 6 14.3% Retrospective (pathology samples), 
multicentre 
Lowes53 1966–1975 UK 60.0 4 6.7% Retrospective survey, single centre 
Robbins145 1970–1977 USA 56.0 7 12.5% Retrospective, single centre 
Grossman146 1951–1979 Israel 228.0 21 9.2% Retrospective, single centre 
Venezio57 1972–1980 USA 32.0 3 9.4% Retrospective, single centre 
Rudolph147 Before 1983 Germany 50.0 11 22.0% Single centre, probably prospective 
Terpenning59 1976–1985 USA 154.0 1 0.6% Retrospective review of patient charts, 
multicentre  
Hodes148 1977–1985 Ethiopia 51.0 1 2.0% Retrospective, single centre 
Mansur149 1978–1986 Brazil 287.0 6 2.1% Retrospective, single centre 
Van der Meer8 1986–1988 Netherlands 349.0 9 3.5% Prospective epidemiologic study, 
multicentre 
Nissen66 1980–1989 Denmark 132.0 8 6.1% Retrospective, multicentre 
Thamlikitkul150 1982–1989 Thailand 75.0 14 13.3% Retrospective, single centre 
Roberts70 1954–1991 USA 96.0 25 26.0% Retrospective, multicentre 
Choudhury151 1981–1991 India 186.0 2 1.1% Retrospective, single centre 
Delahaye71 1990–1991 France 415.0 14 3.4% Prospective survey, multicentre 
Benn152 1984–1993 Denmark 62.0 6 9.7% Retrospective, multicentre 
Sandre75 1985–1993 Canada 80.0 2 2.5% Retrospective review, single centre 
Werner76 1989–1993 Germany 106.0 8 7.5% Retrospective, single centre 
Netzer153 1980–1995 Switzerland 212.0 28 13.0% Retrospective, single centre 
Lamas79 1985–1996 UK 100.0 7 7.0% Prospective, single centre 
Dyson154 1987–1996 UK 78.0 2 2.6% Retrospective, single centre 
Castillo81 1987–1997 Spain 95.0 8 8.0% Prospective case series, single centre 
Cheng155 1994–1999 Australia 40.0 1 2.5% Retrospective, multicentre 
Di Filippo156 1966–2001 France 153.0 1 0.6% Retrospective, single centre 
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Castillo93 1987–2001 Spain 154.0 18 11.5% Prospective observational, multicentre 
Tariq157 1988–2001 Pakistan 159.0 2 1.3% Retrospective, single centre 
McKay158 1989–2001 New Zealand 29.0 2 6.9% Retrospective, multicentre 
Tariq159 1997–2001 Pakistan 66.0 2 3.0% Retrospective, single centre 
Cecchi160 2000–2001 Italy 67.0 5 7.5% Prospective, multicentre 
Chu96 1997–2002 New Zealand 65.0 8 12.3% Retrospective, single centre 
Durante-
Mangoni161 
2000–2005 ICE cohort 2759.0 N/A 10%–28% Prospective, multicentre (ICE cohort) 
Assiri162 2002–2007 Saudi Arabia 44.0 2 4.5% Retrospective, single centre 
Wong113 2002–2007 New Zealand 57.0 5 9.0% Retrospective review, single centre 
Mokhles115 2001–2008 Netherlands 191.0 2 1.0% Retrospective observational cohort study, 
single centre 
Dzupova118 2007–2008 Czech Republic 134.0 4 3.0% Prospective, multicentre 
Leone122 2004–2009 Italy 753.0 20 2.7% Prospective, multicentre 
Nakatani163 2007–2009 Japan 513.0 37 7.2% Prospective survey, multicentre 
Marks164 1998–2010 UK 336.0 3 0.9% Retrospective observational cohort study, 
single centre 
Cecchi165 2007–2010 Italy 677.0 26 3.8% Prospective, multicentre 
Ma166 2002–2011 China 115.0 8 7.0% Single centre 
Begezsan167 2007–2011 Romania 45.0 5 11.1% Retrospective, single centre 
Collins168 2008–2011 USA 95.0 5 5.3% Prospective observational, single centre 
Verheugt141 Before 2011 The Netherlands 922.0 26 2.6% Prospective cohort study, multicentre 
Table 2 – Literature for AS: People with IE with AS as an underlying condition 
AS: aortic valve stenosis; ICE: International Collaboration on Endocarditis; N/A: not available; NVIE: Native valve infective endocarditis 
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Figure 12 – Comparison of study size with prevalence of AS in patients with IE and in association with IE criteria prior to and after modified Duke criteria 
AS: aortic valve stenosis; IE: infective endocarditis 
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7.4.1.3 REVIEW OF AVAILABLE ECHO TECHNIQUES 
Reference Time Available Echo Technique Definition at the Time 
Keane143 1958–1965 M-Mode (1954)26  
Pelletier50 1963–1972 Severe: Conn et al. 1971169: AVA ч 0.5 cm2 
Rapaport et al. 1975170: AVA ч 1.0 cm2 Thell144 1960–1974 
Lowes53 1966–1975 
Robbins145 1970–1977 + B-Mode (2D (1975))34 
Grossman146 1951–1979 + Doppler (CW (1979))36,37 
Venezio57 1972–1980 Chizner et al. 1980171: 
Moderate: AVA 0.71–1.09 cm2, peak ΔP ч 70 mmHg Rudolph147 Before 1983 
Terpenning59 1976–1985 + PW (1982),40 TOE (1983)41 
Hodes148 1977–1985 
Mansur149 1978–1986 
Van der Meer8 1986–1988 Horstkotte et al. 1988172: 
Mild: AVA > 1.5 cm2 
Moderate: AVA 0.8–1.5 cm2, peak ΔP ч 80 mmHg 
Nissen66 1980–1989 Rahimtoola et al. 1989173: 
Mild: AVA > 1.5 cm2, AVAI > 0.9 cm2/m2 
Moderate: AVA 1.1–1.5 cm2, AVAI ш 0.6–0.9 cm2/m2 
Seǀeƌe: AVA ч 0.8–1.0 cm2, AVAI ч 0.4–0.6 cm2/m2 
Thamlikitkul150 1982–1989 
Roberts70 1954–1991 
Choudhury151 1981–1991 
Delahaye71 1990–1991 
Benn152 1984–1993 
Sandre75 1985–1993 
Werner76 1989–1993 
Netzer153 1980–1995 + TDI (1994)174,175 
Lamas79 1985–1996 
Dyson154 1987–1996 
Castillo81 1987–1997 
Cheng155 1994–1999 AHA/ACC 1998176: 
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Di Filippo156 1966–2001 + Real-time 3D first reports in 200143,44 Mild: AVA > 1.5 cm2 
Moderate: AVA > 1.0–1.5 cm2 
Severe: AVA < 1.0 cm2, ŵeaŶ ΔP > 50 mmHg 
Castillo93 1987–2001 
Tariq157 1988–2001 
McKay158 1989–2001 
Tariq159 1997–2001 
Cecchi160 2000–2001 
Chu96 1997–2002 
Durante-Mangoni161 2000–2005 + Speckle tracking (strain (2004))45,46 
Assiri162 2002–2007 AHA/ACC 20065: 
Mild: Vmax < 3 ŵ/s, ΔP < 25 mmHg, AVA > 1.5 cm2 
Moderate: Vmax 3–4 m/s, ŵeaŶ ΔP Ϯϱ–40 mmHg, AVA 1.0–1.5 cm2 
Wong113 2002–2007 
Mokhles115 2001–2008 
Dzupova118 2007–2008 
Leone122 2004–2009 
Nakatani163 2007–2009 
Marks164 1998–2010 
Cecchi165 2007–2010 
Ma166 2002–2011 
Begezsan167 2007–2011 
Collins168 2008–2011 
Verheugt141 Before 2011 
Table 3 – Echocardiographic definitions of AS for the discussed literature 
ΔP: mean pressure difference; 2D: two-dimensional; 3D: three-dimensional; AHA/ACC: American Heart Association/American College of Cardiology; AVA: aortic valve area; AVAI: aortic valve area 
index; CW: continuous wave; PW: pulsed wave TDI: tissue Doppler imaging; TOE: transoesophageal echocardiography; Vmax: maximum velocity 
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7.4.1.4 SUMMARY OF RESULTS 
We identified only one study showing that a history of (congenital) AS was associated with a higher 
risk of IE, with a hazard ratio of 4.9.141 No studies were identified for other causes of AS. 
Forty-five studies were identified that published descriptive statistics on the proportion of patients 
with a history of AS in newly diagnosed IE cases. Of these studies, 11 (24.4%) included patients in the 
study only after the publication of the modified Duke criteria. A paired two-tailed t-test for the 
number of studies before and after 2001 was significant, with a p-value of 0.0003. The mean number 
of patients included in the 45 studies was 242 (median 106, IQR 62–212), in the studies prior to 2001 
was 217 (median 98, IQR 63–179), and in the studies after 2001 was 322 (median 134, IQR 76–595). 
Of the 45 studies, the mean proportion of patients with a history of AS was 7.3% (median 6.7%, IQR 
2.6%–9.7%). The distribution of these variables prior to 2001 was as follows: mean 8.0%, median 
7.0%, IQR 2.5%–12.1%. After 2001, the numbers were as follows: mean 5.2%, median 4.5%, IQR 
2.9%–7.1%. The difference between the two groups was not significant in an unpaired t-test. The dot 
plot that compares the study size with prevalence of prior IE in patients with IE and in association 
with IE in accordance with primary and modified Duke criteria shows a cluster consisting of studies 
with sample sizes below 200 patients and below 10% prevalence. However, the graph indicates that 
in larger and newer studies, the prevalence is most likely smaller than 5%. 
The most important change concerning the echo criteria was the mean gradient, which defines the 
severity of AS. The guidelines from 2006 defined severe AS as having a mean gradient of шϰϬ ŵŵHg 
;iŶstead of шϱϬ ŵŵHg iŶ ϭϵϵϴͿ, aŶd the guideliŶes fƌoŵ ϮϬϭϰ ĐhaŶged the definition of moderate AS 
as beginning at шϮϬ ŵŵHg iŶstead of шϮϱ ŵŵHg. Moreover, low-flow, low-gradient AS was defined 
first in 2006, which is important for patients with reduced systolic ejection fraction. Developments in 
Definition of AS Today (AHA/ACC 20142) 
At risk: Vmax < 2 m/s 
Mild: Vmax 2.0–2.9 m/s or mean ΔP < 20 mmHg 
Moderate: Vmax 3.0–3.9 m/s or mean ΔP 2–9 mmHg 
Severe: Vmax ш 4 m/s or mean ΔP ш 40 mmHg, AVA < 1.0 cm2 oƌ AVAI ч 0.6 cm2/m2 
 
Figure 13 – AS definition today 
ΔP: pressure difference; AHA/ACC: American Heart Association/American College of Cardiology; AS: aortic valve stenosis; 
AVA: aortic valve area; AVAI: aortic valve area index; Vmax: maximum velocity 
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echo techniques and quality (e.g. better resolution of the screens, better transducers) also played an 
important role in improvements in diagnostics.  
The differentiation between mild, moderate, and severe AS was described first in 1989.173 Since 1998 
– the year of the first publication of the ACC/AHA guidelines on valvular heart disease – the definition 
of mild, moderate, and severe AS has evolved. The observation that (i) three-quarters of the studies 
included patients prior to 2001, (ii) the mean and median proportions of patients with AS and IE were 
lower in studies published after 2001 (5.2% vs. 4.5%) than they were in studies published before 
2001 (8% vs. 7%), and (iii) the dot plot demonstrates a prevalence of less than 5% in newer studies 
with large sample sizes indicates that the relevance of mild or moderate AS as a risk factor for IE is 
unknown. This corresponds to the study of Verheugt et al.141 in that only congenital AS was 
statistically associated with a higher risk of developing IE. Gersony et al.142 stated that only severe AS 
is related to the occurrence of IE.  
In the preliminary meta-analysis, the proportion of patients with IE and AS as an underlying condition 
was 6.8% (95% CI 6.4%–7.4%) for a fixed effects model and 6.1% (95% CI 4.2%–8.3%) in a random 
effects model. One study contributed greatly to the overall heterogeneity. 
 
Figure 14 – Heterogeneity in meta-analysis for AS as an underlying condition for IE 
AS: aortic valve stenosis; IE: infective endocarditis 
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7.4.2 AORTIC VALVE INSUFFICIENCY (AI) 
Of the 207 articles considered relevant after the literature review, 39 mentioned AI. 
7.4.2.1 DESCRIPTIVE STATISTICS 
Reference Time Place Cases with (NV)IE Cases (%) with AI % with AI Study Design 
Falase177 1961–1970 Nigeria 90 9 10.0% Retrospective, single centre 
Bailey178 1962–1971 Australia 210 18 8.6% Retrospective, single centre 
Singham179 1968–1977 Malaysia 101 12 11.9% Retrospective, single centre 
Robbins145 1970–1977 USA 56 12 21.4% Retrospective, single centre 
Arbulu180 1968–1984 USA 417 36 26.0% Retrospective, single centre 
Hodes148 1977–1985 Ethiopia 51 1 2.0% Retrospective, single centre 
Blackett181 1984–1986 Cameroon 20 8 40.0% Prospective, single centre 
Mansur149 1978–1986 Brazil 287 15 5.2% Retrospective, single centre 
Van der Meer8 1986–1988 Netherlands 349 64 18.3% Prospective epidemiologic 
study, multicentre 
Agarwal182 1987–1988 India 28 1 3.6% Single centre, probably 
prospective but not clearly 
stated 
Iga183 1980–1989 Japan 32 4 12.5% Retrospective, single centre 
Nissen66 1980–1989 Denmark 132 5 3.8% Retrospective, multicentre 
Thamlikitkul150 1982–1989 Thailand 75 19 25.3% Retrospective, single centre 
Manford184 1983–1989 UK 33 1 3.0% Retrospective, single centre 
Strom9 1988–1990 USA 279 3 1.1% Population-based, case-
control study, multicentre 
Choudhury151 1981–1991 India 186 15 8.1% Retrospective, single centre 
Delahaye71 1990–1991 France 415 27 6.5% Prospective survey, 
multicentre 
Benn152 1984–1993 Denmark 62 5 8.1% Retrospective, multicentre 
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Sandre75 1985–1993 Canada 80 2 2.5% Retrospective review, single 
centre 
Werner76 1989–1993 Germany 106 6 5.7% Retrospective, single centre 
Netzer153 1980–1995 Switzerland 212 40 19.0% Retrospective, single centre 
Lamas79 1985–1996 UK 100 3 3.0% Prospective, single centre 
Castillo81 1987–1997 Spain 95 10 10.0% Prospective case series, single 
centre 
Khanal185 1995–1997 India 46 1 2.2% Prospective observational, 
single centre 
Castillo93 1987–2001 Spain 154 17 10.9% Prospective observational, 
multicentre 
McKay158 1989–2001 New Zealand 29 1 3.4% Retrospective, multicentre 
Garg186 1992–2001 India 192 8 4.2% Retrospective, single centre 
Tariq159 1997–2001 Pakistan 66 1 2.0% Retrospective, single centre 
Cecchi160 2000–2001 Italy 67 6 9.0% Prospective, multicentre 
Rehman187 2000–2001 Pakistan 30 1 3.3% Prospective, single centre 
Murdoch105 2005–2005 ICE cohort 2781 723 26.0% Prospective cohort study, 
multicentre (ICE-PCS) 
Assiri162 2002–2007 Saudi Arabia 44 14 31.8% Retrospective, single centre 
Dzupova118 2007–2008 Czech Republic 134 1 0.7% Prospective, multicentre 
Leone122 2004–2009 Italy 753 32 4.2% Prospective, multicentre 
Nakatani163 2007–2009 Japan 513 76 14.8% Prospective survey, 
multicentre 
Cecchi165 2007–2010 Italy 677 19 2.8% Prospective, multicentre 
Begezsan167 2007–2011 Romania 45 15 33.3% Retrospective, single centre 
Collins168 2008–2011 USA 95 1 1.1% Prospective observational, 
single centre 
Jain188 2011–2013 India 75 17 22.7% Prospective observational, 
single centre 
Table 4 – Literature for AI 
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AI: aortic valve insufficiency/regurgitation; ICE: International Collaboration on Endocarditis; ICE-PCS: International Collaboration on Endocarditis-Prospective Cohort Study; NVIE: native valve 
infective endocarditis 
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Figure 15 – Comparison of study size with prevalence of AI in patients with IE and in association with IE criteria prior to and after modified Duke criteria 
AI: aortic valve insufficiency/regurgitation; IE: infective endocarditis 
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7.4.2.2 REVIEW OF AVAILABLE ECHO TECHNIQUES 
Reference Time Available Echo Technique Definition at the Time 
Falase177 1961–1970 M-Mode (1954)26 
 
 
Bailey178 1962–1971 
Singham179 1968–1977 + B-Mode (2D (1975))34 Danford et al. 1973189: 
Severe: regurgitant flow (named QAr) 1.1–6.5 L/min Robbins145 1970–1977 
Arbulu 180 1968–1984 + Doppler (CW (197936,37), PW (1982)),40 TOE 
(1983)41 
Bonow et al. 1983190: 
Severe: visualisation by aortic root cineangiography (>3+) Hodes148 1977–1985 
Blackett181 1984–1986 
Mansur149 1978–1986 
Van der Meer8 1986–1988 Jaffe et al. 1988191: 
Severe: visualisatioŶ ďǇ aoƌtiĐ ƌoot ĐiŶeaŶgiogƌaphǇ ;шϯ+Ϳ, ‘F ш 30% Agarwal182 1987–1988 
Iga183 1980–1989 
Nissen66 1980–1989 
Thamlikitkul150 1982–1989 
Manford184 1983–1989 
Strom9 1988–1990 
Choudhury151 1981–1991 
Delahaye71 1990–1991 
Benn152 1984–1993 
Sandre75 1985–1993 
Werner76 1989–1993 
Netzer153 1980–1995 + TDI (1994)174,175 
Lamas79 1985–1996 
Castillo81 1987–1997 
Khanal185 1995–1997 
Castillo93 1987–2001 + Real-time 3D first reports in 200143,44 AHA/ACC 1998176 
Mild: not defined 
Moderate: not defined 
McKay158 1989–2001 
Garg186 1992–2001 
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Tariq159 1997–2001 Severe: Austin-Flint rumble, LV dilation (end-diastolic >70 mm, end-
systolic >50 mm), reduced LV function, PHT < 300 ms Cecchi160 2000–2001 
Rehman187 2000–2001 
Murdoch105 2005–2005 + Speckle tracking (strain (2004))45,46 
Assiri162 2002–2007 AHA/ACC 20065 
Mild: jet width < 25% of LVOT, VC < 0.3 cm, RVol < 30 ml/beat, RF < 
30%, effective regurgitant orifice (ERO) < 0.10/m2 
Moderate: jet > mild, no severe AI, VC 0.3–0.6 cm, RVol 30–59 
ml/beat, RF 30–49%, ERO 0.10–0.29/m2 
Severe: jet width > 65% of LVOT, VC > 0.6 cm, ‘Vol ш 60 ml/beat, ‘F ш 
50%, E‘O ш 0.3/m2 
Dzupova118 2007–2008 
Leone122 2004–2009 
Nakatani163 2007–2009 
Cecchi165 2007–2010 
Begezsan167 2007–2011 
Collins168 2008–2011 
Jain188 2011–2013 3D echocardiography recommendations were 
published by EAE/ASE (2012)47 
Table 5 – Echocardiographic definitions of AI for the discussed literature 
2D: two-dimensional; 3D: three-dimensional; AHA/ACC: American Heart Association/American College of Cardiology; AI: aortic valve insufficiency/regurgitation; CW: continuous wave; EAE/ASE: 
European Association of Echocardiography/American Society of Echocardiography; ERO: effective regurgitant orifice; LV: left ventricle; LVOT: left ventricular outflow tract; PHT: pressure half-time; 
PW: pulsed wave; RF: regurgitant fraction; RVol: regurgitant volume; TDI: tissue Doppler imaging; TOE: transoesophageal echocardiography; VC: vena contracta; Vmax: maximum velocity 
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7.4.2.3 SUMMARY OF RESULTS 
In our literature review, no studies with analytical statistics of patients with AI and their risk of 
developing IE could be identified. 
Thirty-nine studies were identified that published descriptive statistics on the proportion of patients 
with a history of AI in newly diagnosed IE cases. Of these studies, eight (20.5%) included patients in 
the study after the publication of the modified Duke criteria. A paired two-tailed t-test for the 
number of studies published before and after 2001 was highly significant, with a p-value of <0.0001. 
The mean number of patients included in the 39 studies was 234 (median 95, IQR 53.5–211), in the 
studies prior to 2001 was 219 (median 95, IQR 53.5–201), and in the studies after 2001 was 292 
(median 114.5, IQR 67.5–554). Of the 39 studies, the mean proportion of patients with a history of AI 
was 10.2% (median 8.1%, IQR 3.1%–16.55%). The distribution prior to 2001 was as follows: mean 
10.2%, median 8.1%, IQR 3.3%–12.2%. After 2001, the numbers were as follows: mean 13.9%, 
median 9.5%, IQR 2.4%–25%. There was no statistical significance between proportions before and 
after 2001. The dot plot does not indicate a typical cluster, making the interpretation of these studies 
difficult. 
Before 1998, visualisation by cineangiogƌaphǇ aŶd ͚eǇeďall guessiŶg͛ of the ƌeguƌgitaŶt ǀoluŵe ǁas 
common. In 2003, with recommendations by the ASE,192 and later in 2006 by implementations in the 
AHA guidelines,5 the echo criteria were published. Since that time, the definition has not changed 
significantly. Eyeballing in transthoracic echocardiography is still common, but requires the skill of an 
experienced investigator and has not found its way into written definitions for the final diagnosis. 
Attention should be paid to inter-examiner variabilities in this context. Finally, finding the correct 
diagnosis almost always means using multimodal measurements and techniques (e.g. magnetic 
Definition of AI Today (AHA/ACC 20142) 
Mild: jet width < 25% of LVOT, VC < 0.3 cm, RVol < 30 ml/beat, RF < 30%, ERO < 0.10/m2 
Moderate: jet 2%–4% of LVOT, VC 0.–.6 cm, RVol 3–9 ml/beat, RF 3%–9%, ERO 0.1–.29/m2 
Severe: jet width > 65% of LVOT, VC > 0.6 Đŵ, ‘Vol ш 60 ml/beat, ‘F ш 50%, E‘O ш 0.3/m2 
Figure 16 – Definition of AI today 
AI: insufficiency/regurgitation; AHA/ACC: American Heart Association/American College of Cardiology;  ERO: effective 
regurgitant orifice; LVOT: left ventricular outflow tract; RF: regurgitant fraction; RVol: regurgitant volume; VC: vena 
contracta 
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resonance imaging [MRI], TOE). Thus, improvement in echo techniques contributed to the 
development of guidelines, and hence, the diagnosis of AI. Given the fact that 80% of publications 
addressed AI as a risk factor prior to the presentation of the modified Duke criteria, overestimation 
of AI as a predisposing condition is possible. The difficulty in assessing AI as a risk factor is reflected in 
the wide IQR of patients with AI and IE in publications after 2001 and the wide distribution in the dot 
plot graph that compares sample size and the prevalence of IE in patients with AI. 
In the preliminary meta-analysis, the proportion of patients with IE and AI as an underlying condition 
was 11.7% (95% CI 11.1%–12.4%) for a fixed effects model and 8.8% (95% CI 5.9%–12.2%) in a 
random effects model. One study contributed greatly to the overall heterogeneity. 
 
 
Figure 17 – Heterogeneity in meta-analysis for AI as an underlying condition for IE 
AI: insufficiency/regurgitation; IE: infective endocarditis 
58 
 
7.4.3 BICUSPID AORTIC VALVE 
Of the 207 articles considered relevant after the literature review, 78 mentioned BAV. 
7.4.3.1 ANALYTICAL STATISTICS 
Verheugt et al.141 described patients from the CONCOR national registry for adults with congenital 
heart disease from the Netherlands. Of 551 patients with BAV, 31 (5.6%) developed IE. This 
correlates to a hazard ratio of 6.3 (95% CI 3.0–13.4). 
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7.4.3.2 DESCRIPTIVE STATISTICS 
Reference Time Place Patients with (NV)IE Cases (n) with BAV Cases (%) with 
BAV  
Study Design 
Mills193 1950   41 3 7.3% Prospective, single centre 
Fenoglio194 1940–1970 USA 152 60 39.5% Retrospective, single centre 
Garvey52 1968–1973 USA 101 3 3.0% Retrospective analysis of 
patient records, autopsy files, 
and files of the infectious 
diseases department 
Thell144 1960–1974 USA 42 5 11.9% Retrospective (pathology 
samples), multicentre 
Welton54 1967–1976 USA 96 3 3.1% Retrospective, single centre 
Cassel195 1974–1976 South Africa 40 2 5.0% Retrospective, single centre 
Auger196 1969–1977 Canada 50 7 14.0% Retrospective, single centre 
Griffin197 1950–1981 USA 78 6 7.7% Retrospective, multicentre 
Rudolph147 Before 1983 Germany 50 4 8.0% Single centre, probably 
prospective 
Terpenning59 1976–1985 USA 154 6 3.9% Retrospective review of patient 
charts, multicentre  
Woo198 1971–1986 Hong Kong 176 1 0.6% Mixed retrospective and 
prospective, single centre 
Steckelberg61 1970–1987 USA 629 N/A 10%–12% Retrospective from 
prospectively collected records, 
multicentre (comparison of a 
population- based cohort vs. 
cohort of Mayo Clinic) 
Varstela63 1976–1987 Finland 58 29 50.0% Retrospective, single centre 
Cheng199 1979–1987 Taiwan 97 2 2.1% Retrospective, single centre 
Borger200 1979–1993 Canada 201 12 6.0% Retrospective, single centre 
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Hogevik65 1984–1988 Sweden 98 7 7.0% Prospective non-randomised, 
single centre 
Kiwan201 1985–1988 Kuwait 60 3 5.0% Prospective, single centre 
Van der Meer8 1986–1988 Netherlands 349 5 1.4% Prospective epidemiologic 
study, multicentre 
Agarwal182 1987–1988 India 28 3 10.7% Single centre, probably 
prospective, but not clearly 
stated 
Strom9 1988–1990 USA 279 5 1.8% Population-based, case-control 
study, multicentre 
Choudhury151 1981–1991 India 186 25 13.4% Retrospective, single centre 
Delahaye71 1990–1991 France 415 2 0.5% Prospective survey, multicentre 
Vlessis202 1982–1992 USA 194 10 5.0% Retrospective, single centre 
Rognon74 1983–1993 Switzerland 179 12 6.7% Retrospective, multicentre 
Sandre75 1985–1993 Canada 80 12 15.0% Retrospective review, single 
centre 
Lamas79 1985–1996 UK 100 26 26.0% Prospective, single centre 
Dyson154 1987–1996 UK 78 13 16.7% Retrospective, single centre 
Jalal203 1982–1997 India 466 55 11.8% Retrospective, single centre 
Lamas204 1970–1998 UK 408 50 12.3% Retrospective, single centre 
Michelena205 1980–1999 USA 212 4 1.9% Prospective, multicentre 
Michelena206,207 1980–1999 USA 486 9 1.9% Retrospective cohort study, 
multicentre 
Tleyjeh87 1970–2000 USA 107 8 7.0% Retrospective (population-
based survey), multicentre 
Alestig89 1984–2000 Sweden 98 7 7.0% Prospective clinical studies 
carried out in Göteborg since 
1984, data obtained from a 
Swedish national registry of IE 
since 1995 and existing 
literature 
Tran208 1998–2000 Denmark 132 10 7.6% Retrospective, single centre 
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Di Filippo156 1966–2001 France 153 4 2.6% Retrospective, single centre 
Tariq157 1988–2001 Pakistan 159 4 2.5% Retrospective, single centre 
McKay158 1989–2001 New Zealand 29 7 24.1% Retrospective, multicentre 
Garg186 1992–2001 India 192 18 9.3% Retrospective, single centre 
Tzemos209 1994–2001 Canada 642 13 2.0% Retrospective, single centre 
Tariq159 1997–2001 Pakistan 66 2 3.0% Retrospective, single centre 
Cecchi160 2000–2001 Italy 67 8 11.9% Prospective, multicentre 
Chu96 1997–2002 New Zealand 65 5 7.7% Retrospective, single centre 
Ferreiros77 2001–2002 Argentina 390 10 2.6% Prospective, multicentre 
Nashmi99 1993–2003 Saudi Arabia 47 1 2.1% Retrospective, single centre 
Hsu100 1995–2003 Taiwan 315 4 1.3% Retrospective review, single 
centre 
Heiro210,211 1980–2004 Finland 326 38 11.7% Retrospective, single centre 
Hill102 2000–2004 Belgium 203 11 5.0% Prospective observational 
cohort study, single centre 
Suzuki212 1988–2005 Japan 27 1 3.7% Retrospective, single centre 
Collins213 2002–2005 Canada 327 5 1.5% Retrospective, single centre 
Correa de Sa107 1970–2006 USA 150 8 5.3% Retrospective, multicentre 
Pazdernik109 1998–2006 Czech Republic 106 14 13.2% Retrospective, single centre 
Kahveci214 2002–2006 Turkey 51 22 43.0% Retrospective, single centre 
Mokhles115 2001–2008 Netherlands 191 8 4.2% Retrospective observational 
cohort study, single centre 
Erbay117 2004–2008 Turkey 107 3 2.8% Retrospective, single centre 
Dzupova118 2007–2008 Czech Republic 134 7 5.2% Prospective, multicentre 
Li215 1998–2009 China 220 40 18.2% Retrospective, single centre 
Fernandez-
Hidalgo121 
2000–2009 Spain 337 19 5.6% Prospective observational 
cohort study, single centre 
Tribouilloy216 2005–2009 France 148 4 2.7% Prospective, observational, 
multicentre 
Tribouilloy216 2005–2009 France 310 50 16.2% Prospective, observational, 
multicentre 
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Nakatani163 2007–2009 Japan 513 24 4.7% Prospective survey, multicentre 
Lu217 1998–2010 Australia 148 18 12.0% Retrospective observational 
study, single centre 
Marks164 1998–2010 UK 336 36 10.7% Retrospective observational 
cohort study, single centre 
Gupta128 2005–2010 India 83 10 16.4% Retrospective, single centre 
Senthilkumar218 2008–2010 India 116 5 4.3% Prospective, single centre 
Sadaka219 2009–2010 Egypt 50 1 2.0% Prospective, single centre 
Ma166 2002–2011 China 115 9 7.8% Single centre 
Collins168 2008–2011 USA 95 18 19.0% Prospective observational, 
single centre 
Collins168 2008–2011 USA 95 11 11.6% Prospective observational, 
single centre 
Turak135 2009–2011 Turkey 122 4 3.0% Retrospective, single centre 
Verheugt141 Before 2011 Netherlands 551 31 5.6% Prospective cohort study, 
multicentre 
Baek220 1987–2012 South Korea 325 1 0.3% Retrospective, single centre 
Elbey221 2005–2012 Turkey 158 5 3.2% Retrospective, multicentre 
Simsek-Yavuz138 2000–2013 Turkey 325 18 5.5% Prospective 102 (first 5 years) 
and retrospective 223 
thereafter, single centre 
Gupta140 2010–2013 India 109 11 10.1% Retrospective, single centre 
Jain188 2011–2013 India 75 4 5.3% Prospective observational, 
single centre 
Table 6 – Literature for BAV: Patients with IE with BAV as an underlying condition 
 
BAV: bicuspid aortic valve; IE: infective endocarditis; N/A: not available; NVIE: native valve infective endocarditis 
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Figure 18 – Comparison of study size with prevalence of BAV in patients with IE and in association with IE criteria prior to and after modified Duke criteria 
BAV: bicuspid aortic valve; IE: infective endocarditis 
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7.4.3.3 REVIEW OF AVAILABLE ECHO TECHNIQUES 
Reference Time Available Echo Technique Definition Then 
Fenoglio194 1940–1970 M-Mode (1954)26  
Garvey52 1968–1973  
Thell144 1960–1974  
Welton54 1967–1976 + B-Mode (2D (1975))34  
Cassel195 1974–1976  
Auger196 1969–1977  
Griffin197 1950–1981 + Doppler (CW (1979))36,37  
Rudolph147 Before 1983 + PW (1982)40   
Terpenning59 1976–1985 + TOE (1983)41  
Woo198 1971–1986  
Steckelberg61 1970–1987  
Varstela63 1976–1987  
Cheng199 1979–1987  
Hogevik65 1984–1988  
Kiwan201 1985–1988  
Van der Meer8 1986–1988  
Agarwal182 1987–1988  
Strom9 1988–1990  
Choudhury151 1981–1991  
Delahaye71 1990–1991  
Vlessis202 1982–1992  
Borger200 1979–1993  
Rognon74 1983–1993  
Sandre75 1985–1993  
Lamas79 1985–1996 + TDI (1994)174,175  
Dyson154 1987–1996  
Jalal203 1982–1997  
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Lamas204 1970–1998  
Michelena205 1980–1999  
Michelena206,207 1980–1999  
Tleyjeh87 1970–2000  
Alestig89 1984–2000  
Tran208 1998–2000  
Di Filippo156 1966–2001 + Real-time 3D first reports in 200143,44  
Tariq157 1988–2001  
McKay158 1989–2001  
Garg186 1992–2001  
Tzemos209 1994–2001  
Tariq159 1997–2001  
Cecchi160 2000–2001  
Chu96 1997–2002  
Ferreiros77 2001–2002  
Nashmi99 1993–2003  
Hsu100 1995–2003  
Heiro210,211 1980–2004 + Speckle tracking (strain (2004))45,46  
Hill102 2000–2004  
Suzuki212 1988–2005  
Collins213 2002–2005  
Correa de Sa107 1970–2006  
Pazdernik109 1998–2006  
Mokhles115 2001–2008  
Erbay117 2004–2008  
Dzupova118 2007–2008  
Li215 1998–2009  
Fernandez-
Hidalgo121 
2000–2009  
Tribouilloy216 2005–2009  
Nakatani163 2007–2009  
Lu217 1998–2010  
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Marks164 1998–2010  
Gupta128 2005–2010  
Senthilkumar218 2008–2010  
Sadaka219 2009–2010  
Ma166 2002–2011  
Collins168 2008–2011  
Turak135 2009–2011  
Verheugt141 Before 2011  
Baek220 1987–2012 + 3D echocardiography recommendations were published by EAE/ASE (2012)47  
Elbey221 2005–2012  
Simsek-Yavuz138 2000–2013  
Gupta140 2010–2013  
Jain188 2011–2013  
Table 7 – Echocardiographic criteria for BAV for the discussed literature 
2D: two-dimensional; 3D: three-dimensional; CW: continuous wave; EAE/ASE: European Association of Echocardiography/American Society of Echocardiography; PW: pulsed wave; TDI: tissue 
Doppler imaging; TOE: transoesophageal echocardiography 
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Figure 19 – Definition of BAV today 
AHA/ACC: American Heart Association/American College of Cardiology; BAV: bicuspid aortic valve 
 
 
7.4.3.4 SUMMARY OF RESULTS 
We identified one study showing that a history of BAV was associated with a higher risk of IE, with a 
hazard ratio of 6.3.141  
Seventy-seven studies were identified that published descriptive statistics on the proportion of 
patients with a history of BAV in newly diagnosed IE cases. Of these studies, 20 (26%) included 
patients in the study after the publication of the modified Duke criteria. A paired two-tailed t-test of 
the number of studies published before and after 2001 was highly significant, with a p-value of 
<0.0001. The mean number of patients included in the 77 studies was 185 (median 134, IQR 79–
249.5), in the studies prior to 2001 was 185 (median 150, IQR 72.5–249.5), and in the studies after 
2001 was 187 (median 119, IQR 95–221). Of the 77 studies, the mean proportion of patients with a 
history of previous IE was 8.8% (median 5.6%, IQR 3%–12%). The distribution prior to 2001 was as 
follows: mean 8.9%, median 7.0%, IQR 3%–12%. After 2001, the numbers were as follows: mean 
8.6%, median 5.0%, IQR 3%–10%. The differences between groups were not significant in an 
unpaired t-test. The dot plot graph that compares the prevalence of IE in patients with BAV and the 
sample size in each study indicates a pattern with a publication bias of less than 30% among the 
included studies. The majority of studies, including those with large sample sizes, indicate a median 
prevalence of approximately 5%.  
BAV is visually detectable by fluoroscopy, but with the introduction of echocardiography, whose use 
was first published in 1974 by Nanda et al.,222 it was possible to more easily and more quickly make a 
diagnosis in a non-invasive manner. In 1974, the authors used M-Mode echocardiography, which is 
not the standard technique today. Consequently, the improvements in echo technique by means of 
2D or 3D echocardiography, TOE, better transducers, and high-definition screens has surely 
influenced the presence or absence of BAV in the reviewed studies. Imaging techniques such as MRI 
and computed tomography-angiography play another important role today. Nonetheless, there are 
no obvious indications that the improvement in technique influenced the presence or absence of 
BAV in the reviewed studies.  
Definition of BAV Today: (AHA/ACC 20142) 
Fusion of aortic valve cusps in different positions 
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In the preliminary meta-analysis, the proportion of patients with IE and BAV as an underlying 
condition was 5.8% (95% CI 5.4%–6.2%) for a fixed effects model and 7.1% (95% CI 5.7%–8.7%) in a 
random effects model. As a few studies contributed greatly to the overall heterogeneity, a second 
meta-analysis with stricter clinical inclusion/exclusion criteria is planned. 
 
Figure 20 – Heterogeneity in meta-analysis for BAV as an underlying condition for IE 
BAV: bicuspid aortic valve; IE: infective endocarditis 
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7.5 MITRAL VALVE 
7.5.1 MITRAL VALVE PROLAPSE (MVP) 
Of the 207 articles considered relevant after the literature review, 111 mentioned MVP. 
7.5.1.1 ANALYTICAL STATISTICS 
Clemens et al. presented 51 patients with IE from Yale-New Haven Hospital (USA) from 1976 to 1980. 
In a case-control study with 153 matched controls without IE, 25% of patients had MVP compared 
with 10% of the controls. The odds ratio for developing IE with MVP was 8.2, indicating a 
substantially higher risk of IE for people with MVP than for people without it.20 
Devereux et al.223 described 31 patients with MI from 1980 to 1983 and 67 patients with native valve 
IE from 1978 to 1982 from the USA. In addition, they reported 81 consecutive relatives with MVP, 
196 population controls, and 2146 clinical controls. They described the odds ratio for developing IE 
with MVP as 4.6 to 4.8 (depending on the control group). With a matched-triplets analysis, the odds 
ratio was 6.7 (95% CI 1.96–22.9). 
MacMahon et al.224 reported 19 patients with IE and MVP from Australia between 1976 and 1984, as 
well as 57 control subjects with MVP. They reported that the relative risk of IE associated with the 
presence of a systolic murmur in a patient with MVP was 13.0 (95% CI 2.1–79.0). The absolute risk of 
developing IE in a patient with MVP and a systolic murmur was 0.0007 per year (95% CI 0.0004–
0.0014). The lifetime risk of IE in a patient with MVP and a murmur increased by 1% every 15 years. 
The absolute risk of IE occurring in a patient with MVP without murmur was estimated to be 0.00002 
per year. 
Danchin et al.225 reported 48 cases of mitral valve IE from 1981 to 1986 from CHU Nancy-Brabois 
(France). Nine (19%) of the patients with mitral valve IE had MVP. Six (6%) of 96 controls had MVP. 
For this reason, the authors stated that the risk of developing IE was three times higher in patients 
with MVP than without MVP. The risk was 14 times higher for patients with MVP and a systolic 
murmur, and there was no increased risk for patients with MVP without a murmur. In patients 
without rheumatic heart disease, the risk of developing IE was increased by 27 times for patients 
with MVP and a murmur compared with healthy controls, and it was increased by six times in 
patients with MVP and no murmur.  
Strom et al.9 reviewed 279 cases of IE from 1988 to 1990 from 54 hospitals in Delaware Valley (USA). 
Compared with that in the controls, the odds ratio of developing IE with MVP was 19.2. 
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Zuppiroli et al.226 reported 275 patients with MVP from 1979 to 1996 from Italy with a mean follow-
up of 98 months, with a total of 2245 patient-years. One patient developed IE, which resulted in a 
rate of 1/2500 patient-years. The authors stated that the risk of IE among MVP patients was about 8 
times that in the general population, but the risk in their study was relatively low compared with 
other reports. 
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7.5.1.2 DESCRIPTIVE STATISTICS 
Reference Time Place Patients with 
(NV)IE 
Cases with MVP % with MVP Study Design 
Mills227 1950s and 1960s   53 3 5.7% Retrospective, single centre 
Thell144 1960–1974 USA 42 2 4.8% Retrospective (pathology samples), 
multicentre 
Lowes53 1966–1975 UK 60 3 5.0% Retrospective survey, single centre 
Corrigall228 1969–1975 USA 87 10 11.5% Retrospective, single centre 
Cassel195 1974–1976 South Africa 40 5 12.5% Retrospective, single centre 
Grossman146 1951–1979 Israel 228 5 2.2% Retrospective, single centre 
Nishimura229 1975–1979 USA 237 3 1.3% Prospective, single centre 
Tresch230 Before 1979   40 4 10.0% Single centre 
Hammel56 1971–1980 Switzerland 31 7 22.6% Single centre, not indicated whether 
prospective or retrospective 
Venezio57 1972–1980 USA 32 3 9.4% Retrospective, single centre 
Griffin197 1950–1981 USA 78 13 17.0% Retrospective, multicentre 
Roucaut231 1970–1982 France 350 14 4.0% Retrospective, single centre 
Beton21 Before 1983 UK 182 8 4.4% Prospective, single centre 
Rudolph147 Before 1983 Germany 50 10 20.0% Single centre, probably prospective 
Duren232 1963–1983 Netherlands 300 24 8.0% Prospective, single centre 
Devereux223 1980–1983 USA 67 11 16.4% Case-control study, single centre 
MacMahon224 1976–1984 Australia 136 19 14.0% Prospective matched case-control 
study, multicentre 
Skehan233 1982–1984 UK 198 38 19.0% Prospective, multicentre 
Terpenning59 1976–1985 USA 154 14 9.1% Retrospective review of patient charts, 
multicentre  
Vered234 Before 1985 Israel 42 5 11.9% Retrospective, single centre 
Naggar235 Before 1986 USA 145 7 4.8% Retrospective, single centre 
Peat236 1976–1986 New Zealand 78 5 6.4% Retrospective, single centre 
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Mansur149 1978–1986 Brazil 287 26 9.1% Retrospective, single centre 
Wells237 1979–1986 New Zealand 102 11 10.8% Retrospective, single centre 
Zuppiroli226 1979–1986 Italy 316 2 0.6% Prospective observational, single centre 
Danchin225 1981–1986 France 102 9 8.8% Retrospective case-control study, single 
centre 
Marks238 1982–1986 USA 456 11 2.4% Retrospective, single centre 
Steckelberg61 1970–1987 USA 697 N/A 15-17% Retrospective from prospectively 
collected records, multicentre 
(comparison of a population- based 
cohort vs. cohort of Mayo Clinic) 
Weinberger23 1970–1987 Israel 135 19 14.0% Retrospective, single centre 
Cheng199 1979–1987 Taiwan 97 11 11.3% Retrospective, single centre 
Manford184 1983–1987 UK 33 1 3.0% Retrospective, single centre 
Hogevik65 1984–1988 Sweden 98 7 7.0% Prospective non-randomised, single 
centre 
Kiwan201 1985–1988 Kuwait 60 5 8.3% Prospective, single centre 
Van der Meer8 1986–1988 Netherlands 349 29 8.3% Prospective epidemiologic study, 
multicentre 
Nissen66 1980–1989 Denmark 132 0 0.0% Retrospective, multicentre 
Thamlikitkul150 1982–1989 Thailand 75 5 6.7% Retrospective, single centre 
Schon67 1980–1989 Germany 51 6 11.8% Retrospective, single centre 
Watanakunakorn69 1980–1990 USA 181 12 6.6% Retrospective 1980–1985, prospective 
1986–1990, single centre 
Strom9 1988–1990 USA 279 52 18.6% Population-based, case-control study, 
multicentre 
Choudhury151 1981–1991 India 186 2 1.1% Retrospective, single centre 
Delahaye71 1990–1991 France 415 13 3.1% Prospective survey, multicentre 
Tornos73 1975–1992 Spain 194 20 10.3% Prospective observational, single centre 
Vlessis202 1982–1992 USA 194 22 11.4% Retrospective, single centre 
Benn152 1984–1993 Denmark 62 1 1.6% Retrospective, multicentre 
Sandre75 1985–1993 Canada 80 10 13.0% Retrospective review, single centre 
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Kim239 1986–1993 Japan 229 1 0.4% Prospective, single centre 
Werner76 1989–1993 Germany 106 7 6.6% Retrospective, single centre 
Siddiq240 1990–1993 USA 159 5 3.1% Prospective, single centre 
Yeo241 1991–1993 Singapore 98 5 5.1% Retrospective, single centre 
Ferreiros77 1992–1993 Argentina 294 28 9.5% Prospective registry, multicentre 
Borer242 1980–1994 Israel 71 7 9.9% Retrospective, single centre 
Weng78 1984–1994 Taiwan 109 9 8.3% Retrospective, single centre 
Netzer153 1980–1995 Switzerland 212 11 5.0% Retrospective, single centre 
Zuppiroli226 1979–1996 Italy 275 1 0.4% Prospective observational, single centre 
Lamas 79 1985–1996 UK 100 6 6.0% Prospective, single centre 
Dyson154 1987–1996 UK 78 9 11.5% Retrospective, single centre 
Bouza80 1994–1996 Spain 109 1 0.9% Prospective observational case series, 
single centre 
Jalal203 1982–1997 India 466 4 0.9% Retrospective, single centre 
Castillo81 1987–1997 Spain 95 8 8.0% Prospective case series, single centre 
Khanal185 1995–1997 India 46 2 4.3% Prospective observational, single centre 
Cetinkaya84 1974–1999 Turkey 228 5 2.2% Retrospective (hospital charts) review, 
single centre 
Ako243 1980–1999 Japan 194 13 6.7% Single centre, retrospective (admission 
records) 
Fefer85 1990–1999 Israel 108 9 12.0% Retrospective (medical records), single 
centre 
Hoen244 1999 France 390 35 9.0% Retrospective population based survey, 
multicentre 
Tleyjeh87 1970–2000 USA 107 18 17.0% Retrospective (population-based 
survey), multicentre 
Alestig 89 1984–2000 Sweden 98 7 7.0% Prospective clinical studies carried out 
in Göteborg since 1984, data obtained 
from a Swedish national registry of IE 
since 1995 and existing literature 
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Koegelenberg91,92 1997–2000 South Africa 47 1 2.1% Prospective observational study, single 
centre 
Loupa245 1997–2000 Greece 101 2 2.0% Prospective, multicentre 
Di Filippo156 1966–2001 France 153 4 2.6% Retrospective, single centre 
Castillo93 1987–2001 Spain 154 20 12.7% Prospective observational, multicentre 
Tariq157 1988- 2001 Pakistan 159 10 6.3% Retrospective, single centre 
McKay158 1989–2001 New Zealand 29 3 10.3% Retrospective, multicentre 
Garg186 1992–2001 India 192 6 3.1% Retrospective, single centre 
Tariq159 1997–2001 Pakistan 66 5 8.0% Retrospective, single centre 
Cecchi160 2000–2001 Italy 67 25 37.3% Prospective, multicentre 
Rehman187 2000–2001 Pakistan 30 3 10.0% Prospective, single centre 
Chu96 1997–2002 New Zealand 65 4 6.1% Retrospective, single centre 
Yousuf97 2000–2002 Malaysia 45 2 4.4% Retrospective analysis of case records, 
single centre 
Ferreiros77 2001–2002 Argentina 390 36 9.2% Prospective, multicentre 
Heiro210,211 1980–2004 Finland 326 33 10.1% Retrospective, single centre 
Hill102 2000–2004 Belgium 203 19 9.0% Prospective observational cohort study, 
single centre 
Yiu246 1995–2005 Hong Kong 172 14 8.1% Retrospective cohort, single centre 
Correa de Sa107 1970–2006 USA 150 25 16.7% Retrospective, multicentre 
Knudsen247 2000–2006 Denmark 172 5 2.9% Prospective, single centre 
Math248 2004–2006 India 104 3 2.9% Prospective observational study, single 
centre 
Tugcu110 1997–2007 Turkey 28 2 7.1% Retrospective review, single centre 
Assiri162 2002–2007 Saudi Arabia 44 2 4.5% Retrospective, single centre 
Wong113 2002–2007 New Zealand 57 8 14.0% Retrospective review, single centre 
Scudeller249 2004–2008 Italy 254 27 10.6% Prospective observational, multicentre 
Castillo250 1987–2009 Spain 228 30 13.0% Prospective, single centre 
Nakagawa251 1990–2009 Japan 112 10 8.9% Retrospective, single centre 
Li215 1998–2009 China 220 40 18.2% Retrospective, single centre 
Sun252 2000–2009 South Korea 328 82 25.0% Retrospective, single centre 
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Nakatani163 2007–2009 Japan 513 55 10.7% Prospective survey, multicentre 
Hajihossainlou253 1995–2010 Iran 286 71 24.8% Retrospective, multicentre 
Lu217 1998–2010 Australia 148 7 5.0% Retrospective observational study, 
single centre 
Poesen127 2003–2010 Belgium 88 1 1.1% Retrospective, single centre 
Gupta128 2005–2010 India 83 2 3.3% Retrospective, single centre 
Cecchi165 2007–2010 Italy 677 45 6.7% Prospective, multicentre 
Senthilkumar218 2008–2010 India 116 7 6.0% Prospective, single centre 
Sadaka219 2009–2010 Egypt 50 1 2.0% Prospective, single centre 
Ma166 2002–2011 China 115 12 10.4% Single centre 
Al Abri254 2006–2011 Oman 48 8 13.8% Single centre, retrospective 
(computerised activity register) 
Collins168 2008–2011 USA N/A N/A 7.0% Prospective observational, single centre 
Collins168 2008–2011 USA 95 5 5.3% Prospective observational, single centre 
Turak135 2009–2011 Turkey 122 5 4.0% Retrospective, single centre 
Elbey221 2005–2012 Turkey 158 9 5.7% Retrospective, multicentre 
Watt255 2010–2012 Thailand 132 19 14.4% Prospective observational, multicentre 
Gupta140 2010–2013 India 109 8 7.3% Retrospective, single centre 
Jain188 2011–2013 India 75 5 6.7% Prospective observational, single centre 
Table 8 – Literature for MVP: Patients with IE with MVP as an underlying condition 
IE: infective endocarditis; MVP: mitral valve prolapse; N/A: not available; NVIE: native valve infective endocarditis 
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Figure 21 – Comparison of study size with prevalence of MVP in patients with IE and in association with IE criteria prior to and after modified Duke criteria 
IE: infective endocarditis; MVP: mitral valve prolapse 
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7.5.1.3 REVIEW OF AVAILABLE ECHO TECHNIQUES 
Reference Time Available Echo Technique Definition at the Time 
 
Mills227 1950s and 
1960s 
M-Mode (1954)26 Barlow et al. (1966, 1968)256,257: 
Clinical: mid- to late systolic click 
Pathological: 
- excessive myxomatous tissue 
- annular dilatation 
- leaflet thickening  
- bileaflet prolapse 
- chordal lengthening 
- frequently, valvular tissue calcification 
 
Engle et al. (1969)258: 
ECG: abnormal T-waves and late systolic click 
 
Popp et al. (1974)259: 
Echo: during systole the normal pattern of gradual anterior migration of the closed 
mitral leaflets is replaced by the pattern of an initial horizontal, slight anterior, or 
posterior motion, followed by an abrupt posterior motion 
Thell144 1960–1974 
Lowes53 1966–1975 + B-Mode (2D (1975))34 Weiss et al. (1975)260: 
Echo: mid-systolic buckling and pansystolic hammock-like posterior motion of the valve 
leaflets  
 
Devereux et al. (1976)261: 
Echo: late systolic prolapse of one or both leaflets can be directly visualised by 
echocardiography as posterior movement interrupting the normal anterior motion  
 
Nishimura et al. (1985, years including 1975-1979)229: 
Echo (M-Mode):  
- 3 mm or more below the C-D line (line of coaptation) 
- leaflet thiĐkŶess шϱ mm 
Corrigall228 1969–1975 
Cassel195 1974–1976 
Grossman146 1951–1979 + Doppler (CW (1979))36,37 
Nishimura229 1975–1979 
Tresch230 Before 1979 
Hammel56 1971–1980 
Venezio57 1972–1980 
Griffin197 1950–1981 
Roucaut231 1970–1982 + PW (1982)40 
Rudolph147 Before 1983 
Beton21 Before 1983 
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Duren232 1963–1983 
Devereux223 1980–1983 + TOE (1983)41 
MacMahon224 1976–1984 
Skehan233 1982–1984 
Vered234 Before 1985 
Terpenning59 1976–1985 
Peat236 1976–1986 
Mansur149 1978–1986 
Wells237 1979–1986 
Zuppiroli226 1979–1986 
Danchin225 1981–1986 
Marks238 1982–1986 
Naggar235 Before 1986 
Steckelberg61 1970–1987 Barron et al. (1987/1988)262: 
Echo: MVP was diagnosed by systolic motion of either or both mitral valve leaflets 
beyond the plane of the mitral ring into the left atrium in both the parasternal long-axis 
and apical four-chamber views (at least 1–2 mm) 
Weinberger23 1970–1987 
Cheng199 1979–1987 
Manford184 1983–1987 
Hogevik65 1984–1988 
Kiwan201 1985–1988 
Van der Meer8 1986–1988 
Nissen66 1980–1989 
Thamlikitkul150 1982–1989 
Schon67 1980–1989 
Watanakunakorn69 1980–1990 
Strom9 1988–1990 
Choudhury151 1981–1991 
Delahaye71 1990–1991 
Tornos73 1975–1992 
Vlessis202 1982–1992 
Benn152 1984–1993 
Sandre75 1985–1993 
Kim239 1986–1993 
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Werner76 1989–1993 
Siddiq240 1990–1993 
Ferreiros77 1992–1993 
Borer242 1980–1994 + TDI (1994)174,175 
Weng78 1984–1994 
Netzer153 1980–1995 
Zuppiroli226 1979–1996 
Lamas 79 1985–1996 
Dyson154 1987–1996 
Bouza80 1994–1996 
Jalal203 1982–1997 
Castillo81 1987–1997 
Khanal185 1995–1997 
Cetinkaya84 1974–1999 AHA/ACC 1998176: 
Clinical: midsystolic click, frequently followed by a late systolic murmur 
ECG: 
- often normal 
- non-specific ST-T wave changes, T-wave inversion, prominent U waves, and QT 
prolongation can occur 
Echo: 
- no consensus on the 2D echocardiographic criteria for MVP  
- M-Mode eĐho defiŶitioŶ of MVP iŶĐludes шϮ ŵŵ posteƌioƌ displaĐeŵeŶt of oŶe oƌ 
both leaflets or holosystolic posterior ͚ham-mocking͛ шϯ ŵŵ 
- 2D echo: high likelihood of MVP if systolic displacement of one or both mitral leaflets 
in the parasternal long-axis view, particularly when they coapt on the atrial side of the 
annular plane  
- MVP is more certain when leaflet thickness is >5 mm 
- on Doppler MVP is more likely when MR is detected as a high-velocity eccentric jet in 
late systole  
- definition should include structural changes such as leaflet thickening, redundancy, 
annular dilatation, and chordal elongation  
 
Ako243 1980–1999 
Fefer85 1990–1999 
Yeo241 1991–1993 
Hoen244 1999 
Tleyjeh87 1970–2000 
Alestig 89 1984–2000 
Koegelenberg91,92 1997–2000 
Loupa245 1997–2000 
Di Filippo156 1966–2001 + Real-time 3D first 
reports in 200143,44 Castillo93 1987–2001 
Tariq157 1988–2001 
McKay158 1989–2001 
Garg186 1992–2001 
Tariq159 1997–2001 
Cecchi160 2000–2001 
Rehman187 2000–2001 
Chu96 1997–2002 
Yousuf97 2000–2002 
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Ferreiros77 2001–2002 
Heiro210,211 1980–2004 + Speckle tracking (strain 
(2004))45,46 Hill102 2000–2004 
Yiu246 1995–2005 
Correa de Sa107 1970–2006 AHA/ACC 2006176: 
Clinical: 
- principal auscultatory feature is the midsystolic click (a high-pitched sound of short 
duration), may be followed by a late systolic murmur that is usually medium to high-
pitched and loudest at the cardiac apex 
- no further testing is recommended without clinical signs  
 
ECG: 
- usually normal 
- non-specific ST-T wave changes, T-wave inversions, prominent Q waves, and 
prolongation of the QT interval also occur  
 
Echo: 
- 2D and Doppler echo is the most useful non-invasive test for defining MVP 
-  valve prolapse of 2 mm or more above the mitral annulus in the long-axis parasternal 
view and other views, especially when the leaflet coaptation occurs on the atrial side of 
the annular plane, indicates a high likelihood of MVP  
- leaflet thickness of 5 mm or more indicates abnormal leaflet thickness and its added 
presence makes MVP even more certain  
- leaflet redundancy is often associated with an enlarged mitral annulus and elongated 
chordae tendineae  
- absence or presence of MR is an important consideration and MVP is more likely 
when MR is detected as a high-velocity eccentric jet in late systole 
Knudsen247 2000–2006 
Math248 2004–2006 
Tugcu110 1997–2007 
Assiri162 2002–2007 
Wong113 2002–2007 
Scudeller249 2004–2008 
Castillo250 1987–2009 
Nakagawa251 1990–2009 
Li215 1998–2009 
Sun252 2000–2009 
Nakatani163 2007–2009 
Hajihossainlou253 1995–2010 
Lu217 1998–2010 
Poesen127 2003–2010 
Gupta128 2005–2010 
Cecchi165 2007–2010 
Senthilkumar218 2008–2010 
Sadaka219 2009–2010 
Ma166 2002–2011 
Al Abri254 2006–2011 
Collins168 2008–2011 
Turak135 2009–2011 
Elbey221 2005–2012 3D echocardiography 
recommendations were 
published by EAE/ASE 
(2012)47 
Watt255 2010–2012 
Gupta140 2010–2013 
Jain188 2011–2013 
Table 9 – Echocardiographic definitions of MVP for the discussed literature 
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2D: two-dimensional; 3D: three-dimensional; AHA/ACC: American Heart Association/American College of Cardiology; CW: continuous wave; EAE/ASE: European Association of 
Echocardiography/American Society of Echocardiography; ECG: electrocardiogram; MR: mitral regurgitation; MVP: mitral valve prolapse; PW: pulsed wave; TDI: tissue Doppler imaging; TOE: 
transoesophageal echocardiography 
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7.5.1.4 SUMMARY OF RESULTS 
We identified six studies showing that a history of MVP was associated with a higher risk of IE. One 
study was excluded because of small patient numbers.224 Two studies reported an odds ratio of 
approximately 8,20,226 one an odds ratio of 3,225 another an odds ratio of 6.7,223 and another an odds 
ratio of 19.2.9 However, all studies were performed prior to the release of the modified Duke criteria 
(published 2000). 
A total of 110 studies were identified that published descriptive statistics on the proportion of 
patients with MVP in newly diagnosed IE cases. Of these studies, 20 (18.2%) included patients in the 
study after the publication of the modified Duke criteria. A paired two-tailed t-test of the number of 
studies published before and after 2001 was highly significant, with a p-value of <0.0001. The mean 
number of patients included in the 110 studies was 160 (median 111, IQR 72–202), in the studies 
prior to 2001 was 158 (median 122, IQR 68–210), and in the studies after 2001 was 166 (median 107, 
IQR 81–139). Of the 110 studies, the mean proportion of patients with MVP was 8.5% (median 7.7%, 
IQR 4.4%–11.4%). The distribution prior to 2001 was as follows: mean 8.8%, median 8.1%, IQR 4.4%–
11.5%. After 2001, the numbers were as follows: mean 7.28%, median 6.7%, IQR 4.4%–10.5%. The 
differences between the groups were not significant in an unpaired t-test. The dot plot graph shows 
a cloud consisting of studies with a sample size of less than 200 and a prevalence ranging from 1% to 
13%.  
The 1998 definition stated that there was no consensus on the 2D echocardiographic criteria for MVP 
and no single view should be considered diagnostic.176 Valve prolapse of шϮ ŵŵ, leaflet thiĐkŶess 
;iŶĐƌeasiŶg ĐeƌtaiŶtǇ ǁith thiĐkŶess шϱ ŵŵ), and redundancy were, however, diagnostic criteria. The 
guidelines in 2006 changed in that the long-axis parasternal view was mentioned first and the 
disagreement concerning the reliability of the echocardiographic appearance of anterior leaflet 
billowing, only observed in the four-chamber view, was emphasised. In 1987, Levine et al.263 found 
that the mitral annulus is not a plane but in particular a ͚saddle-shaped͛ stƌuĐtuƌe. The M-Mode 
Definition of MVP Today: (AHA/ACC 20142) 
In contrast to the AHA/ACC 2006 guidelines5, MVP is not precisely described in the 2014 
guideliŶes ďut suďsuŵed uŶdeƌ ͚pƌiŵaƌǇ M‘͛. 
Figure 22 – Definition of MVP today 
AHA/ACC: American Heart Association/American College of Cardiology; MR: mitral regurgitation; MVP: mitral valve 
prolapse 
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technique would not satisfy that anatomical fact in a supportive way. The authors were ultimately 
not able to propose a certain view to diagnose MVP, but they stated that it would be judicious to rely 
on the parasternal long-axis view because overdiagnosis of MVP could be avoided. The strict use of 
the parasternal long axis has the limitation that only the A2 and P2 are well seen in this axis and 
prolapse can involve any other part of the valve.264 Meanwhile, the echo technique improved and 
with 3D echocardiography, ǁe aƌe Ŷoǁ aďle to deteĐt MVP eǀeŶ ŵoƌe pƌeĐiselǇ. Thus, fƌoŵ todaǇ͛s 
perspective, there is a tendency to believe that the prevalence of MVP was overestimated prior to 
the publication of modified Duke criteria. Nonetheless, we cannot judge the influence of technique 
development on the diagnosis of MVP as a risk factor for IE, despite the numerous publications.  
In the preliminary meta-analysis, the proportion of patients with IE and mitral valve stenosis (MS) as 
an underlying condition was 7.2% (95% CI 6.8%–7.6%) for a fixed effects model and 7.5% (95% CI 
6.3%–8.7%) in a random effects model. As a few studies contributed greatly to the overall 
heterogeneity, a second meta-analysis with stricter clinical inclusion/exclusion criteria is planned. 
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Figure 23 – Heterogeneity in meta-analysis for MVP as an underlying condition for IE 
IE: infective endocarditis; MVP: mitral valve prolapse 
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7.5.2 MITRAL VALVE STENOSIS (MS) 
Of the 207 articles considered relevant after the literature review, 23 mentioned MS. 
7.5.2.1 DESCRIPTIVE STATISTICS 
Reference Time Place Patients with (NV)IE Cases (%) with MS % with MS Study Design 
Falase177 1961–1970 Nigeria 90 5 5.6% Retrospective, single centre 
Bailey178 1962–1971 Australia 210 9 4.3% Retrospective, single centre 
Singham179 1968–1977 Malaysia 101 3 3.0% Retrospective, single centre 
Hodes148 1977–1985 Ethiopia 51 3 5.9% Retrospective, single centre 
Mansur149 1978–1986 Brazil 287 11 3.8% Retrospective, single centre 
Blackett181 1984–1986 Cameroon 20 4 20.0% Prospective, single centre 
Van der Meer8 1986–1988 Netherlands 349 3 0.9% Prospective epidemiologic 
study, multicentre 
Iga183 1980–1989 Japan 32 2 6.3% Retrospective, single centre 
Thamlikitkul150 1982–1989 Thailand 75 13 17.3% Retrospective, single centre 
Roberts70 1954–1991 USA 104 4 3.8% Retrospective, multicentre 
Delahaye71 1990–1991 France 415 4 1.0% Prospective survey, 
multicentre 
Benn152 1984–1993 Denmark 62 8 12.9% Retrospective, multicentre 
Werner76 1989–1993 Germany 106 6 5.7% Retrospective, single centre 
Cheng199 1994–1999 Australia 40 2 5.0% Retrospective, multicentre 
Castillo93 1987–2001 Spain 154 13 8.5% Prospective observational, 
multicentre 
Tariq157 1988–2001 Pakistan 159 1 0.6% Retrospective, single centre 
Tariq159 1997–2001 Pakistan 66 5 8.0% Retrospective, single centre 
Cecchi160 2000–2001 Italy 67 2 3.0% Prospective, multicentre 
Assiri162 2002–2007 Saudi Arabia 44 12 27.3% Retrospective, single centre 
Dzupova118 2007–2008 Czech Republic 134 1 0.7% Prospective, multicentre 
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Leone122 2004–2009 Italy 753 3 0.4% Prospective, multicentre 
Nakatani163 2007–2009 Japan 513 12 2.3% Prospective survey, 
multicentre 
Cecchi165 2007–2010 Italy 677 17 2.5% Prospective, multicentre 
Table 10 – Literature for MS 
MS: mitral valve stenosis; NVIE: native valve infective endocarditis 
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Figure 24 – Comparison of study size with prevalence of MS in patients with IE and in association with IE criteria prior to and after modified Duke criteria 
IE: infective endocarditis; MS: mitral valve stenosis 
7.5.2.2 REVIEW OF AVAILABLE ECHO TECHNIQUES 
Reference Time Available Echo Technique Definition at the Time 
Falase177 1961–1970 M-Mode (1954)26 Kennedy et al. (1970)265: 
MVA < 2.5 cm2 Bailey178 1962–1971 
Singham179 1968–1977 + B-Mode (2D (1975))34 
Hodes148 1977–1985 
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Mansur149 1978–1986 + Doppler (CW (1979),36,37 PW (1982)),40 
TOE (1983)41 Blackett181 1984–1986 
Van der Meer8 1986–1988 Jaffe et al. (1988)191: 
Severe: MVA < 1.5 cm2, MPG ш 12 mmHg Iga183 1980–1989 
Thamlikitkul150 1982–1989 
Roberts70 1954–1991 
Delahaye71 1990–1991 
Benn152 1984–1993 
Werner76 1989–1993 
Cheng199 1994–1999 + TDI (1994)174,175 AHA/ACC 1998176: 
Mild: MVA > 1.5 cm2, ŵeaŶ ΔP < 5 mmHg 
Moderate: MVA 1.0–1.5 cm2, ŵeaŶ ΔP ш 5 mmHg, sPAP > 50 mmHg 
Severe: MVA < 1.0 cm2, sPAP > 60 mmHg 
Castillo93 1987–2001 + Real-time 3D first reports in 200143,44 
Tariq157 1988–2001 
Tariq159 1997–2001 
Cecchi160 2000–2001 
Assiri162 2002–2007 + Speckle tracking (strain (2004))45,46 AHA/ACC 20065: 
Mild: ŵeaŶ ΔP < 5 mmHg, sPAP < 30 mmHg, MVA > 1.5 cm2 
Modeƌate: ŵeaŶ ΔP ϱ–10 mmHg, sPAP 30–50 mmHg, MVA 1.0–1.5 
cm2 
Seǀeƌe: ŵeaŶ ΔP > 10 mmHg, sPAP > 50 mmHg, MVA < 1.0 cm2 
Dzupova118 2007–2008 
Leone122 2004–2009 
Nakatani163 2007–2009 
Cecchi165 2007–2010 
Table 11 – Echocardiographic definitions of MS for discussed literature 
ΔP: pressure difference; 2D: two-dimensional; 3D: three-dimensional; AHA/ACC: American Heart Association/American College of Cardiology; CW: continuous wave; MPG: Mean-Pressure-Gradient; 
MVA: mitral valve area; PW: pulsed wave; sPAP: systolic pulmonary pressure; TDI: tissue Doppler imaging; TOE: transoesophageal echocardiography 
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7.5.2.3 SUMMARY OF RESULTS 
In the literature review, no studies reporting an odds ratio for patients with MS and developing IE 
were identified. 
Twenty-three studies were identified that published descriptive statistics on the proportion of 
patients with MS in newly diagnosed IE cases. Of these studies, five (21.7%) included patients after 
the publication of the modified Duke criteria. A paired two-tailed t-test of the number of studies 
published before and after 2001 was significant, with a p-value of 0.004, although more patients 
(absolute numbers) were included in studies after the presentation of the Duke criteria. The mean 
number of patients included in the 23 studies was 196 (median 104, IQR 64–249), in the studies prior 
to 2001 was 133 (median 96, IQR 63–158), and in the studies after 2001 was 424 (median 513, IQR 
134–667). Of the 23 studies, the mean proportion of patients with MS was 6.5% (median 4.3%, IQR 
3.2%–7.6%). The distribution prior to 2001 was as follows: mean 6.4%, median 5.3%, IQR 3.2%–7.6%. 
After 2001, the numbers were as follows: mean 6.6%, median 2.3%, IQR 0.7%–2.5%. The difference 
between groups was not significant in an unpaired t-test. Similarly, the dot plot graph indicates that 
with increasing sample size number in the corresponding studies with definitions in accordance with 
the modified Duke criteria, the prevalence of IE iŶ patieŶts ǁith MS is чϭ%. 
MS has been a well-known entity.266 With the help of echocardiography and especially continuous 
wave Doppler imaging (CW Doppler, 1979), a non-invasive diagnosis and grading of MS became 
easier and could be performed bedside. The definition of MS has not changed since the introduction 
of CW Doppler, but the gradient was made easier to determine. Since then, it cannot be firmly 
concluded that the imaging technique has influenced the diagnosis of MS as a predisposing heart 
condition for IE. 
Definition Today: (AHA/ACC 20142) 
Mild: MVA > 1.5 cm2, diastolic PHT < 150 ms 
Severe: MVA ч 1.5 cm2, diastoliĐ PHT ш 150 ms 
Very seǀeƌe: MVA ч 1.0 cm2, diastoliĐ PHT ш 220 ms 
Figure 25 – Definition of MS today 
AHA/ACC: American Heart Association/American College of Cardiology; MVA: mitral valve area; PHT: pressure half-time 
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In the preliminary meta-analysis, the proportion of patients with IE and MS as an underlying 
condition was 2.12% (95% CI 1.7%–2.6%) for a fixed effects model and 4.3% (95% CI 2.7%–6.2%) in a 
random effects model. As a few studies contributed greatly to the overall heterogeneity, a second 
meta-analysis with stricter clinical inclusion/exclusion criteria is planned. 
 
 
 
Figure 26 – Heterogeneity in meta-analysis for MS as an underlying condition for IE 
IE: infective endocarditis; MS: mitral valve stenosis 
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7.5.3 MITRAL VALVE INSUFFICIENCY (MI) 
Of the 207 articles considered relevant after the literature review, 41 mentioned MI. 
7.5.3.1 DESCRIPTIVE STATISTICS 
Reference Time Place Patients with (NV)IE Cases with MI % with MI Study Design 
Falase177 1961–1970 Nigeria 90 17 18.9% Retrospective, single centre 
Bailey178 1962–1971 Australia 210 22 10.5% Retrospective, single centre 
Lowes53 1966–1975 UK 60 18 30.0% Retrospective survey, single centre 
Corrigall228 1969–1975 USA 87 18 20.7% Retrospective, single centre 
Singham179 1968–1977 Malaysia 101 16 15.8% Retrospective, single centre 
Robbins145 1970–1977 USA 56 16 28.6% Retrospective, single centre 
Hodes148 1977–1985 Ethiopia 51 4 7.8% Retrospective, single centre 
Mansur149 1978–1986 Brazil 287 56 16.0% Retrospective, single centre 
Blackett181 1984–1986 Cameroon 20 7 35.0% Prospective, single centre 
Cheng199 1979–1987 Taiwan 97 16 16.5% Retrospective, single centre 
Van der Meer8 1986–1988 Netherlands 349 89 25.5% Prospective epidemiologic study, 
multicentre 
Agarwal182 1987–1988 India 28 2 7.1% Single centre, probably prospective, 
but not clearly stated 
Iga183 1980–1989 Japan 32 11 34.4% Retrospective, single centre 
Nissen66 1980–1989 Denmark 132 0 0.0% Retrospective, multicentre 
Thamlikitkul150 1982–1989 Thailand 75 35 46.7% Retrospective, single centre 
Manford184 1983–1989 UK 33 5 15.2% Retrospective, single centre 
Strom9 1988–1990 USA 279 3 1.1% Population-based, case-control 
study, multicentre 
Choudhury151 1981–1991 India 186 9 4.8% Retrospective, single centre 
Delahaye71 1990–1991 France 415 51 12.3% Prospective survey, multicentre 
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Rognon74 1983–1993 Switzerland 179 47 26.3% Retrospective, multicentre 
Werner76 1989–1993 Germany 106 5 4.7% Retrospective, single centre 
Netzer153 1980–1995 Switzerland 212 38 18.0% Retrospective, single centre 
Lamas79 1985–1996 UK 100 5 5.0% Prospective, single centre 
Cheng155 1994–1999 Australia 40 7 17.5% Retrospective, multicentre 
Di Filippo156 1966–2001 France 153 8 5.2% Retrospective, single centre 
McKay158 1989–2001 New Zealand 29 1 3.4% Retrospective, multicentre 
Garg186 1992–2001 India 192 3 1.6% Retrospective, single centre 
Tariq159 1997–2001 Pakistan 66 2 3.0% Retrospective, single centre 
Cecchi160 2000–2001 Italy 67 3 4.5% Prospective, multicentre 
Rehman187 2000–2001 Pakistan 30 5 16.7% Prospective, single centre 
Durante-Mangoni161 2000–2005 ICE cohort 2759 N/A 38%–57% Prospective, multicentre (ICE cohort) 
Murdoch105 2000–2005 ICE cohort 2781 1196 43.0% Prospective cohort study, 
multicentre (ICE-PCS) 
Math248 2004–2006 India 104 10 9.6% Prospective observational study, 
single centre 
Assiri162 2002–2007 Saudi Arabia 44 18 40.9% Retrospective, single centre 
Dzupova118 2007–2008 Czech Republic 134 5 3.7% Prospective, multicentre 
Leone122 2004–2009 Italy 753 80 10.6% Prospective, multicentre 
Nakatani163 2007–2009 Japan 513 145 28.3% Prospective survey, multicentre 
Cecchi165 2007–2010 Italy 677 60 8.9% Prospective, multicentre 
Begezsan167 2007–2011 Romania 45 17 37.8% Retrospective, single centre 
Elbey221 2005–2012 Turkey 148 142 95.9% Retrospective, multicentre 
Jain188 2011–2013 India 75 28 37.3% Prospective observational, single 
centre 
Table 12 – Literature for MI 
ICE: International Collaboration on Endocarditis; ICE-PCS: International Collaboration on Endocarditis-Prospective Cohort Study; MI: mitral valve insufficiency/regurgitation; N/A: not available; 
NVIE: native valve infective endocarditis  
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Figure 27 – Comparison of study size with prevalence of MI in patients with IE and in association with IE criteria prior to and after modified Duke criteria 
IE: infective endocarditis; MI: mitral valve insufficiency/regurgitation 
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7.5.3.2 REVIEW OF AVAILABLE ECHO TECHNIQUES 
Reference Time Available Echo 
Technique 
Definition at the Time 
Falase177 1961–1970 M-Mode (1954)26 Kennedy et al. 1970265: 
MR > 2L/min Bailey178 1962–1971 
Lowes53 1966–1975 + B-Mode (2D 
(1975))34 Corrigall228 1969–1975 
Singham179 1968–1977 
Robbins145 1970–1977 
Hodes148 1977–1985 + Doppler (CW 
(1979),36,37 PW 
(1982)),40 TOE 
(1983)41 
Mansur149 1978–1986 
Blackett181 1984–1986 
Cheng199 1979–1987 
Van der Meer8 1986–1988 Jaffe et al. 1988191: 
Seǀeƌe: ‘F ш 30%, cardiac catheterisatioŶ ш 3+ Agarwal182 1987–1988 
Iga183 1980–1989 
Nissen66 1980–1989 
Thamlikitkul150 1982–1989 
Manford184 1983–1989 
Strom9 1988–1990 
Choudhury151 1981–1991 
Delahaye71 1990–1991 
Rognon 1983–1993 
Werner76 1989–1993 
Netzer153 1980–1995 + TDI (1994)174,175 
Lamas79 1985–1996 
Cheng155 1994–1999 
Di Filippo156 1966–2001 + Real-time 3D first 
reports in 200143,44 McKay158 1989–2001 
Garg186 1992–2001 
Tariq159 1997–2001 
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Cecchi160 2000–2001 
Rehman187 2000–2001 
Durante-
Mangoni161 
2000–2005 + Speckle tracking 
(strain (2004))45,46 
Murdoch105 2000–2005 
Math248 2004–2006 AHA/ACC 20065: 
Mild: jet < 4 cm2 or < 20% LA, VC < 0.3 cm, RVol < 30 ml, RF < 30%, ERO < 0.2 cm2 
Moderate: jet > mild but no severe MI, VC 0.3–0.69 cm, RVol 30–59 ml, RF 30%–49%, ERO 0.2– 
0.39 cm2 
Severe: jet > ϰϬ% LA oƌ ǁall iŵpiŶgiŶg, VC ш 0.7 Đŵ, ‘Vol ш 60 ŵl, ‘F ш ϱϬ%, E‘O ш 0.40 cm2 
Assiri162 2002–2007 
Dzupova118 2007–2008 
Leone122 2004–2009 
Nakatani163 2007–2009 
Cecchi165 2007–2010 
Begezsan167 2007–2011 
Elbey221 2005–2012 + 3D 
echocardiography 
recommendations 
were published by 
EAE/ASE (2012)47 
Jain188 2011–2013 
Table 13 – Echocardiographic definitions of MI for discussed literature 
2D: two-dimensional; 3D: three-dimensional; AHA/ACC: American Heart Association/American College of Cardiology; CW: continuous wave; EAE/ASE: European Association of 
Echocardiography/American Society of Echocardiography; ERO: effective regurgitant orifice; LA: Left atrium; MI: mitral valve insufficiency/regurgitation; MR: mitral regurgitation; PW: pulsed 
wave; RF: regurgitant fraction; RVol: regurgitant volume; TDI: tissue Doppler imaging; TOE: transoesophageal echocardiography; VC: vena contracta 
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7.5.3.3 SUMMARY OF RESULTS 
In the literature review, no studies reporting analytical statistics for patients with MI for developing 
IE could be identified. 
Forty-one studies were identified that published descriptive statistics on the proportion of patients 
with MI in newly diagnosed IE cases. Of these studies, nine (22%) included patients in the study after 
the publication of the modified Duke criteria. A paired two-tailed t-test of the number of studies 
published before and after 2001 was significant, with a p-value pf 0.0001. The mean number of 
patients included in the 41 studies was 288 (median 101, IQR 56–210), in the studies prior to 2001 
was 291 (median 99, IQR 55–197), and in the studies after 2001 was 277 (median 134, IQR 75–513). 
Of the 41 studies, the mean proportion of patients with a history of previous IE was 19.9% (median 
16%, IQR 5.2%–28.6%). The distribution prior to 2001 was as follows: mean 17%, median 15.9%, IQR 
5%–25.7%. After 2001, the numbers were as follows: mean 30.3%, median 28.3%, IQR 9.6%–37.8%. 
The difference between the groups was not significant in an unpaired t-test. The dot plot indicates 
that there are many studies with a publication bias. This may be also be because the research 
question is difficult to answer in this constellation. For example, some studies may represent that 
their patients developed MI because of IE and not that MI was a risk factor for developing IE.  
The definitions of the graduation of MI was implemented rather late in the guidelines 2006,5 again 
after the recommendations by ASE.192 Echo criteria were mentioned earlier in the AHA guidelines in 
1998 concerning the time of surgery and considering LV diameters.176 It can be concluded that the 
development of echo techniques and, with that, improvements in imaging most likely played an 
important role in defining MI.   
In the preliminary meta-analysis, the proportion of patients with IE and MI as an underlying condition 
was 2.7% (95% CI 2.6%–2.7%) for a fixed effects model and 1.7% (95% CI 1.1%–2.3%) in a random 
Definition of MI Today: (AHA/ACC 20142) 
At risk: jet < 20% LA on Doppler, VC < 0.3 cm 
Progressive: central jet 20%–40% LA, VC < 0.7 cm, RVol < 60 ml, RF < 50%, ERO < 0.4 cm2 
Severe: central jet > ϰϬ% LA, VC ш 0.7 Đŵ, ‘Vol ш 60 ml, ‘F ш ϱϬ%, E‘O ш 0.40 cm2 
Figure 28 – Definition of MI today 
AHA/ACC: American Heart Association/American College of Cardiology; ERO: effective regurgitant orifice; LA: left atrium; MI: 
mitral valve insufficiency/regurgitation; RF: regurgitant fraction; RVol: regurgitant volume; VC: vena contracta 
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effects model. As a few studies contributed greatly to the overall heterogeneity, a second meta-
analysis with stricter clinical inclusion/exclusion criteria is planned. 
 
Figure 29 – Heterogeneity in meta-analysis for MI as an underlying condition for IE 
IE: infective endocarditis; MI: mitral valve insufficiency/regurgitation 
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7.6 TRICUSPID VALVE 
Of the 207 articles considered relevant after the literature review, nine mentioned TI or TS. 
7.6.1 DESCRIPTIVE STATISTICS 
Reference Time Place Patients with IE Cases with TI/TS % with TI/TS Study Design 
Blackett181 1984–1986 Cameroon 20 1 5% Prospective, single centre 
Van der Meer8 1986–1988 Netherlands 349 19 5.4% Prospective epidemiologic study, multicentre 
Thamlikitkul150 1982–1989 Thailand 75 8 10.7% Retrospective, single centre 
Delahaye71 1990–1991 France 415 1 0.2% Prospective survey, multicentre 
Garg186 1992–2001 India 192 4 2.1% Retrospective, single centre 
Rehman187 2000–2001 Pakistan 30 1 3.3% Prospective, single centre 
Assiri162 2002–2007 Saudi Arabia 44 8 18.2% Retrospective, single centre 
Nakatani163 2007–2009 Japan 513 13 2.5% Prospective survey, multicentre 
Begezsan167 2007–2011 Romania 45 7 15.5% Retrospective, single centre 
Table 14 – Literature for TI/TS 
IE: infective endocarditis; TI: tricuspid valve insufficiency/regurgitation; TS: tricuspid valve stenosis 
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Figure 30 – Comparison of study size with prevalence of TI/TS in patients with IE and in association with IE criteria prior to and after modified Duke criteria 
IE: infective endocarditis; TI: tricuspid valve insufficiency/regurgitation; TS: tricuspid valve stenosis 
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7.6.1.1 REVIEW OF AVAILABLE ECHO TECHNIQUES 
Reference Time Available Echo 
Technique 
Definition at the Time 
Blackett181 1984–1986 M-Mode 
(1954),26 B-Mode 
(2D (1975)),34 
Doppler (CW 
(1979),36,37 PW 
(1982)),40 TOE 
(1983)41 
Various publications 1970s and 1980s267-271: 
 
Insufficiency: 
clinical and ECG definition of severe insufficiency, mostly post-tƌauŵa aŶd EďsteiŶ͛s anomaly 
 
Stenosis: 
no data 
Van der Meer8 1986–1988 
Thamlikitkul150 1982–1989 
Delahaye71 1990–1991 
Garg186 1992–2001 + TDI 
(1994),174,175 
Real-time 3D first 
reports in 
200143,44 
AHA/ACC 1998176: 
not defined Rehman187 2000–2001 
Assiri162 2002–2007 + Speckle 
tracking (strain 
(2004))45,46 
AHA/ACC 20065: 
Severe insufficiency: VC > 0.7 cm, hepatic vein flow: systolic reversal 
Severe stenosis: valve area < 1.0 cm2 
Nakatani163 2007–2009 
Begezsan167 2007–2011 
Table 15 – Echocardiographic definitions of TI/TS for discussed literature 
2D: two-dimensional; 3D: three-dimensional; AHA/ACC: American Heart Association/American College of Cardiology; CW: continuous wave; ECG: electrocardiogram; PW: pulsed wave; TDI: tissue 
Doppler imaging; TOE: transoesophageal echocardiography; VC: vena contracta 
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7.6.2 SUMMARY OF RESULTS 
No studies reporting an odds ratio for patients with TI or TS for developing IE could be identified. 
Nine studies were identified that published descriptive statistics on the proportion of patients with a 
history of IE in newly diagnosed IE cases. Of these studies, three included patients in the study after 
the publication of the modified Duke criteria. The mean number of patients included in the nine 
studies was 187 (median 75, IQR 44–349), in the studies prior to 2001 was 180 (median 134, IQR 41–
310), and in the studies after 2001 was 201 (median 45, IQR 44.5–279). Of the nine studies, the mean 
proportion of patients with TS or TI was 7% (median 5%, IQR 2.5%–10.7%). The distribution prior to 
2001 was as follows: mean 4.5%, median 4.2%, IQR 2.4%–5.3%. After 2001, the numbers were as 
follows: mean 12.1%, median 15.5%, IQR 9%–16.9%. The dot plot graph indicates that the prevalence 
is low and that at least three studies may have a publication bias. 
Severe TI/TS was first described in the guidelines 2006.272 The recent guidelines from 20142 gave a 
more precise definition of the different grades of TI/TS (defining mild, moderate, and severe), 
whereas for the clinician, mild and moderate play a subordinate role. Evolution of echocardiography 
techniques was crucial for the new definitions, but even more for finding the real cause of TI, which 
is often secondary, particularly in the context of right ventricle dysfunction and dilatation. The 
Definition of TI/TS Today: (AHA/ACC 20142) 
Insufficiency 
Mild: central jet area < 5 cm2, VC not defined 
Moderate: central jet 5–10 cm2, VC not defined but <0.7 cm, hepatic vein flow: systolic blunting 
Severe: central jet > 10 cm2, VC > 0.7 cm, hepatic vein flow: systolic reversal 
 
Stenosis 
Severe: PHT ш 190 ms, valǀe aƌea ч 1.0 cm2 
Figure 31 – Definition of TI/TS today 
AHA/ACC: American Heart Association/American College of Cardiology; PHT: pressure half-time; TI: tricuspid valve 
insufficiency/regurgitation; TS: tricuspid valve stenosis; VC: vena contracta 
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relevance of the development of this technique in light of the few studies and low incidence of IE is 
difficult to estimate. 
In the preliminary meta-analysis, the proportion of patients with IE and TI/TS as an underlying 
condition was 2.3% (95% CI 1.6%–3.2%) for a fixed effects model and 4.9% (95% CI 1.9%–9.0%) in a 
random effects model. A few studies contributed greatly to the overall heterogeneity. Because of the 
limited number of studies, however, no further evaluation is planned. 
 
 
Figure 32 – Heterogeneity in meta-analysis for TI/TS as an underlying condition for IE 
IE: infective endocarditis; TI: tricuspid valve insufficiency/regurgitation; TS: tricuspid valve stenosis 
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7.7 PULMONARY VALVE 
Of the 207 articles considered relevant after the literature review, 18 mentioned PS or PI. 
 
7.7.1 ANALYTICAL STATISTICS 
Verheugt et al.141 described patients from the CONCOR national registry for adults with congenital 
heart disease from the Netherlands. Of 778 patients with congenital PS, three (0.39%) developed IE. 
This equals a hazard ratio of 1.1 (95% CI 0.3–4.0). 
 
7.7.2 DESCRIPTIVE STATISTICS 
Dodo et al.273 reported 186 patients with disease resulting in high-velocity flow over pulmonary 
and/or tricuspid valves. They found only one patient with IE (and one IVDU), resulting in a rate of 
0.61 episodes per 1000 patient-years, or 0.54% of patients. They stated that those instances might be 
at low risk or no risk for IE. 
Gersony et al.142 described 592 patients with PS from the Second Natural History Study of Congenital 
Heart Defects conducted in the USA between 1958 and 1965. They reported a prevalence rate of 
16.9 per 10,000 patients (95% CI 0.4–94.1). Follow-up was conducted for 10,688 person-years, with 
an incidence rate of 0.9 per 10,000 person-years (95% CI 0.02–5.2). They stated that this is a very low 
incidence of infection. 
Hayes et al.274 described 592 patients with PS from the Second Natural History Study of Congenital 
Heart Defects conducted in the USA between 1958 and 1969. They reported that IE did not occur 
during follow-up and concluded that IE is a rare condition for patients with PS. 
 
 
 
 
 
 
 
104 
 
Reference Time Place Patients with 
(NV)IE 
Cases with PI or 
PS 
% with 
PI/PS 
Study Design 
Gersony142 1958–1965 USA 592 1 0.2% Prospective cohort study, multicentre 
Cassel195 1974–1976 South Africa 40 1 2.5% Retrospective, single centre 
Singham179 1968–1977 Malaysia 101 2 2.0% Retrospective, single centre 
Sawae275 1964–1983 Japan 91 2 2.2% Retrospective, multicentre 
Woo198 1971–1986 Hong Kong 176 2 1.1% Mixed retrospective and prospective, single 
centre 
Mansur149 1978–1986 Brazil 287 2 0.7% Retrospective, single centre 
Van der 
Meer8 
1986–1988 Netherlands 349 1 0.3% Prospective epidemiologic study, multicentre 
Verheul276 1966–1991 Netherlands 141 15 10.6% Retrospective, single centre 
Choudhury151 1981–1991 India 186 2 1.1% Retrospective, single centre 
Lamas79 1985–1996 UK 100 1 1.0% Retrospective, single centre 
Jalal203 1982–1997 India 466 2 0.4% Retrospective, single centre 
Dodo273 Before 
1998 
  186 1 0.5% Prospective, observational, single centre 
Di Filippo156 1966–2001 France 153 1 0.6% Retrospective, single centre 
Rehman187 2000–2001 Pakistan 30 1 3.3% Prospective, single centre 
Nashmi99 1993–2003 Saudi Arabia 47 2 4.2% Retrospective, single centre 
Nakatani163 2007–2009 Japan 513 1 0.2% Prospective survey, multicentre 
Verheugt141 Before 
2011 
The 
Netherlands 
778 3 0.4% Prospective cohort study, multicentre 
Table 16 – Literature for PI/PS: Patients with IE with PS/PI as an underlying condition 
IE: infective endocarditis; NVIE: native valve infective endocarditis; PI: pulmonary valve insufficiency/regurgitation; PS: pulmonary valve stenosis 
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Figure 33 – Comparison of study size with prevalence of PI/PS in patients with IE and in association with IE criteria prior to and after modified Duke criteria 
IE: infective endocarditis; PI: pulmonary valve insufficiency/regurgitation; PS: pulmonary valve stenosis 
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7.7.2.1 REVIEW OF AVAILABLE ECHO TECHNIQUES 
Reference Time Available Echo 
Technique 
Definition at the Time 
Gersony142 1958–1965 M-Mode (1954),26  
Cassel195 1974–1976 + B-Mode (2D 
(1975))34 
Johnson et al. (1972)277: 
 
Stenosis: 
Mild:  right ventricle systolic pressure > 50 mmHg  
Moderate: 50–99 mmHg 
Severe: > 100 mmHg 
 
Insufficiency: no data 
Singham179 1968–1977 
Sawae275 1964–1983 + Doppler (CW 
(1979),36,37 PW 
(1982)),40 TOE 
(1983)41 
Woo198 1971–1986 
Mansur149 1978–1986 
Van der Meer8 1986–1988 
Verheul276 1966–1991 
Choudhury151 1981–1991 
Lamas79 1985–1996 + TDI (1994)174,175 
Jalal203 1982–1997 
Dodo273 Before 1998 
Di Filippo156 1966–2001 + Real-time 3D first 
reports in 200143,44 
AHA/ACC 1998176: 
not defined Rehman187 2000–2001 
Nashmi99 1993–2003 
Nakatani163 2007–2009 + Speckle tracking 
(strain (2004))45,46 
AHA/ACC 20065: 
 
Severe insufficiency: 
colour jet fills outflow tract; dense continuous wave Doppler signal with a steep deceleration 
slope 
 
Severe stenosis: 
Vmax > 4 m/s or maximum gradient > 60 mmHg 
Verheugt141 Before 2011 
Table 17 – Echocardiographic definitions of PI/PS for discussed literature 
2D: two-dimensional; 3D: three-dimensional; AHA/ACC: American Heart Association/American College of Cardiology; CW: continuous wave; PW: pulsed wave; TDI: tissue Doppler imaging; TOE: 
transoesophageal echocardiography; Vmax: maximum velocity. 
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7.7.3 SUMMARY OF RESULTS 
We identified one study analysing the risk of developing IE in patients with congenital PS, reporting a 
hazard ratio of 1.1.141 No studies for PI or other aetiologies of PS were identified in the literature 
review. 
Seventeen studies were identified that published descriptive statistics on the proportion of patients 
with a history of IE in newly diagnosed IE cases. Of these studies, two included patients in the study 
after the publication of the modified Duke criteria. A paired two-tailed t-test of the number of 
studies published before and after 2001 was significant, with a p-value of 0.0002. The mean number 
of patients included in the 17 studies was 249 (median 176, IQR 100–349), in the studies prior to 
2001 was 196 (median 153, IQR 95.5–236.5), and in the studies after 2001 was 645.5 (median 645.5, 
IQR 579.3–711.8). Of the 17 studies, the mean proportion of patients with a history of previous IE 
was 1.8% (median 1%, IQR 0.4%–2.2%). The distribution prior to 2001 was as follows: mean 2%, 
median 1.1%, IQR 0.57%–2.35%. After 2001, the numbers were as follows: mean 0.3%, median 0.3%, 
IQR 0.2%–0.3%. The difference between groups was not significant in an unpaired t-test. Similarly, 
the dot plot graph indicated a very low prevalence throughout all studies. 
As mentioned earlier (in the chapter on TI/TS [7.6]), the development of echo techniques played a 
role in defining PI/PS. Regarding the publications listed earlier, PI was first defined in the guidelines in 
20065 and profited most from advanced echo techniques because, with the help of colour Doppler, PI 
can be made easily visible. PS is most important when considering congenital heart disease. The 
clinical role in adults, however, is less important and may result from rare causes, such as carcinoid 
plaques.278 
The relevance of this technique development in light of the few studies and low incidence of IE is 
difficult to estimate. 
Definition of PS/PI Today: (AHA/ACC 20142) 
Severe insufficiency: colour jet fills right ventricular outflow tract, CW jet dense, steep 
deceleration, may terminate abruptly 
Severe stenosis: Vmax > 4 m/s, peak instantaneous gradient > 64 mmHg 
Figure 34–- Definition of PS/PI today 
AHA/ACC: American Heart Association/American College of Cardiology; CW: continuous wave; PI: pulmonary valve 
insufficiency/regurgitation; PS: pulmonary valve stenosis; Vmax: maximum velocity 
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In the preliminary meta-analysis, the proportion of patients with IE and TI/TS as an underlying 
condition was 0.4% (95% CI 0.2%–0.7%) for a fixed effects model and 0.9% (95% CI 0.3%–1.7%) in a 
random effects model. A few studies contributed greatly to the overall heterogeneity. Because of the 
limited number of studies, however, no further evaluation is planned. 
 
 
Figure 35 – Heterogeneity in a meta-analysis for PI/PS as an underlying condition for IE 
IE: infective endocarditis; PI: pulmonary valve insufficiency/regurgitation; PS: pulmonary valve stenosis 
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7.8 QUESTIONNAIRE 
In total, 318 questionnaires were received and included for analysis. 
7.8.1 DATE OF FINAL EXAMINATION IN MEDICAL SCHOOL 
In total, 98% of participants answered this question (Fehler! Verweisquelle konnte nicht gefunden 
werden., page Fehler! Textmarke nicht definiert.). As shown in Figure 36 (page 109), most 
participants passed their state examination after 2000. 
 
Figure 36 – Year of final examination of participants 
 
To quantify the clinical experience of study participants, we formed three groups: little experience 
(1–2 years, from 2014), intermediate experience (3–5 years, 2011–2013), and experienced 
professionals (>5 years, final examination before 2011). This does not account for gap years or years 
in clinical research, but because of the limited information on the working experience of our study 
participants, a more detailed analysis is not possible. Thirteen participants (4.2%) had 1–2 years of 
experience, 60 (19.2%) had 2–5 years of experience, and 237 (75.7%) were very experienced, having 
clinical experience of more than 5 years. 
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Figure 37 – Years of clinical experience of participants 
 
 
7.8.2 APPOINTMENTS OF STUDY PARTICIPANTS 
In total, 93.3% of participants responded to the question: What is your current appointment? Of 
these, 50% were in postgraduate training for a medical speciality. In 31.8% of the questionnaire 
responders, a double specialisation (i.e. internal medicine and cardiology) was indicated, and in 
12.9% of responders, postgraduate training for their second specialisation was notable (data shown 
below). This is well in line with the majority of our study participants having extensive clinical 
experience, as noted in the previous section. 
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Figure 38 – Appointments 
 
A total of 306 participants (96.2%) indicated the size of institution in which they are employed. The 
majority of participants work at a cantonal hospital. Approximately one-third of the participants work 
at a university hospital, and only a minority work at regional hospitals or in private practice. 
 
Figure 39 – Place of employment 
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7.8.3 INVOLVEMENT OF DIAGNOSTIC OR THERAPY OF IE 
In total, 290 participants (91.2%) indicated whether or not they are involved in the diagnostics or 
therapy of IE in clinical practice; 90% of the responders answered this question with a ͚yes͛. 
7.8.4 SPECIALISATION 
A total of 286 participants (90%) indicated their specialisation. The vast majority (176 participants, 
61.5%) of participants completed training in general internal medicine. As noted previously, of these 
176 participants, 91 (31.8% of total participants) completed training in two specialities, and 37 
(12.9%) are currently in training for a second speciality. Fifty-one participants (17.8%) completed 
training in infectious diseases and 35 (12.2%) in cardiology. Only 19 participants (6.6%) completed a 
different type of training (seven in nephrology, four in endocrinology/diabetology, two in 
anaesthesiology, two in intensive care, two in oncology, one in rheumatology, one in angiology). In 
most cases, this was in addition to training in general internal medicine. 
 
Figure 40 – Specialisation of participants 
GIM: general internal medicine 
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7.8.5 QUESTION 1 
Question 1 was a knowledge question. Physicians were asked what – according to their knowledge – 
a predisposing heart condition is. 
A total of 306 participants (96.2%) answered this question, of which 296 answers (96.7%) were 
reasonable. In 10 questionnaires, the answers could not be interpreted by the study team. The total 
is >100% because multiple answers were possible. To calculate the percentage, we used the number 
of participants who answered this question. 
Forty-five participants (14.7%) indicated at least one wrong answer. A wrong answer was defined as 
an answer that did not include heart conditions (e.g. IVDU, immunosuppression, in-dwelling 
catheter), as we specifically asked for heart conditions. The rate of wrong answers for each specialty 
was not different (internal medicine, 14.2%; cardiology, 15.7%; infectious diseases, 14.3%; other, 
15.8%). In addition, the same analysis was conducted for the appointments of the participants, with 
no difference in the rate of wrong answers (registrars, 15.3%; consultants, 13.5%; lead physicians, 
14.3%; head of departments, 11.8%). There was a difference in analysis for years of clinical 
experience: 30.7% wrong answers for 1–2 years of clinical experience, 11.7% for 3–5 years of clinical 
experience, and 14.3% for >5 years of clinical experience. 
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Answer (More Than 1 Possible) Number of Participants % 
IVDU 33 10.8 
Prior IE 99 32.4 
AI 31 10.1 
AS 35 11.4 
BAV 39 12.7 
MI 39 12.7 
MS 27 8.8 
MVP 37 12.1 
PI 20 6.5 
PS 14 4.6 
TI 25 8.2 
TS 17 5.6 
Foreign body material (devices, pacemakers, valve 
replaceŵeŶts…) 
205 67.0 
Previous heart surgery (without foreign body material, or 
not specified) 
12 3.9 
Heart transplant 9 2.9 
Defect leading to significant turbulence 8 2.6 
Dilatative cardiomyopathy 1 0.3 
Obstructive cardiomyopathy 4 1.3 
Heart failure 10 3.3 
Vitium (not specified) 50 16.3 
GUCH 58 19.0 
Shunt 48 15.7 
Valve vitium 80 26.1 
Cyanotic heart defect 25 8.2 
Rheumatic heart disease 28 9.2 
Degenerative valve disease 16 5.2 
Immunosuppression 10 3.3 
In-dwelling catheter 2 0.7 
Table 18 – Answers to Question 1 
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AI: aortic valve insufficiency/regurgitation; AS: aortic valve stenosis; BAV: bicuspid aortic valve; IE: infective endocarditis; 
GUCH: grown-up with congenital heart disease; IVDU: intravenous drug user; MI: mitral valve insufficiency/regurgitation; 
MS: mitral valve stenosis; MVP: mitral valve prolapse; PI: pulmonary valve insufficiency/regurgitation; PS: pulmonary valve 
stenosis; TI: tricuspid valve insufficiency/regurgitation; TS: tricuspid valve stenosis 
 
 
 Wrong Answers Participants in Group % 
Internal medicine 25 176 14.2 
Cardiology 8 51 15.7 
Infectious diseases 5 35 14.3 
Other 3 19 15.8 
Table 19 – Wrong answers to Question 1 analysed by speciality 
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Figure 41 – Statistical analysis of speciality compared with rate of wrong answers in Q1, ANOVA 
ANOVA: analysis of variance; Q1: Question 1 
 
 
 
 Wrong Answers Participants in Group % 
Registrar 23 150 15.3 
Consultant 10 74 13.5 
Lead physician 7 49 14.3 
Head of department 2 17 11.8 
Table 20 – Wrong answers to Question 1 analysed by appointment 
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Figure 42 – Statistical analysis of rate of wrong answers in Q1 and appointments of participants, ANOVA 
ANOVA: analysis of variance; Q1: Question 1 
 
 
 Wrong Answers Participants in Group % 
1–2 years 4 13 30.8 
3–5 years 7 60 11.7 
>5 years 34 237 14.3 
Table 21 – Question 1 wrong answers analysed by years of clinical experience 
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Figure 43 – Statistical analysis of rate of wrong answers and years of clinical experience, t-test 
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Figure 44 – Statistical analysis of average years of clinical experience of participants with and without wrong answers, t-test 
7.8.6 QUESTION 2 
Question 2 was another knowledge question. We asked whether predisposing heart conditions for 
native valve IE are specifically defined in either European or American guidelines for IE.  
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In total, 312 participants (98.1%) answered this question. Fifty-four participants (17.3%) answered 
yes, 83 participants (26.6%) answered no, and 175 participants (56.1%) indicated that they do not 
know the answer. 
 
Figure 45 – Answers to Question 2 
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Figure 46 – Statistical analysis of answers to Q2 compared with participants with wrong answers to Q1, t-test 
 Q1: Question 1; Q2: Question 2 
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7.8.7 QUESTION 3 
A total of 297 (93.4%) participants answered this question. The total is >100% because multiple 
answers were possible. To calculate the percentage, we used the number of participants who 
answered this question. As this question asked for the opinion of participants, no answers could be 
defined as wrong. 
Answer Number of Participants % 
IVDU 7 2.4 
Prior IE 68 22.9 
AI 61 20.5 
AS 92 31.0 
BAV 86 29.0 
MVP 96 32.3 
MI 96 32.3 
MS 79 26.6 
TI 53 17.8 
TS 43 14.5 
PI 40 13.5 
PS 40 13.5 
Prior myocardial infarction, coronary heart disease 4 1.3 
Foreign body material (valve replacement, devices, 
paceŵakers…) 
51 17.2 
Heart transplant 5 1.7 
Heart failure 7 2.4 
Atrial fibrillation, other arrhythmias 2 0.7 
Hypertrophic cardiomyopathy 1 0.3 
Vitium (not specified) 23 7.7 
Valve vitium 35 11.8 
Shunt 39 13.1 
Cyanotic heart disease 13 4.4 
Rheumatic heart disease 37 12.5 
GUCH 26 8.8 
HOCM 4 1.3 
DCM 3 1.0 
Thrombus 2 0.7 
Tumour 1 0.3 
Endothelial damage 3 1.0 
Valve sclerosis/calcification 45 15.2 
Cardiac surgery (without foreign body material) 13 4.4 
Paravalvular leakage 1 0.3 
Dental disease 1 0.3 
Cardiac disease causing significant turbulences 8 2.7 
Low flow 1 0.3 
Immunosuppression (also diabetes ŵellitus, HIV…) 2 0.7 
Chronic inflammation 11 3.7 
Kidney failure, hyperparathyroidism 1 0.3 
Table 22 – Answers to Question 3 
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AI: aortic valve insufficiency/regurgitation; AS: aortic valve stenosis; BAV: bicuspid aortic valve; DCM: dilated 
cardiomyopathy;  IE: infective endocarditis; GUCH: grown-up with congenital heart disease; HOCM: hypertrophic obstructive 
cardiomyopathy; IVDU: intravenous drug user; MI: mitral valve insufficiency/regurgitation; MS: mitral valve stenosis; MVP: 
mitral valve prolapse; PI: pulmonary valve insufficiency/regurgitation; PS: pulmonary valve stenosis; TI: tricuspid valve 
insufficiency/regurgitation; TS: tricuspid valve stenosis 
The cardiac conditions specified in both Question 1 and Question 3 did not differ significantly, as 
shown in Table 23. 
Condition Knowledge Question 1 
(% of Participants) 
Opinion Question 3  
(% of Participants) 
Aortic valve insufficiency 10.1 20.5 
Aortic valve stenosis 11.4 31.0 
Arrhythmias 0 0.7 
Bicuspid aortic valve 12.7 29.0 
Cardiac surgery (without 
foreign body material) 
3.9 4.4 
Cyanotic heart disease 8.2 4.4 
DCM 0.3 1.0 
Degenerative valve disease 5.2 0 
Endothelial damage 0 1.0 
Foreign body material 67 17.2 
GUCH 19.0 8.8 
Heart failure 3.3 2.4 
Heart transplant 2.9 1.7 
Hypertrophic cardiomyopathy 0 0.3 
HOCM 1.3 8.8 
Low flow 0 0.3 
Mitral valve insufficiency 12.7 32.3 
Mitral valve prolapse 12.1 32.3 
Mitral valve stenosis 8.8 26.6 
Paravalvular leakage 0 0.3 
Prior infective endocarditis 32.4 22.9 
Prior myocardial 
infarction/coronary heart 
disease 
0 1.3 
Pulmonary valve insufficiency 6.5 13.5 
Pulmonary valve stenosis 4.6 13.5 
Rheumatic heart disease 9.2 12.5 
Significant turbulence 2.6 2.7 
Shunt 15.7 13.1 
Thrombus 0 0.7 
Tricuspid valve insufficiency 8.2 17.8 
Tricuspid valve stenosis 5.6 14.5 
Tumour 0 0.3 
Valvular vitium 26.1 11.8 
Vitium (not specified) 16.3 7.7 
Table 23 – Comparison between conditions named in answers to Question 1 and Question 3 
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DCM: dilated cardiomyopathy; GUCH: grown-up with congenital heart disease; HOCM: hypertrophic obstructive 
cardiomyopathy 
 
 
 
Figure 47 – Bidirectional graph comparing answers to Question 1 with answers to Question 3 
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Knowledge Question Opinion Question
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7.8.8 QUESTION 4 
Question 4 asked participants to state the expected outcome if the study of Clemens et al.20 were 
repeated today. Clemens et al. conducted a case-control study with 51 patients with IE and 153 
matched controls without IE. They stated that patients with MVP had a significantly higher risk of 
developing IE compared with patients without MVP (odds ratio 8.2, 95% CI 2.4–28.4). 
A total of 308 participants (96.9%) answered this question. The total is >100% because multiple 
answers were possible. To calculate the percentage, we used the number of participants who 
answered this question.  
Answer 1 stated that participants would expect the repeat study to yield similar results. 
Answer 2 stated that participants would expect similar results, but with a lower odds ratio. 
Answer 3 stated that participants would not expect similar results, as the criteria in use today for 
MVP are different from those used in 1982. 
Answer 4 stated that participants would not expect similar results, as the echocardiographic 
technique used today is better than it was in 1982, and thus MVP was overdiagnosed in 1982. 
Answer 5 stated that participants would not expect similar results, as results from almost all 
cardiologic studies that are older than 30 years cannot be applied today. 
 
Answer Number of Participants % 
1 51 16.0% 
2 81 25.5% 
3 92 28.9% 
4 117 36.8% 
5 35 11.0% 
Table 24 – Answers to Question 4 
Twelve participants (3.9%) chose contradictory answers (e.g. Answer 1 and Answer 3). 
In the analysis for speciality, appointment, and years of clinical experience, the number of answers 
can be higher than the number of participants, as several answers were possible. 
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 Yes: Answers 1 or 2 (%) No: Answers 3, 4, or 5 
(%) 
Contradiction (%) 
Internal medicine 60 (34.1%) 154 (87.5%) 19 (10.8%) 
Cardiology 14 (27.5%) 53 (103.9%) 4 (7.8%) 
Infectious diseases 20 (57.1%) 25 (71.4%) 7 (20.0%) 
Other 5 (26.3%) 18 (94.7%) 0 (0.0%) 
Table 25 – Answers to Question 4 analysed by speciality 
 
 Yes: Answers 1 or 2 
(%) 
No: Answers 3, 4, or 5 
(%) 
Contradiction (%) 
Registrar 73 (48.7%) 95 (63.3%) 30 (20.0%) 
Consultant 30 (40.5%) 61 (82.4%) 11 (14.9%) 
Lead physician 17 (34.7%) 44 (89.8%) 6 (12.2%) 
Head of department 4 (23.5%) 18 (105.9%) 1 (5.9%) 
Table 26 – Answers to Question 4 analysed by appointment 
 
 Yes: Answers 1 or 2 (%) No: Answers 3, 4, or 5 
(%) 
Contradiction (%) 
1–2 years of 
experience 
9 (69.2%) 9 (69.2%) 5 (38.5%) 
3–5 years of 
experience 
30 (50.0%) 32 (53.3%) 12 (20.0%) 
>5 years of 
experience 
93 (39.2%) 199 (84.0%) 34 (14.3%) 
Table 27 – Answers to Question 4 analysed by years of clinical experience 
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8 DISCUSSION 
In a study by Rognon et al.,74 76% of patients with IE had a predisposing heart condition as a minor 
criterion for diagnosing IE. The authors stated that in the absence of the minor criterion, 27% of 
definite IE would be relegated to lower diagnostic categories. In a study by Durante-Mangoni et al.161, 
the criterion ͚predisposing native cardiac condition͛ was fulfilled in 29.7% of younger IE patients and 
in 34.9% of elderly patients. In a study by Habib et al.,279 the criterion ͚predisposition, heart disease͛ 
was fulfilled in 71% of patients. These data underline that it is commonly accepted that certain heart 
valve pathologies predispose for IE. In clinical practice, however, it is unclear which of the possible 
heart pathologies pose a significant risk for developing an IE, and if they do, to what extent.  
Our general objective was to narrow the definition of predisposing heart condition in native valves 
for the diagnosis of IE. Therefore, we divided the objective into three specific aims: first, to review 
the literature and the evidence on specific heart conditions reported to be a risk factor for IE; second, 
to align the findings from the first aim with the imaging technique available at that time and to 
theoretically compare, via extrapolation, the ƌesults ǁith iŵagiŶg fƌoŵ todaǇ͛s peƌspeĐtiǀes aŶd 
current definitions of a specific heart condition (i.e. valvular disease); and third, to evaluate the 
knowledge and opinion of clinicians about the term predisposing heart condition. 
The vast majority of the studies were descriptive. Only a few studies investigated a valve pathology 
as a risk factor for IE via analytical statistics. Moreover, three-quarters of all included studies involved 
patients who presented with IE prior to the publication of the modified Duke criteria. On the basis of 
our analyses, we can categorise the publications – irrespective of quality – into three groups. The first 
group included risk factors with a large number of publications. Studies belonging to this group 
focussed on (i) MVP (111 publications), (ii) prior IE (91 publications), and (iii) BAV (78 publications). In 
contrast, there was a group with few publications. Studies belonging to this group included (i) 
patients with MS (23 publications), (ii) pathologies involving the pulmonary valve (18 publications), 
and (iii) pathologies involving the tricuspid valve (nine publications). Between these two groups, we 
allocated a third group as having a medium number of number of publications. This group included 
patients with (i) AS (46 publications), (ii) MI (41 publications), and (iii) AI (39 publications). 
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8.1 GROUP 1 – PREDISPOSING HEART CONDITIONS WITH A HIGH NUMBER OF 
PUBLICATIONS 
8.1.1 MVP 
We identified six studies showing that a history of MVP was associated with a higher risk of IE. One 
study was excluded because of small patient numbers.224 Two studies reported an odds ratio of 
approximately 8,20,226 one an odds ratio of 3,225 another an odds ratio of 6.7,223 and another an odds 
ratio of 19.2.9 However, all of these analyses were performed in studies prior to the release of the 
modified Duke criteria (published 2000). Similarly, 81.2% of the 110 descriptive studies included 
patients after the publication of the modified Duke criteria. Moreover, our review on the evolution of 
imaging methods in parallel with the published studies indicates that the diagnostic accuracy of MVP 
is uncertain in a large proportion of these studies. For many years, MVP was diagnosed via 
auscultation. In 1998, ACC stated that there was no consensus in on the 2D echocardiographic 
criteria for MVP.176 On the basis of these arguments, the risk of developing IE and the prevalence of 
patients with MVP among those with IE cannot be ƋuaŶtified fƌoŵ todaǇ͛s peƌspeĐtiǀe. Given this 
line of reasoning, the meaning of the proportion of patients with MVP who developed IE (mean 8.5%, 
median 7.7%, IQR 4.4%–11.4%) is unclear. 
8.1.2 PRIOR IE 
The evolution of imaging methods did not – in our view – influence these results. Among the 
descriptive studies, 24.7% included patients after the publication of the modified Duke criteria. 
However, in earlier studies, the diagnosis was made on the basis of other defined criteria or via 
autopsy. Although we cannot estimate whether the variable prior IE was over- or underestimated in 
these studies, there were no considerable reasons to mistrust the diagnosis. Two studies showed an 
odds ratio of approximately 2.548,49 for developing IE when patients had previously experienced an 
episode of IE. The mean proportion of patients with IE plus a history of previous IE was 8.3% (median 
7.1%, IQR 4.9%–10.2%). These results did not alter significantly when we compared studies before 
and after 2001. These numbers indicate that every tenth to twentieth patient with a history of IE will 
develop a second episode of IE. 
8.1.3 BICUSPID AORTIC VALVE 
We identified one analytical study showing that a history of BAV was associated with a higher risk of 
IE, with a hazard ratio of 6.3.141 In the 77 descriptive studies, a median of 5.6% (before 2001, 7.0%; 
after 2001, 5.0%) of patients with IE had BAV as an underlying condition. Of these 77 studies, 20 
(26%) included patients after the publication of the modified Duke criteria. Nonetheless, given the 
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fact that the presence of BAV could be imagined in the mid-70s, we judged the influence of imaging 
over time as minor.  
 
8.2 GROUP 2 – PREDISPOSING HEART CONDITIONS WITH A LOW NUMBER OF 
PUBLICATIONS 
8.2.1 MITRAL VALVE STENOSIS 
MS is often associated with rheumatic heart disease, which by itself has been suggested as a risk 
factor for developing IE. The prevalence of rheumatic fever has been constantly decreasing in the 
Western world. The mean prevalence of patients with MS and IE in publications prior to 2001 was 
6.4% (median 5.3%, IQR 3.2%–7.6%). After 2001, the IQR dropped to 0.7%–2.5%. Similarly, the dot 
plot graph indicates that with the increasing sample size number in the corresponding studies with 
definitions in accordance with the modified Duke criteria, the prevalence of IE in patients with MS is 
чϭ%. Although it appears meaningful that turbulence caused by MS predisposes to IE, it is difficult to 
say whether MS itself poses an increased risk or whether rheumatic fever is a surrogate marker. Our 
literature review on the evolution of imaging methods did not provide important arguments that the 
diagnosis of MS was underdiagnosed. More likely, MS was overdiagnosed before 1998 because of 
the diagnostic criteria for rheumatic feǀeƌ. Fƌoŵ todaǇ͛s peƌspeĐtiǀe, patieŶts ǁith diagŶosed MS 
frequently experience valve replacement, and hence, MS per se cannot be quantified as a risk for 
developing IE. 
8.2.2 PULMONARY VALVE 
We identified one study analysing the risk of developing IE in patients with congenital PS, reporting a 
hazard ratio of 1.1.141 No studies of PI or other aetiologies of PS were identified in the literature 
review. From the 17 descriptive studies, a median of 1% of patients with IE had PS or PI. Only four 
studies were published after the modified Duke criteria, and among those, the median of patients 
with PS and IE was 0.3% (mean 0.3%, IQR 0.2%–0.3%). Similarly, the dot plot graph indicates a very 
low prevalence throughout all studies. PS is most important when considering congenital heart 
disease. The clinical role in adults, however, is less important and may result from rare causes, such 
as in patients with carcinoid plaques,278 or in the modern era, in patients who had heart surgery in 
their childhood. As definitions of PI/PS were not added to the guidelines until 2006,5 it is improbable 
that this severely influenced reporting in our case, as most studies reported here were published 
before 2006.  
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8.2.3 TRICUSPID VALVE 
No studies reporting an odds ratio for patients with TI or TS for developing IE were identified. Of the 
nine studies with descriptive reporting, a median of 5% of patients with IE had TI or TS as an 
underlying condition. 
Of these nine studies, three included only patients after the publication of the modified Duke criteria. 
Echocardiographic criteria were not included in the guidelines until 2006272 and were made more 
precise in 2014.2 Moreover, the dot plot graph indicates that some of these studies have a 
publication bias. As only a small number of studies were published on TI/TS and IE, it is difficult to 
speculate on the relevance.  
 
8.3 GROUP 3 – PREDISPOSING HEART CONDITIONS WITH A MEDIUM NUMBER 
OF PUBLICATIONS 
This group is – within the aims of our thesis – the most difficult for the following reasons. First, in 
comparison to group 1, the number of publications in this group is below 50, and hence, there is less 
postulated evidence. Second, AS, MI, and AI are among the most common valve pathologies in our 
population. This is in particular true for the Western world with its growing number of elderly 
people. In the proportion analyses, this makes the denominator difficult to estimate. Third, with the 
evolution of imaging, these pathologies haven been classified differently over time. Thus, what might 
have been a risk factor in previous studies is no longer oŶe fƌoŵ todaǇ͛s peƌspeĐtiǀe, ďeĐause a ǀalǀe 
pathology is classified as mild, moderate, or severe, and each category does not fulfil the statistical 
criteria. 
8.3.1 AORTIC STENOSIS 
We identified only one study showing that a history of (congenital) AS was associated with a higher 
risk of IE, with a hazard ratio of 4.9.141 Of the 45 studies with descriptive analyses, 11 (24.4%) 
included patients in the study after the publication of the modified Duke criteria. The differentiation 
between mild, moderate, and severe AS was described first in 1989, although it was only after 1998 
that the definitions of mild, moderate, and severe AS were published in guidelines. The observation 
that (i) three-quarters of the studies included patients prior to 2001, (ii) the mean and median 
proportion of patients with AS and IE was lower in studies published after 2001 (5.2% and 4.5%, 
respectively) than in studies published before 2001 (8% and 7%, respectively), and (iii) the dot plot 
demonstrates a prevalence of less than 5% in newer studies with large sample sizes indicates that the 
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relevance of mild or moderate AS as a risk factor for IE is unknown. This is in line with the study of 
Gersony et al.142 in which they postulated that only severe AS is related to the occurrence of IE. 
8.3.2 MITRAL VALVE INSUFFICIENCY 
In the literature review, no studies reporting analytical statistics for patients with MI for developing 
IE could be identified. Forty-one studies were identified that published descriptive statistics on the 
proportion of patients with MI in newly diagnosed IE cases. Of these studies, nine (22%) included 
patients in the study after the publication of the modified Duke criteria. The proportion of patients 
with IE and MI had a wide distribution of results, i.e. the overall IQR was 5.2%–28.6%, was 5%–25.7% 
in publications prior to 2001, and was 9.6%–37.8% in publications after 2001. The dot plot also 
indicates that the literature research included studies with a publication bias. This may be because 
the research question is difficult to answer in this constellation. For example, some studies may 
represent that their patients developed MI because of IE and not that MI was a risk factor for 
developing IE. Finally, the definitions of the graduation of MI were implemented rather late, namely 
in the 2006 guidelines,5 again after the recommendations by ASE.192 Taken together, these findings 
indicate that the current literature research result does not allow any conclusion regarding MI as risk 
factor for IE. Refining of the included studies may therefore be more helpful (see Outlook section 
below [8.6]). 
8.3.3 AORTIC VALVE INSUFFICIENCY 
In our literature review, no studies with analytical statistics for patients with AI and their risk of 
developing IE could be identified. Thirty-nine studies were identified that published descriptive 
statistics on the proportion of patients with a history of AI in newly diagnosed IE cases. Of these 
studies, eight (20.5%) included patients in the study after the publication of the modified Duke 
criteria. Before 1998, visualisation by cineangiography and eyeball guessing of the regurgitant 
volume was common. In 2003, with recommendations by ASE,192 and later in 2006 with 
implementations in the AHA guidelines,5 the echo criteria were published. Given the fact that 80% of 
publications addressed the AI risk factor prior to the presentation of the modified Duke criteria, 
overestimation of AI as a predisposing condition is possible. The difficulty in assessing AI as a risk 
factor is reflected by the wide range (IQR 2.4%–25%) in the number of patients with AI and IE in 
publications after 2001 and the wide distribution in the dot plot graph comparing sample size and 
prevalence of IE in patients with AI. With the current data, AI as a risk factor in developing IE cannot 
be quantified. 
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8.4 HOW DO WE CURRENTLY INTERPRET THE DUKE MINOR CRITERION 
PREDISPOSING HEART CONDITION IN NATIVE VALVES? 
Our survey shows that in clinical practice, there is uncertainty regarding what is considered a Duke 
minor criterion predisposing heart condition in a native valve. The range of answers regarding the 
nature of a predisposing heart condition was very broad. The answers regarding what participants 
believed to be true (knowledge question) and what they felt should be true (opinion question) were 
not similar on many of the questionnaires. On the one hand, these results may underline the 
difficulty in diagnosing IE in clinical practice, and on the other, they may point towards uncertainty in 
how to interpret and apply the Duke minor criterion of a predisposing heart condition. We found an 
association only between the wrong answers (very narrowly defined) in clinicians with less than 
3 years of clinical experience. Two-thirds of the participants were convinced that in previous years, 
the diagnosis of MVP was overestimated. If this is true, a certain proportion of patients was falsely 
postulated to be at risk for IE. This again may have influenced the statistical risk stratification. A 
repetition of this study with current diagnostic methods may help to answer this question. Our 
survey does not provide final results other than to show that there is a trend for uncertainty 
regarding what is considered a Duke minor criterion predisposing heart condition in a native valve.  
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8.5 LIMITATIONS 
The thesis results have limitations. First, the literature review includes studies with considerable 
heterogeneity. In many articles, the underlying heart disease was not specified in detail. It was often 
reported by aetiology (rheumatic, congenital, degenerative), but not categorised as mild, moderate, 
or severe. The means by which the diagnosis of the predisposing cardiac conditions was made remain 
unreported in most studies. In addition, in some studies, it was unclear – despite detailed full text 
information – as to whether the reported cardiac condition was present before IE, or whether it was 
caused by IE itself (e.g. valve insufficiency). In a significant number of studies, the corresponding 
valve pathology in a population was not reported (i.e. patients with valve pathology but without IE). 
Thus, it is possible that the reported number of predisposing heart conditions overestimates the true 
prevalence in IE. By using a dot plot graph that associates sample size with proportion of IE, we 
aimed to identify studies with publication bias (e.g. shown for MI). Finally, the diagnostic criteria 
varied among the studies. Some articles used the original Duke criteria even after the modified 
criteria were published. We tried to counterbalance this observation by categorising studies prior to 
2001 and after 2001. We thereby focused on the years in which the patients were included in each 
study and not on the publication year of the corresponding study. 
Second, our historical view on the evolution of imaging methods is based on the published literature. 
The extrapolation about whether each study could use imaging methods that were modern in their 
time is theoretical.  
Third, the survey has a selection bias of participants because only physicians present at morning 
meetings on the date of investigation filled out the questionnaire. Although the questionnaire was 
tested on several occasions, it was not validated prior to the study. 
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8.6 OUTLOOK 
Our systematic review of the literature is the basis for further analyses, in particular meta-analyses. 
In a first step, we will address the limitations mentioned above and exclude studies that do not 
address the research questions properly. Further tests are necessary to look for publication bias (e.g. 
Egger test). The heterogeneity can be addressed with a plot of precision versus response proportion 
(e.g. Freeman-Tukey, Begg funnel plot). By doing this, it will become apparent which studies with a 
smaller sample size or precision will have a larger random error and thus a larger spread when 
graphed. These steps are necessary for every variable mentioned in this thesis to obtain a proper 
data set. We can thereby process our current systematic literature review into a second meta-
analysis. Finally, we may also proceed with a sensitivity analyses to estimate the proportion risk of IE 
for each valve disease. With the aid of mathematical models a more narrow definition of the term 
predisposing heart condition can be targeted. 
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8.7 CONCLUDING REMARKS AND POTENTIAL CONSEQUENCES FOR CLINICAL 
PRACTICE 
Our work demonstrates that there is uncertainty about what is considered a predisposing heart 
condition for the diagnosis of IE. This uncertainty is found even with an extensive literature review. 
The vast majority of studies contained only descriptive statistics and included patients in the study 
prior to the publication of the modified Duke criteria. The highest number of articles in the literature 
were related to MVP, a prior episode of IE, and BAV. Among these three variables, MVP is most likely 
affected by the evolution of imaging methods, in particular because for many years, diagnosis of this 
valve pathology was made via auscultation. The uncertainty was also found after analysing the 
responses of 318 physicians in a questionnaire.  
This diagnostic uncertainty may lead to overdiagnosis of IE in patients with positive results of blood 
cultures (e.g. non-staphylococcal bacteraemia) but inconclusive imaging results. Nonetheless, in the 
early phase of disease and with suspicion of IE, it may be prudent to overdiagnose disease and 
perform echocardiography. In the longer course of the disease, however, overtreatment of IE 
contributes to the development of organism resistance in the microbiome and is associated with 
adverse events from antimicrobial agents. An imprecise Duke minor criterion is, in our view, not 
helpful in decision-making for or against the final diagnosis of IE. In our view, it is reasonable to 
encounter anatomical variants that cause significant turbulence and may be risk factors when IE is 
suspected at first clinical presentation. However, over a 2-week period, the clinical course, the 
microbiological criteria, and repeated imaging with modern techniques should allow confirmation or 
rejection of the definite diagnosis of IE in most cases, irrespective of the presence of valve disease. 
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13 TABLE WITH ADDITIONAL INFORMATION FOR ALL STUDIES 
Reference Inclusion Criteria # of Patients Initial Population Study Design 
Abramczuk83 NVIE (Duke criteria3) 152 Mean age 46 y (range 10–76 y) 
76% male 
0% PVIE  
Retrospective, single  centre 
Agarwal182 IE (von Reyn criteria4) 28 Mean age 24 y ± 11 y  
75% male 
25% CHD 
Single  centre, probably prospective, but not 
clearly stated 
Ako243 IE (Duke criteria3) 194 Age range 6–82 y 
71% male 
0% IVDU  
6% CHD 
22% PVIE 
Single  centre, retrospective (admission 
records) 
Al Abri254 Discharge code of IE (ICD 10-133.0), and 
analysis according to modified Duke 
criteria1 
58 Mean age 44 y (range 14–85 y) 
69% male 
16% PVIE 
9% CHD 
5% IVDU 
Single  centre, retrospective (computerised 
activity register) 
Alagna49 Possible or definite IE (Duke criteria3) 1874 68% male 
24% PVIE 
9% IVDU 
9% CHD 
Prospective, multicentre 
Alestig89 Diagnosis of IE, not specified. Most likely 
also includes autopsies 
98 Not specified Prospective clinical studies carried out in 
Göteborg since 1984, data obtained from a 
Swedish national registry of IE since 1995 and 
existing literature 
Arbulu180 Patient with IE (criteria not mentioned) 417 62% male  
67% IVDU 
3% CHD 
Retrospective, single centre 
Assiri162 Definite IE (modified Duke criteria1) 44 Mean age 31 ± 16 y (range 13–
65 y)  
Retrospective, single centre 
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64% male 
23% PVIE 
Auger196 IE (Pelletier50 criteria) 50 Mean age 43 y 
48% PVIE 
Retrospective, single centre 
Baek220 Definite IE (modified Duke criteria1) 325 28% CHD  Retrospective, single centre 
Bailey178 IE (Hickie definition280) 202 Mean age 43 y  
63% male 
18% CHD 
8% PVIE 
Retrospective, single centre 
Baskerville112 IE (modified Duke criteria1) 
Inclusion of most recent case in patient 
with multiple episodes 
89 Median age 45 y  
(IQR 36–61) 
63% male 
19% PVIE 
9% CHD 
17% IVDU 
Retrospective review (medical records), 
multicentre 
Bayliss58 IE (criteria not specified) 541 Mean age 52 y (range 2–87 y)  
67% male  
4% CHD 
1% IVDU 
14% PVIE 
Retrospective, multicentre (British Isles) 
Begezsan167 IE (Duke criteria3) 45 Mean age 49 y (range 9–76 y) 
78% male 
Retrospective, single centre 
Benito104 Definite NVIE (modified Duke criteria1), in 
non-IVDU and an identified place of 
acquisition 
253 62% male 
0% IVDU 
 
Prospective cohort study, multicentre (data 
from the ICE-PCS) 
Benn152 IE or suspected IE (von Reyn criteria4) 59 Mean age 55 y (range 15–83 y)  
71% male 
12% CHD 
15% PVIE 
5% IVDU 
Retrospective, multicentre 
Beton21 Echocardiographically diagnosed MVP 182 Mean age 48 y (range 12–87 y)  
55% male 
Prospective, single centre 
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Blackett181 IE in patients >8 y, criteria: 
Clinical features suggestive of IE (fever, 
deteriorating general health, weight loss, 
sweating, anaemia, clubbing, 
splenomegaly) 
with echocardiography showing 
thickening of valve, changing valve 
morphology or vegetations 
and had blood cultures done on at least 3 
occasions. 
Positive blood cultures or all other clinical 
and paraclinical features of IE despite 
negative blood cultures 
20 Mean age 26.8 y (range 8–70 
y) 
55% male 
10% PVIE 
Prospective, single centre 
Borer242 Definite or possible IE (Duke criteria3) >15 
y 
71 Mean age 55 y (range 16–84 y) 
55% male 
1% IVDU 
29% PVIE 
11% CHD 
Retrospective, single centre 
Borger200 Aortic valve replacement patients with 
BAV  
 Mean age 56 y ± 15 y  
76% male 
Retrospective, single centre 
Bouza80 IE, criteria (1 or more): 
(1) Clinical IE (von Reyn4, Steckelberg,61 or 
Duke criteria3) 
(2) Echocardiographic evidence of IE  
(3) Bloodstream infections by S. viridans, 
S. bovis, HACEK, S. aureus, Enterococcus 
spp. were screened 
(4) Histologic findings of IE 
109 Mean age 50 y (range 19–89 y) 
73% male 
16.5% PVIE 
36% IVDU 
Prospective observational case series, single 
centre 
Cassel195 IE (criteria not clearly specified) in adults 40 Mean age 43 y (range 13–69 y) 
43% male  
15% CHD 
13% PVIE 
Retrospective, single centre 
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Castillo81 IE (von Reyn criteria4 until 1994 and Duke 
criteria3 thereafter) in non-IVDU  
138 Mean age 40 y ± 20 y (range 
0–72 y) 
0% IVDU 
21% CHD 
31% PVIE 
Prospective case series, single centre 
Castillo250 NVIE (von Reyn criteria4 until 1994, Duke 
criteria3 until 2000, modified Duke 
criteria1 until 2004, and from 2004 
definition according to ESC281) in non-
IVDU 
 
228 Mean age 50 ± 20 y 
66% male  
0% IVDU 
0% PVIE 
Prospective, single centre 
Castillo93 Definite NVIE (von Reyn criteria4 until 
1994, Duke criteria3 thereafter [and 
retrospectively applied to all cases]) in 
non-IVDU 
154 60% male 
0% PVIE 
32% CHD 
Prospective observational, multicentre 
Cecchi165 Patient with definite IE (modified Duke 
criteria1) 
677 Median age 62 y (range 13–91 
y) 
73% male 
12% IVDU 
26% PVIE 
6% CHD 
Prospective, multicentre 
Cecchi160 Definite IE (Duke criteria)3 after 
confirmation by autopsy, pathology, or 
surgery data or 3-month follow-up data 
147 10% IVDU 
25% PVIE 
Prospective, multicentre 
Cetinkaya84 Diagnostic codes for IE from patient 
records in ID sections and autopsy 
records 
(Duke criteria3 and von Reyn criteria4 and 
additional minor criteria to Duke by 
Lamas79) 
147 Mean age 34 y ± 14 y (range 
16–75 y) 
57% male  
20% PVIE 
5% CHD 
0% IVDU 
Retrospective (hospital charts) review, single 
centre 
Cheng155 IE (Duke criteria)3 58 Median age 63 y (range 20–94 
y) 
71% male 
Retrospective, multicentre 
166 
 
0% IVDU 
31% PVIE 
Cheng199 IE, criteria: 
Definite: Direct evidence of IE noted at 
surgery 
Probable: Positive blood cultures plus at 
least 3 of the following: fever, 
predisposing heart disease or new 
regurgitant murmur, systemic embolism, 
and echocardiographic evidence of 
valvular vegetation 
Possible: (A) Positive blood cultures with 
fever, and predisposing heart condition 
or new regurgitant murmur 
(B) Negative blood cultures with all 3 of 
the following: fever, predisposing heart 
disease, echocardiographic evidence of 
valvular vegetation or systemic 
embolisation 
97 Mean age 39 y ± 16 y (range 
14-76 y) 
60% male 
21% CHD 
20% PVIE 
Retrospective, single centre 
Choudhury151 IE, criteria: 
(1) Demonstration of a vegetation on 2D 
echocardiography in accordance with 
Stewart et al.282 
(2) ш2 positive blood cultures growing the 
same organism(s) with the presence of шϮ 
of the following – fever lasting for >3 
days, evidence of systemic or septic 
pulmonary emboli in the presence of 
heart disease, changing murmur or 
appearance of a new murmur during 
hospitalisation, recent worsening of heart 
failure, and presence of certain features 
strongly associated with IE such as fundal 
186 Mean age 25 y ± 12 y (range 
2–75 y) 
72% male  
33% CHD 
1% PVIE  
1% IVDU 
Retrospective, single centre 
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haemorrhages, mycotic aneurysms, 
Osleƌ͛s nodes 
Chu96 Definite and possible IE (Duke criteria 
(1994)3) 
65 Mean age 65 y ± 18 y (range 
7–89 y) 
68% male 
24% PVIE  
13% CHD 
Retrospective, single centre 
Chu136 Definite left-sided, non-cardiac device-
related IE (modified Duke criteria1) 
1296 Median age 62 y (IQR 47–72)  
68% male  
25% PVIE 
5% IVDU 
Prospective cohort study, multicentre (ICE-
PLUS cohort) 
Cicalini98 Definite IE (Duke criteria3)  283 Mean age 39 y ± 15 y 
67% male  
12% PVIE 
60% IVDU 
Retrospective (patient records), single centre 
Clemens20 IE in patients with no predisposing heart 
conditions except for MVP, criteria: 
Either pathological documentation of 
bacterial endocarditis or fulfilment of 
clinical criteria 
Clinical criteria: Heart murmur, at least 2 
blood cultures obtained at separate times 
and yielding the same organism, and at 
least 1 of the following: new or changed 
heart murmur, peripheral stigmata of IE 
on physical examination, or laboratory 
evidence of endocarditis 
51 Mean age 47 y ± 18 y 
63% male 
27% IVDU 
0% PVIE 
0% CHD 
 
Collins168 Patients undergoing valve replacement 
surgery due to IE (criteria not defined) 
95 Mean age 51 y 
67% male 
0% PVIE 
25% IVDU 
Prospective observational, single centre 
Collins213 Patients with aortic valve replacement 1025  Retrospective, single centre 
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Correa de 
Sa107 
Possible or definitive IE (modified Duke 
criteria1) in patients ш18 y 
150 67% male 
7% CHD 
22% PVIE 
Retrospective, multicentre 
Corrigall228 IE (criteria not clearly stated) 25 Mean age 47 y (range 19–69 y) 
62% male 
 
Retrospective, single centre 
Danchin225 Mitral valve NVIE, criteria: 
Pathological evidence of IE at operation 
or necropsy, or 
fever and 2 major criteria, or 
fever, 1 major and 3 minor criteria 
Major criteria: at least 2 positive blood 
cultures, new or changing heart murmur, 
and typical echocardiographic vegetation 
Minor criteria: arterial embolism, 
immunological disorders, splenomegaly, 
regurgitation murmur, congestive heart 
failure, pre-existing heart disease, clinical 
signs of vasculitis 
48 70% male 
0% PVIE 
Retrospective case-control study, single centre 
Delahaye71 IE (modified from von Reyn)4: Definite: 
Direct evidence of IE based on 
macroscopy and/or histology from 
surgery or autopsy, and/or bacteriology 
(Gram stain or culture) of valvular 
vegetation or peripheral embolus 
Probable: (A) Persistently positive blood 
cultures plus 1 of the following: (1) New 
regurgitant murmur, or (2) Predisposing 
heart disease and vascular phenomena 
(at least 2), or (3) Predisposing heart 
disease and echocardiographic 
vegetation, or (4) Vascular phenomena 
(at least 2) and echocardiographic 
415 Mean age 56 y ± 19 y (range 
0–91 y) 
64% male 
22% PVIE 
5% IVDU 
Prospective survey, multicentre 
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vegetation  
(B) Negative or intermittently positive 
blood cultures plus 1 of the following: (1) 
Fever and new regurgitant murmur and 
vascular phenomenal (at least 2), or (2) 
Fever and predisposing heart disease and 
vascular phenomena (at least 2) and 
echocardiographic vegetation 
Possible: (A) Persistently positive blood 
cultures plus 1 of the following: (1) 
Predisposing heart disease, or (2) 
Vascular phenomena (at least 2) (B) 
Negative or intermittently positive blood 
cultures plus all 3 of the following: (1) 
Fever (2) Predisposing heart disease, and 
(3) Vascular phenomenal (at least 2) 
Persistently positive blood cultures: At 
least 2 blood cultures obtained, with 2 of 
2 positive, 3 of 3 positive, or at least 70% 
of cultures positive if 4 or more cultures 
obtained  
Vascular phenomena: Petechiae, splinter 
haemorrhages, conjunctival 
haemorrhages, Roth spots, Osier͛s nodes, 
Janeway lesions, aseptic meningitis, 
glomerulonephritis, and pulmonary, 
central nervous system, coronary, or 
peripheral emboli  
Intermittently positive blood culture: Any 
rate of blood culture positivity that does 
not need the definition of persistently 
positive  
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Devereux223 NVIE patients (diagnostic criteria not 
further specified) with M-Mode and 2D 
echocardiography studies and isolated, 
pure, moderate to severe mitral 
regurgitation by clinical criteria (not 
further specified) 
141 68% male 
0% PVIE 
Case-control study, single centre 
Di Filippo156 Definite IE (Duke criteria3) in children and 
adults with CHD 
153 Mean age 13 y ± 11% 
57% male 
5% PVIE 
100% CHD 
Retrospective, single centre 
Dodo273 Adult patients with CHD who had 
pulmonary vascular disease with 
inherently normal pulmonary and 
tricuspid valves 
186 Mean age 39 y ± 9 y (range 
22–68 y) 
42% male 
100% CHD 
0% PVIE 
Prospective, observational, single centre 
Durante-
Mangoni161 
Definite IE (modified Duke criteria1) 2759 20% PVIE 
10% IVDU 
Prospective, multicentre (ICE cohort) 
Duren232 Idiopathic mitral valve prolapse 300 Mean age 42 y (range 10–87 y)  
45% male  
Prospective, single centre 
Dyson154 Microbiologically positive NVIE, criteria: 
(1) There were at least 2 positive blood 
cultures (yielding identical isolates) or a 
positive valve culture or positive 
serology. (2) There was evidence 
(echocardiographic or histopathological) 
of endocardial involvement and/or 
evidence of any 3 of the following: (i) 
predisposing heart condition, (ii) fever 
(>38.0C), (iii) vascular phenomena (e.g. 
arterial emboli, intracranial 
haemorrhages, conjunctival 
haemorrhages), (iv) immunological 
77 Mean age 53 y 
70% male 
0% PVIE 
27% CHD 
0% IVDU 
Retrospective, single centre 
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phenomena (e.g. glomerulonephritis, 
Osleƌ͛s Ŷodes, Roth spots) 
Dzupova118 Possible or definite IE (modified Duke 
criteria1) in patients with permanent 
residence in defined catchment area of 
each participating hospital during 
specified time 
122 Median age 63 y (range 18–98 
y) 
66% male 
7.5% IVDU 
38% PVIE 
11% CHD 
Prospective, multicentre 
Elbey221 Definite NVIE (modified Duke criteria1) 158 Mean age 47 y ± 18 y (range 
13–87 y)  
55% male 
0% PVIE 
7% CHD 
Retrospective, multicentre 
Erbay117 Definite IE (modified Duke criteria1), 
exclusion of pacemaker patients 
107 Mean age 45 y ± 16 y (range 
19–77 y)  
73% male  
0% IVDU 
44% PVIE 
7% CHD 
Retrospective, single centre 
Falase177 IE, criteria (2 or more): 
(1) Repeatedly positive blood cultures 
during a febrile illness in a patient with 
previous valvular or congenital heart 
disease 
(2) Evidence of peripheral manifestation 
IE 
(3) Prolonged febrile illness and 
development of a significant murmur 
while under observation 
(4) Favourable response to antibiotic 
therapy 
90 56% male Retrospective, single centre 
Fefer85 IE (von Reyn4 or Duke criteria3) 108 Mean age 57 y ± 22 y  
56% male  
Retrospective (medical records), single centre 
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31% PVI 
19% CHD 
Fenoglio194 Congenital BAV in patients ш20 y in 
pathology samples (valves or hearts or 
photographs or autopsy descriptions) 
152 100% CHD 
0% PVIE 
Retrospective, single centre 
Fernandez-
Hidalgo131 
Definite or possible LSIE (modified Duke 
criteria1Ϳ iŶ adult patieŶts ;шϭϴ ǇͿ 
438 Mean age 66 y (IQR 51.8–74.9) 
65% male  
23% PVIE 
3% IVDU 
Prospective observational cohort study, single 
centre 
Fernandez-
Hidalgo121 
Definite or possible LSIE (modified Duke 
criteria1Ϳ iŶ adult patieŶts ;шϭϴ ǇͿ  
334 66% male 
21% PVIE 
8% CHD 
Prospective observational cohort study, single 
centre 
Ferraris126 Possible or definite NVIE (modified Duke 
criteria1) 
111 Median age 53 y (IQR 42–71)  
65% male  
0% PVIE  
30% IVDU 
5% CHD 
Retrospective, single centre 
Ferreira132 Possible or definite LSIE (modified Duke 
criteria1) 
147 Median age 63 y (IQR 45–74) 
71% male 
13% PVIE 
8% CHD 
Retrospective, multicentre (2 hospitals) 
Ferreiros77 
EIRA-2 data 
(1992-1993) 
IE (Duke criteria3) in adult patients (>18 y) 294 Mean age 52 y ± 19 y  
70% male 
14% IVDU 
9% PVIE 
Prospective registry, multicentre 
Ferreiros77 
new data 
(2001-2002) 
IE (modified Duke criteria1) in adult 
patients (>18 y) 
470 Mean age 58 y ± 18 y  
70% male 
4% IVDU 
19% PVIE 
Prospective, multicentre 
Fukuchi139 Definite IE (modified Duke criteria1) 82 Mean age 61 y ± 15 y  
65% male  
4% CHD 
0% IVDU 
Prospective, multicentre 
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12% PVIE 
Galvez-
Acebal108 
LSIE (Duke criteria3)  705 Median age 56 y (IQR 41–68 y)  
69% male  
24% PVIE 
7% IVDU 
Observational multicentre study 
Garg186 Definite IE (Duke criteria3) 192 Mean age 28 y ± 13 y (range 
4–68 y) 
73% male  
29% CHD 
10% PVIE 
2% IVDU 
Retrospective, single centre 
Garvey52 IE, criteria: 
At least 2 positive blood cultures prior to 
initiation of therapy, surgical 
confirmation by pathologic abnormality 
and/or culture of the heart valve at 
operation or autopsy confirmation,  
or single positive culture and compatible 
course of disease,  
or clinical presentation only with 
convincing response and clinical 
presentation 
154 60% male 
7% IVDU 
6% CHD 
21% PVIE 
Retrospective analysis of patient records, 
autopsy files, and files of the infectious 
diseases department 
Gentry68 IE (criteria not stated) 94 Mean age 53 y (range 20–86 y) 
80% male 
13% CHD 
43% PVIE 
4% IVDU 
Retrospective review, single centre 
Gersony142 Patients included in the First Natural 
History Study of Congenital Heart Defects 
(NHS-1), meaning patients with AS or PS 
2401 100% CHD Prospective cohort study, multicentre 
Giannitsioti103 Definite or possible IE (modified Duke 
criteria1) 
195 65% male 
7% IVDU 
22% PVIE 
Prospective cohort study, multicentre 
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Gotsman90 Definite IE (Duke criteria3) 100 Mean age 55 y ± 20 y (range 
1–97 y) 
55% male 
23% PVIE 
 
Retrospective, single centre 
Griffin197 Definite, probable, and possible IE (von 
Reyn criteria4) in defined area of 
residence 
78 Mean age 58 y (range 0–90 y)  
58% male 
14% CHD 
5% PVIE 
Retrospective, multicentre 
Grossman146 IE, criteria: 
(1) At least 2 separate positive blood 
cultures from patients with known 
underlying heart disease and negative 
blood cultures in patients with known 
underlying heart disease, together with 
fever (>38°C) and new regurgitant heart 
murmur or embolic phenomena, or 
(2) histological evidence of infected 
endocardial vegetations in tissue 
obtained during open-heart surgery or 
autopsy 
213 64% male 
17% CHD 
Retrospective, single centre 
Gupta128 Definite IE (modified Duke criteria1)in 
adult patients (>18 y) 
83 Mean age 49 y ± 14 y (range 
19–84 y)  
77% male 
31% PVIE 
23% CHD 
1% IVDU 
Retrospective, single centre 
Gupta140 Definite IE (modified Duke criteria1) 109 Mean age 33 y ± 17 y (range 
2–70 y) 
75% male 
32% CHD 
10% PVIE 
Retrospective, single centre 
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Habib279 IE (pathologic confirmation by surgical 
intervention) 
93 Age not mentioned, no ratio 
of males:females mentioned, 
32% PVIE 
Retrospective, single centre 
Haddy55 IE, criteria: 
(1) Autopsy evidence of IE, or 
(2) a compatible clinical history and 2 
positive blood cultures prior to the 
initiation of adequate therapy or, where 
less than 4 cultures were taken, only 1 
positive culture for Streptococcus viridans 
(alpha-haemolytic streptococcus), 
Staphylococcus aureus, or Streptococcus 
pneumoniae, or 
(3) a compatible clinical history with 
evidence of macro- or microembolism 
;peteĐhiae, Osleƌ͛s Ŷodes, ‘oth͛s spotsͿ, 
the demonstrated absence of other 
diseases that might produce the clinical 
picture (i.e. pneumonia, renal infection, 
systemic lupus erythematosus, blood 
dyscrasia), and a response to what would 
be considered an adequate regimen of 
therapy 
66 Mean age 44 y (range 6–83 y) 
64% male 
23% IVDU 
Retrospective, single centre 
Hajihossainlou
253 
Definite or possible IE (Duke criteria3) in 
discharge or postmortem diagnosis 
286 Mean age 30 y ± 16 y (range 
3–81 y) 
60% male  
9% CHD 
14% PVIE 
27% IVDU 
Retrospective, multicentre 
Hammel56 IE (criteria not clearly indicated) 31 Mean age 39 y (range 12–68 y) 
74% male 
3% IVDU 
6% PVIE 
Single centre, not indicated whether 
prospective or retrospective 
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Hayes274 Patients with PS from the First Natural 
History Study of Congenital Heart Defects 
(NHS-1) 
464 Median age 30 y (range 18–77 
y) 
50% male 
100% CHD 
Prospective cohort study, multicentre 
Heiro211 IE (Duke criteria3) patients who survived 
>1 y after the initial admission for IE 
226 Mean age 52 y ± 17 y (range 
18–87 y) 
72% male 
24% PVIE 
4% CHD 
8% IVDU 
Retrospective, single centre 
Heiro210 IE (Duke criteria)3) in adults 303 Mean age 54 y ± 17 y  
72% male  
3% CHD 
8% IVDU 
21% PVIE 
Retrospective, single centre 
Hill102 Definite IE (modified Duke criteria1) in 
patients >16 y 
203 Median age 67 y (IQR 54–73 y)  
60% male  
34% PVIE 
1% IVDU 
Prospective observational cohort study, single 
centre 
Hodes148 Cases of IE (criteria not clearly indicated) 47 Mean age 20.5 y  
68% male 
Retrospective, single centre 
Hoen244 Definite IE (Duke criteria3) 390 Mean age 60 y ± 17 y (range 
16–95 y)  
71% male  
16% PVIE 
1% CHD 
5% IVDU 
Retrospective population based survey, 
multicentre 
Hogevik65 IE (modified von Reyn criteria4):  
Modification was detection of vegetation 
by sonography as an alternative to 
embolisation,  
retrospectively included were patients 
90 Mean age 62 y (range 8–88 y)  
46% male 
10% CHD 
15% PVIE 
7% IVDU 
Prospective non-randomised, single centre 
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with IE identified at autopsy or by ICD 9 
code 
Hsu100 Definite or possible IE (modified Duke 
criteria1) 
315 Mean age 51 y ± 22 y (range 
0–92 y)  
59% male  
11% CHD 
8% PVIE 
4% IVDU 
Retrospective review, single centre 
Iga183 NVIE (criteria not clearly indicated) 32 Mean age 52 y (range 27–74 y) 
78% male 
19% CHD 
0% IVDU 
Retrospective, single centre 
Jaffe64 Discharge diagnosis of IE, criteria: 
(1) At surgery or autopsy, valvular 
vegetations or embolic material, or both, 
were present with histologic or 
bacteriologic evidence of active infection 
(2) Two or more positive sets of blood 
cultures in the presence of a new 
regurgitant murmur or systemic 
embolism 
(3) When 2 of the following conditions 
were present: fever >38.5°C, new 
regurgitant murmur, embolic 
phenomenon 
70 Mean age 47 y ± 19 y 
(range 15–88 y)  
57% male 
29% IVDU 
16% PVIE 
6% CHD 
Retrospective review, single centre 
Jain188 Definite IE (modified Duke criteria1) 75 Mean age 27 ± 17 y (range 0–
80 y)  
69% male 
0% IVDU 
35% CHD 
9% PVIE 
Prospective observational, single centre 
Jain101 Definite or possible IE (modified Duke 
criteria1) 
238 71% male 
74% IVDU 
Retrospective, single centre 
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Jalal203 IE, criteria: 
(1) Two or more positive blood cultures 
showing growth of the same 
microorganism, or 
(2) demonstration of vegetation on 
echocardiography in association with 
fever, evidence of vascular/immunologic 
phenomena, changing/new murmur, or 
worsening of heart failure 
466 Mean age 23 y (range 0–60 y) 
59% male  
23% CHD 
1% PVIE 
Retrospective, single centre 
Kahveci214 Definite aortic valve NVIE (modified Duke 
criteria1) 
51 Median age 39 y (range 9–75 
y) 
86% male  
0% IVDU 
0% PVIE 
Retrospective, single centre 
Keane143 Patients with AS from the Natural History 
Study of Congenital Heart Defects (NHS-1 
and NHS-2) 
462  Prospective cohort study, multicentre 
Khaled114 Discharge diagnosis of IE (modified Duke 
criteria1 with an additional minor 
criterion, namely increased erythrocyte 
sedimentation rate) 
 Mean age 29 y ± 15 y (range 
12–60 y)  
42% male  
3% PVIE 
Prospective, single centre 
Khanal185 Definite IE (Duke criteria3) 46 Median age 26 y (range 2–73 
y) 
57% male 
9% CHD 
2% PVIE 
 
Kim62 IE (von Reyn criteria4) 55 Mean age 52 y (range 19–83 y) 
71% male 
16% CHD 
23% PVIE 
7% IVDU 
Retrospective, single centre 
Kim239 Echocardiographically diagnosed primary 
MVP 
229 Mean age 51 y (range 14–88 y) 
47% male 
Prospective, single centre 
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King60 IE, criteria: 
Definite: Culture or Gram stain evidence 
of organisms on valvular tissue or 
peripheral embolus obtained at surgery 
or autopsy 
Probable: 100% of either 2 or 3 blood 
cultures or ш72% of 4 or more cultures 
positive for the same organism plus 
evidence of a new regurgitant murmur or 
an intracardiac defect in a febrile patient 
Possible: One of only 2 blood cultures 
positive, plus fever and an intracardiac 
defect or embolic lesions, or 3 positive 
blood cultures in a patient with a valvular 
prosthesis and fever, or negative cultures 
in a persistently febrile patient with no 
explanatory diagnosis plus an intracardiac 
defect or valvular prosthesis 
75 Mean age 48 y ± 18 y (range 
15–90 y) 
56% male 
21% PVIE 
18% IVDU 
Prospective, multicentre 
Kiwan201 IE, criteria: 
(1) Strong clinical evidence of the disease 
(2) Cardiac lesions or murmurs 
(3) Positive microbiological reports and or 
(4) Echocardiographic lesions 
60 Mean age 28 y  
67% male  
7% PVIE 
13% CHD 
Prospective, single centre 
Knudsen247 IE (modified Duke criteria1) 172 19% PVIE 
2% CHD 
4% IVDU 
Prospective, single centre 
Knudsen124 Definite or possible IE (modified Duke 
criteria1) 
147 Mean age 65 y ± 14 y 
62% male 
29% PVIE 
3% IVDU 
Prospective, single centre 
Knudsen125 Definite or possible IE (modified Duke 
criteria1) 
145 Mean age 65 y ± 14 y 
60% male 
26% PVIE 
Prospective, single centre 
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3% IVDU 
Koeda130 Definite IE (Duke criteria 3) in adult 
patients ;шϮϬ y) 
 Mean age 58 y ± 16 y  
60% male 
 
Retrospective, single centre 
Koegelenberg9
1,92 
Definite IE (Duke criteria3)  47 Mean age 38 y ± 13 y  
62% male 
17% PVIE 
6% CHD 
0% IVDU 
Prospective observational study, single centre 
Korem134 Definite NVIE (modified Duke criteria1) in 
adults 
37 Mean age 64 y ± 15 y 
0% PVIE 
Prospective observational study, single centre 
Lamas79 NVIE (pathologically proven, and Duke 
criteria3) 
100 80% male  
0% PVIE 
6% IVDU 
Prospective, single centre 
Lamas204 IE (Duke criteria3) on BAV with 
modifications of the criteria: following 
additional minor criteria: the presence of 
newly diagnosed clubbing, splenomegaly, 
splinter haemorrhages, and petechiae; a 
high erythrocyte sedimentation rate; a 
high C-reactive protein level; and the 
presence of central non-feeding lines, 
peripheral lines, and microscopic 
haematuria 
408 Study only reports on subsets Retrospective, single centre 
Leone122 Definite or possible NVIE (modified Duke 
criteria1) 
753 Mean age 62 y (range 4–95 y) 
71% male 
12% IVDU 
9% CHD 
0% PVIE  
Prospective, multicentre 
Li215 Surgically treated definite or possible IE 
(modified Duke criteria1) 
 
220 Mean age 39 y ± 14 y (range 
3–75 y) 
71% male  
33% CHD 
Retrospective, single centre 
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Loupa245 Definite or possible IE (Duke criteria3, in 
case of pacemaker IE modified by Klug et 
al.283) 
101 Mean age 54 y ± 17 y (range 
17–86 y) 
70% male 
31% PVIE 
3% IVDU 
Prospective, multicentre 
Lowes53 IE (criteria not specified) 60 60% male 
22% CHD 
Retrospective survey, single centre 
Lu217 Definite IE (modified Duke criteria1) in 
adults 
148 Mean age 57 y ± 17 y  
66% male 
12% IVDU 
Retrospective observational study, single 
centre 
Ma166 Definite IE (modified Duke criteria1) in 
patients ш18 y 
115 Mean age 46 y ± 15 y 
71% male 
10% PVIE 
24% CHD 
Single centre 
MacMahon224 IE, criteria: 
Evidence of cardiac involvement such as 
echocardiographically defined valvular 
vegetations or a murmur, with a positive 
blood culture on 2 or more occasions or 
histologic evidence of valvular 
vegetations, together with other 
evidence of infection such as pyrexia or 
elevated circulating immune complexes 
and evidence of the peripheral stigmata 
of IE such as embolic phenomena or 
splenomegaly. 
MVP diagnosis with Hickey definition284 
136 Only subgroups presented Prospective matched case-control study, 
multicentre 
Manford184 IE (criteria not defined) with positive 
blood cultures 
31 Mean age 58 y ± 18 y (range 
23–85 y) 
58% male  
32% PVIE 
6% IVDU 
3% CHD 
Retrospective, single centre 
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Mansur149 IE, criteria:  
Clinical presentation consistent with 
diagnosis and causative microorganism 
isolated in at least 2 blood cultures  
287 Mean age 31 y ± 16 y (range 
0.2–78 y)  
64% male 
12% CHD 
23% PVIE 
8% IVDU 
Retrospective, single centre 
Marks238 MVP (defined as systolic displacement 
into the left atrium of one or both leaflets 
beyond the plane of the mitral annulus in 
the parasternal long-axis view) 
456 Only subgroups presented Retrospective, single centre 
Marks164 IE (modified Duke criteria1) in patients 
ш18 y referred for surgical management 
336 Median age 52 y (IQR 41–67 y) 
75% male 
8% IVDU 
18% CHD 
21% 
Retrospective observational cohort study, 
single centre 
Math248 Definite IE (modified Duke criteria1) 104 Mean age 24 y (IQR 9–38 y) 
71% male 
39% CHD 
20% PVIE 
Prospective observational study, single centre 
McKay158 IE (criteria not defined) patients 
undergoing cardiac surgery (excluding 
homografts) 
29 Mean age 55 y (range 31–79 y)  
66% male  
6% PVIE 
Retrospective, multicentre 
Michelena205 Echocardiographically diagnosed BAV 
with no cardiovascular symptoms at 
diagnosis and with normal function or 
minimal dysfunction of the aortic valve, 
based on clinical evaluation confirmed by 
echocardiography showing no or at most 
mild stenosis (wide systolic valvular 
opening with mean gradient <20 mmHg 
in patients who underwent continuous 
wave Doppler) and no or mild 
regurgitation (no or mild left ventricular 
212 Mean age 32 y ± 20 y  
65% male  
Prospective, multicentre 
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enlargement, no or mild regurgitation by 
pulsed-wave of LVOT and of aortic arch or 
by colour flow Doppler) and with left 
ǀeŶtƌiĐulaƌ ejeĐtioŶ fƌaĐtioŶ шϱϬ% 
Michelena206 
207 
Definite BAV of any type 416 Mean age 35 y ± 21 y  
69% male 
Retrospective cohort study, multicentre 
Mills193 Non-stenotic BAV  41 Age range at follow-up 6–71 y  
68% male 
Prospective, single centre 
Mills227 Mid-systolic click or late systolic murmur 
(or both) documented 
phonocardiographically 
53 64% male Retrospective, single centre 
Mirabel129 Definite IE (modified Duke criteria1) in 
patients шϭϴ Ǉ 
51 Median age  52 y (IQR 33–70 
y) 
61% male 
26% PVIE 
12% CHD 
Retrospective, single centre 
Mokhles111 
(subgroup of 
Mokhles115) 
Adult patients who underwent surgery 
for definite IE (modified Duke criteria1)  
138 Mean age 54 y ± 14 y  
77% male  
12% CHD 
1% IVDU 
18% PVIE 
Retrospective observational cohort study, 
single centre 
Mokhles115 Definitive IE (modified Duke criteria1) in 
adult patients 
191 Mean age 55 y 
72% male 
13% CHD 
1% IVDU 
21% PVIE 
Retrospective observational cohort study, 
single centre 
Mouly82 IE (Duke criteria3) in patients ш15 y 89 Median age 60 y 
66% male 
8% IVDU 
24% PVIE 
Retrospective observational, single centre 
Moura94 NVIE (Duke criteria3) 69 Mean age 56 y ± 15 y  
65% male  
46% PVIE 
Retrospective, single centre 
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10% IVDU 
15% CHD 
Murdoch105 Definite IE (modified Duke criteria1) in 
patients ш18 y  
2781 Mean age 57 y (IQR 43.2–71.8)  
68% male 
10% IVDU 
23% PVIE 
Prospective cohort study, multicentre (ICE-
PCS) 
Naggar235 Echocardiographically diagnosed MVP 
(Popp259) in patients aged 60 y or older 
145 49% male Retrospective, single centre 
Nakagawa251 Definite or probable IE (modified Duke 
criteria1) 
118 Mean age 58 y (range 16–82 y) 
58% male 
0% IVDU 
8% CHD 
13% PVIE 
Retrospective, single centre 
Nakatani163 IE (Duke criteria3) 513 Mean age 60 y ± 18 y (range 
1–97 y) 
62% male 
2% IVDU 
Prospective survey, multicentre 
Nashmi99 Definitive IE (modified Duke criteria1)  47 Mean age 32 y ± 20 y (range 
0.4–78 y) 
61% male 
21% CHD 
4% IVDU 
21% PVIE 
Retrospective, single centre 
Netzer88 
(same data set 
as Netzer153, 
longer follow-
up) 
IE (Duke criteria3) 212 Mean age 53 y (range 17–90 y) 
75% male 
4% CHD 
17% PVIE 
10% IVDU 
Retrospective review of clinical records, single 
centre 
Netzer153 
(same data set 
as Netzer88, 
shorter 
follow-up) 
Definite or possible IE (Duke criteria3) 212 75% male 
4% CHD 
17% PVIE 
10% IVDU 
Retrospective, single centre 
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Nishimura229 Echocardiographically diagnosed MVP 
with an age between 10 and70 y and no 
associated congenital anomalies or other 
valvular diseases, NYHA III-IV or diastolic 
dimension of >70 mm at the onset of the 
study 
237 Mean age 44 y (range 10–69 y) 
40% male 
Prospective, single centre 
Nissen66 NVIE, criteria: 
Definite IE: Positive histopathological 
evidence of IE by autopsy or cardiac 
surgery. 
Probable IE: Cases with a documentation 
of positive blood cultures, fever, and 
either cardiac murmurs or 
echocardiographic signs of IE 
132 53% male 
5% CHD 
0% PVIE 
Retrospective, multicentre 
Nomura120 Definite or probable IE (modified Duke 
criteria1) 
62 Mean age 67 y ± 15 y 
56% male 
19% PVIE 
8% CHD 
 
Retrospective, single centre 
Nunes116 Definite or possible IE (modified Duke 
criteria1) 
62 Mean age 45 ± 17 y (range 15–
76 y)  
63% male 
8% IVDU 
Prospective, single centre 
Olmos137 Definite and possible IE (Duke criteria3 
until 2002, and modified Duke criteria1 
thereafter) 
1122 Mean age 64 y ± 22 y 
Median age 62 y (IQR 47–72)  
68% male  
6% IVDU 
Prospective, multicentre 
Pachirat86 IE (Duke criteria3) 160 Mean age 39 y ± 16 y  
66% male 
5% PVIE 
 
Single centre, combined retrospective and 
prospective data collection 
Pazdernik109 Definite IE (modified Duke criteria1) 106 Mean age 57 y ± 15 y 
80% male 
Retrospective, single centre 
186 
 
18% PVIE 
1% IVDU 
Peat236 IE (von Reyn criteria4) 78 Mean age 50 y ± 26 y 
54% male 
21% PVIE 
Retrospective, single centre 
Pedersen51 (1) Endocarditis at autopsy  
(2) Fever, heart murmur, at least 1 
positive blood culture and absence of 
other diseases that might produce the 
observed clinical picture  
(3) Fever, heart murmur, evidence of 
peripheral embolism, absence of other 
diseases that might produce the 
observed clinical picture, and adequate 
response to antibiotic therapy despite 
negative blood cultures  
(4) In all cases classified as acute bacterial 
endocarditis, the heart murmur was 
required to be definitely changing during 
the period of observation 
80 Mean age 42–46 y  
54% male 
10% CHD 
Retrospective, single centre 
Pelletier50 Discharge diagnosis IE, criteria: 
(1) Definite IE: Histologic evidence of 
infected endocardial vegetation(s) from 
examination of tissue obtained from 
cardiac surgery, embolectomy, or 
autopsy 
(2) Probable IE: Either uniformly positive 
blood cultures with known underlying 
heart disease and evidence of emboli to 
the skin or viscera, or negative blood 
cultures in individuals with fever (>38°C), 
new regurgitant valvular heart murmurs, 
and embolic phenomena 
125 73% male 
15% IVDU 
Retrospective review of patient charts, 
multicentre  
187 
 
(3) Possible IE: Either uniformly positive 
blood cultures with known underlying 
heart disease or embolic phenomena, or 
negative blood cultures with fever, 
known underlying heart disease, and 
embolic episodes 
Poesen127 Probable or definite IE (modified Duke 
criteria1) 
83 Median age 72 y (IQR 59–81 y) 
66% male 
8% PVIE 
6% CHD 
Retrospective, single centre 
Rehman187 IE (Duke criteria3) 30 Mean age 24 y 
70% male 
23% CHD 
3% PVIE 
Prospective, single centre 
Rizzi133 Possible or definite IE (modified Duke 
criteria1) 
1056 (NVIE) Median age 65 y (IQR 50–64)  
71% male  
11% IVDU 
0% PVIE 
9% CHD 
Retrospective analysis of a multicentre, 
prospective observational cohort study 
Robbins145 IE in patients ш65 y, criteria: 
(1) Discharge diagnosis of IE, or 
(2) autopsy-proven IE, or 
(3) persistently positive blood cultures 
without a known primary site of infection 
56 Mean age 72 y (range 65–92 y) 
64% male 
 
Retrospective, single centre 
Roberts70 Necropsy patients with IE with 
vegetations on the aortic valve 
96 78% male 
11% IVDU 
22% PVIE 
Retrospective, multicentre 
Rognon74 IE (Duke criteria3) 151 (NVIE) Mean age 55 y (range 16–89 y) 
70% male 
0% PVIE 
6% IVDU 
14% CHD 
Retrospective, multicentre 
Roucaut231 IE (von Reyn criteria4) 350  Retrospective, single centre 
188 
 
Rudolph147 IE (criteria not stated) 50 Mean age 44 y ± 13 y 
78% male 
Single centre, probably prospective 
Sadaka219 Definite IE (Duke as reported in ESC 
guidelines14) 
50 Mean age 33 y ± 11 y (range 
16–78  y) 
58% male 
26% IVDU 
22% PVIE 
8% CHD 
Prospective, single centre 
Sandre75 IE (Duke criteria3 and von Reyn4 criteria), 
IVDU and PVIE excluded 
80 Mean age 49 y (range 17–87 y) 
69% male  
0% IVDU 
0% PVIE 
9% CHD 
Retrospective review, single centre 
Sawae275 IE (criteria not clearly indicated) 91 25% CHD Retrospective, multicentre 
Schon67 IE (criteria not indicated) 51 Mean age 46 y ± 11 y (range 
15–78 y) 
69% male 
20% PVIE 
2% IVDU 
Retrospective, single centre 
Scudeller249 IE (criteria not indicated) 254 Mean age 67 y ± 14 y 
67% male 
32% PVIE 
2% IVDU 
Prospective observational, multicentre 
Selton-Suty119 Patients with diagnosis of definite IE, age 
шϭϴ Ǉ iŶ pƌedefiŶed ƌegioŶs iŶ FƌaŶĐe 
497 Mean age 62 y ± 16 y (range 
18–96 y) 
74% male 
6% IVDU 
21% PVIE 
Prospective population-based observational 
study, multicentre 
Selton-Suty72 
(study data 
from 
Delahaye,71 
modified) 
IE (von Reyn criteria4, modified with 
echocardiographic and macroscopic 
findings71), excluding prosthetic devices 
297 65% male Prospective, multicentre 
189 
 
Senthilkumar2
18 
IE (modified Duke criteria1) with referral 
to tertiary centre 
116 Mean age 30 y ± 14 y 
70% male 
4% PVIE 
10% CHD 
Prospective, single centre 
Servy285 Definite IE (modified Duke criteria1) 
among adults (ш18 y) living in the study 
area 
497 73% male 
6% IVDU 
21% PVIE 
4% CHD 
Prospective, multicentre 
Siddiq240 IE, criteria: 
(1) Histopathologic evidence of the 
disease;  
(2) multiple positive blood cultures in the 
absence of another known primary 
source of bacteremia, together with at 
least 2 of the following signs or 
symptoms—fever, new or changing 
murmur, newly developed splenomegaly, 
hypersensitivity, or microvascular 
phenomena (e.g. Janeway lesions, Osier 
nodes, Roth spots, and splinter 
haemorrhages); and  
(3) intermittently positive blood cultures, 
or negative blood cultures when cultures 
were first obtained only after empiric 
antibiotic therapy, with at least 3 signs or 
symptoms. For right-sided endocarditis, 
entry criteria included positive blood 
cultures plus vegetation that was 
visualised on echocardiography, or 
positive blood cultures plus fever, septic 
pulmonary emboli, or heart murmur 
159 Mean age 46 y ± 19 y (range 
12–97 y) 
64% male 
67% IVDU 
Prospective, single centre 
190 
 
Simsek-
Yavuz138 
IE (modified Duke criteria1) in 
hospitalised patients >14 y  
325 Mean age 47 y ± 17 y (range 
14–90 y) 
58% male 
43% PVIE 
1% IVDU 
8% CHD 
Prospective 102 cases (first 5 y) and 
retrospective 223 cases thereafter, single 
centre 
Singham179 IE, criteria: 
(1) All patients with evidence of heart 
disease and a positive blood culture 
(2) Patients with evidence of heart 
disease and negative blood cultures but 
with evidence of embolic episodes, fever 
with splenomegaly, finger clubbing, 
Osleƌ͛s Ŷodes, spliŶteƌ haeŵoƌƌhages aŶd 
microscopic haematuria 
101 60% male 
30% CHD 
1% PVIE 
Retrospective, single centre 
Skehan233 IE (criteria not stated) 185 7% IVDU 
10% PVIE 
Prospective, multicentre 
Steckelberg61 IE (modified von Reyn criteria4): 
 (1) Histopathologic evidence of infective 
endocarditis; or  
(2) multiple positive blood cultures (at 
least 2 positive cultures within a 24-hour 
period and at least 66% of cultures 
positive before initiation of antibiotics) 
with the same microorganism without 
another known primary source of 
bacteremia, and at least 2 of the 
following stigmata of infective endo- 
carditis: (a) fever, (b) new or changing 
cardiac murmur, (c) newly developed 
splenomegaly, (d) hypersensitivity or 
microvascular phenomena (e.g. Janeway 
697  Retrospective from prospectively collected 
records, multicentre (comparison of a 
population- based cohort vs. cohort of Mayo 
Clinic) 
191 
 
lesions, Osler nodes, Roth spots, 
conjunctival petechiae), or (e) emboli; or  
(3) intermittently positive blood cultures 
or negative blood cultures first obtained 
after administration of empiric 
antimicrobial therapy, together with at 
least 3 stigmata of infective endocarditis 
Strom9 Community-acquired IE (as assessed by 
study authors, criteria not indicated), 
IVDU excluded. 
Community-matched controls 
273 Mean age 59 y ± 17 y 
0% IVDU 
10% CHD 
Population-based, case-control study, 
multicentre 
Sun252 IE (criteria not indicated), excluding PVIE 
and devices 
 Mean age 48.6 y 
61% male 
0% PVIE 
Retrospective, single centre 
Suzuki212 Cardiac surgery for IE (criteria not stated) 27 26% CHD Retrospective, single centre 
Tariq159 IE (modified Duke criteria1) 66 Mean age 29 y 
67% male 
50% CHD 
2% IVDU 
8% PVIE 
Retrospective, single centre 
Tariq157 IE (modified Duke criteria1) 159 Mean age 35 y ± 21 y 
65% male 
25% CHD 
1% IVDU 
5% PVIE 
Retrospective, single centre 
Terpenning59 Definite or probable bacterial IE (von 
Reyn4 criteria, Pelletier criteria50) 
144 23% IVDU Retrospective review of patient charts, 
multicentre  
Thamlikitkul15
0 
IE in patients ш13 y, criteria (modified 
from Von Reyn4): 
Positive blood culture for the same 
microorganism on at least 2 specimens 
plus 
105 Mean age 32 y 
71% male 
29% IVDU 
Retrospective, single centre 
192 
 
(1) pathological evidence of infective 
endocarditis at autopsy or operation, or 
(2) cardiac vegetation detected by 
echocardiography, or 
(3) presence of heart disease and/or 
history of intravenous drug abuse with 
embolic phenomena or with unidentified 
foci of bacteremia 
Thell144 Pathologic samples (autopsy and 
excision) of valves with IE diagnosis in 
patients >60 y 
42 69% male 
5% PVIE 
Retrospective (pathology samples), 
multicentre 
Tleyjeh87 IE (modified Duke criteria 1Ϳ iŶ adults шϭϴ 
y  
102 Mean age 62 y (range 19–91 y)  
72% male 
21% PVIE 
3% IVDU 
7% CHD 
Retrospective (population-based survey), 
multicentre 
Todd48 TTE studies with primary indication of IE 
diagnosis, TTE or TOE suggesting IE 
diagnosis 
29  Retrospective, single centre 
Tornos73 NVIE in non-IVDU, criteria for IE: 
(1) Clinical findings consistent with 
infective endocarditis, including at least 2 
of the following signs: fever, heart 
murmur, emboli, splenomegaly, and 
microvascular phenomena;  
(2) 2 or more blood cultures positive for 
the same microorganism; and  
(3) histopathological evidence of valvular 
infection at necropsy or operation 
194 Median age 50 y (range 7–82 
y) 
66% male 
0% IVDU 
0% PVIE 
10% CHD 
Prospective observational, single centre 
Tran208 IE (Duke criteria3) 132 Mean age 54 y (range 19–83 y) 
61% male 
22% PVIE 
13% IVDU 
Retrospective, single centre 
193 
 
11% CHD 
Tresch230 Echocardiographically diagnosed MVP in 
patients >60 y 
40  Single centre 
Tribouilloy216 Definite IE (Duke criteria)3) with native 
aortic valve involvement 
310 Mean age 59 y ± 15 y 
82% male 
0% PVIE 
Prospective, observational, multicentre 
Tugcu110 Possible or definite IE (modified Duke 
criteria1) 
28 (NVIE) Mean age 46 y (range 16—88 
y) 
68% male 
0% PVIE 
7% CHD 
Retrospective review, single centre 
Turak135 Definite IE (modified Duke criteria1) in 
adults  
121 Mean age 55 y ± 14 y  
53% male 
42% PVIE 
6% CHD 
Retrospective, single centre 
Tzemos209 BAV on transthoracic echocardiography 
and absence of complex congenital 
cardiac defects 
642 Mean age 35 y ± 16 y  
68% male 
 
Retrospective, single centre 
Van der Meer8 IE (von Reyn criteria4) 349 (NVIE) Median age 47 y (range 2—89 
y) 
61% male 
11% CHD 
0% PVIE 
0% IVDU 
Prospective epidemiologic study, multicentre 
Varstela63 Patients with aortic valve surgery for IE 58 Mean age 47 y (range 19—71 
y) 
88% male 
Retrospective, single centre 
 
Venezio57 (1) Typical histopathology found at 
surgery or autopsy; or  
(2) 3 or more positive blood cultures plus 
at least 2 of the following: fever, heart 
murmur, systemic embolisation or 
biopsy-proved vasculitic skin lesions, and 
37  Retrospective, single centre 
194 
 
echocardiographic evidence of a valvular 
vegetation 
Vered234 Patients with echocardiographically 
diagnosed MVP 
42  Retrospective, single centre 
Verheugt141 Patients with CHD ш18 y, included in 
CONCOR registry286 
IE (modified Duke criteria1) 
10210 49% male 
100% CHD 
Prospective cohort study, multicentre 
Verheul276 NVIE (von Reyn criteria4) 141 Mean age 45 y (range 18—77 
y) 
74% male 
Retrospective, single centre 
Vlessis202 IE (modified69 von Reyn criteria4) 140 Mean age 57 y ± 3 y 
65% male 
11% IVDU 
22% PVIE 
4% CHD 
Retrospective, single centre 
Walls106 IE patients (modified Duke criteria1) in 
ICE-PCS cohort105 from New Zealand 
336 Median age 60 y (range 15—
98 y) 
68% male 
31% PVIE 
13% CHD 
5% IVDU 
Prospective cohort (ICE-PCS cohort study105), 
multicentre 
Watanakunak
orn69 
IE (modified Steckelberg criteria61)  204 Median age 60–70 y (range 
0—91 y) 
56% male  
16% IVDU 
14% PVIE 
4% CHD 
Retrospective 1980–1985, prospective 1986–
1990, single centre 
Watt255 IE in patients ш16 y (modified Duke 
criteria1) 
132 Median age 47 y (range 16–85 
y) 
69% male 
10% PVIE 
8% CHD 
Prospective observational, multicentre 
Weinberger23 NVIE (von Reyn criteria4) 135 Mean age 60 y (range 18–85 y) Retrospective, single centre 
195 
 
63% male 
0% PVIE (excluded) 
11% CHD 
1% IVDU 
Wells237 IE in patients ш15 y (von Reyn criteria4) 98 Mean age 52 y ± 20 y 
64% male 
8% PVIE 
3% CHD 
4% IVDU 
Retrospective, single centre 
Welton54 (1) Persistent bacteremia proved by 2 or 
more blood cultures separated by an 
interval of 12 to 24 hours demonstrating 
the same organism with concomitant 
clinical features of endocarditis consisting 
of fever, cardiac murmur, and, 
frequently, 1 or more of the following: 
systemic emboli, splenomegaly, 
haematuria or echocardiographic valvular 
vegetations  
(2) Pathologic confirmation of 
endocarditis at surgery or autopsy and a 
preceding clinical course consistent with 
infective endocarditis  
117 Mean age 36 y 
29% IVDU 
3% CHD 
3% PVIE 
Retrospective, single centre 
Weng78 IE (Duke criteria3) 109 Mean age 38 y (range 8–78 y) 
73% male 
14% CHD 
5% IVDU 
25% PVIE 
Retrospective, single centre 
Werner76 IE (Duke criteria3) 104 Median age 59 y 
26% PVIE 
Retrospective, single centre 
Wong113 Definite or possible IE (modified Duke 
criteria1) 
47 Mean age 66 y (range 16–93 y)  
77% male 
28% PVIE 
Retrospective review, single centre 
196 
 
4% CHD 
Woo198 Primary referrals with IE (diagnostic 
criteria not specified) 
176 Mean age 30 y ± 13 y 
48% male 
5% PVIE 
22% CHD 
3% IVDU 
Mixed retrospective and prospective, single 
centre 
Wu123 Definite IE in patients шϭϴ Ǉ ;ŵodified 
Duke criteria1) 
192 Median age 50 y (range 19–92 
y) 
75% male 
29.5% IVDU 
9% PVIE 
Retrospective, single centre 
Yeo241 Echocardiographically diagnosed MVP 
(Feigenbaum287) 
98 Mean age 42 y ± 17 y 
55% male 
Retrospective, single centre 
Yiu246 Community-acquired IE (modified Duke 
criteria1) in adults 
172 Mean age 52 y ± 17 y  
66% male 
30% IVDU 
9% CHD 
Retrospective cohort, single centre 
Yoshinaga95 IE (modified Duke criteria1) 239 Median age 12 y (range 1–62 
y) 
90% CHD  
Retrospective observational cohort study, 
multicentre (66 institutes) 
Yousuf97 IE (Duke criteria3) 45 Mean age 31.9 y 
98% male 
86.7% IVDU 
Retrospective analysis of case records, single 
centre 
Zuppiroli226 Patients with MVP referred for evaluation 275 Mean age 43 ± 19 y 
47% men 
Prospective observational, single centre 
Zuppiroli288 Patients with MVP (echocardiographically 
diagnosed) 
316 Mean age 42 ± 15 y  
30% male 
Prospective observational, single centre 
Table 28 – Inclusion criteria, population data, and designs of included studies 
2D: two-dimensional; AS: aortic valve stenosis; BAV: bicuspid aortic valve; CHD: congenital heart disease; ESC: European Society of Cardiology; ICE: International Collaboration on Endocarditis; ICE-
PCS: International Collaboration on Endocarditis-Prospective Cohort Study; ICD: International Statistical Classification of Diseases and Related Health Problems; IE: infective endocarditis; IQR: 
interquartile range; IVDU: intravenous drug user; LSIE: left-sided infective endocarditis; LVOT: left ventricular outflow tract; MVP: mitral valve prolapse; NVIE: native valve infective endocarditis; 
NYHA: New York Heart Association; PS: pulmonary valve stenosis; PVIE: prosthetic valve infective endocarditis; TOE: transoesophageal echocardiography; TTE: transthoracic echocardiography 
 
